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Abstract 
Depression is a major disease burden worldwide and, despite its prevalence and 
socioeconomic costs, around 30% of patients do not respond to currently 
available treatments. Inflammation is increasingly associated with, not only 
depressive illness but also resistance to existing therapies. This highlights the 
need for investigation of the mechanisms of neuro-inflammation, particularly in 
the context of peripheral inflammatory stimuli. Specifically, the chemokine 
molecular family is increasingly associated with human depressive illness, and 
neuro-inflammation and behavioural change in rodent models, making this an 
attractive molecular family for study. This thesis describes research aimed at 
investigating the association of these molecules with human depression and 
analysis of their role in an animal model of peripherally stimulated neuro-
inflammation, the Aldara model of psoriasis-like inflammation. 
Systematic review and meta-analysis of the human biomarker literature using a 
random effects, inverse variance model revealed that a number of chemokines 
(CCL2, CCL3, CCL4, CCL11, CXCL4, CXCL7, CXCL8) are significantly associated 
with depressive illness in a human population. However this work revealed that 
there are a number of limitations of the human literature primarily associated 
with the methodological challenges of studies in human populations and 
confounding factors. 
Alongside this work, the Aldara model, which utilises the toll-like receptor 7 
(TLR7) ligand imiquimod (IMQ), was investigated as a tool for studying 
neuroinflammation. Initial time-course investigation revealed that significant 
chemokine and cytokine transcriptional alterations occur within four hours at 
the local site of cutaneous treatment, the peripheral tissues and the brain. In 
addition, protein quantification in the brain confirmed that many of these 
transcriptional responses are translated to protein. Interestingly, it was shown 
that the brain response was temporally distinct from that of the peripheral 
tissues, and that in general brain responses were induced slightly more slowly 
and persisted for a longer period of time than those in the periphery. 
Investigation of Iba1+ (microglia/monocytes), GFAP+ (astrocytes) and CD3+ (T-
cells) cells within the brain revealed significant changes in the microglial and T-
cell populations, which were consistent with microgliosis and T-cell recruitment 
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to the brain parenchyma. Changes in astrocyte populations were more equivocal 
although there was evidence of astrogliosis. 
Mechanistic investigations into responses to the Aldara model in inflammatory 
chemokine receptor (iCCR) KO mice did not reveal significant alterations in 
chemokine and cytokine transcription or in microglial responses to cutaneous 
Aldara treatment in the absence of the iCCRs (CCR1, CCR2, CCR3 and CCR5), but 
there did appear to be evidence of reduced CD3+ T-cell recruitment. In contrast, 
investigations in type I interferon receptor (IFNAR) KO mice identified a clear 
role for type I IFN signalling through IFNAR in the induction of chemokine and 
cytokine gene expression in the brain, and associated changes in Iba1+ microglial 
and CD3+ T-cell populations in response to cutaneous Aldara treatment. Mass 
spectrometric analysis of IMQ, the main active ingredient of Aldara, revealed 
that within four hours it enters both the circulation and the brain. The finding of 
IMQ within the brain parenchyma suggests that, while it is not an appropriate 
tool for studying peripheral-central immune crosstalk, it is a useful non-invasive 
model of TLR7 mediated neuroinflammation. 
These data provide compelling evidence of a role for chemokines in human 
depression and in neuro-inflammation, although the precise actions of this 
family of molecules remain unclear. In addition, building on previous work, the 
Aldara model appears to be a suitable tool for the study of neuro-inflammation, 
particularly interferon-driven immune responses, but is less appropriate for 
studying peripherally driven CNS immune reactions. Further work into the 
specific role of chemokines and associated cellular populations will hopefully 
provide additional insight into how CNS immune reactions are co-ordinated.   
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Chapter 1 Introduction 
1.1 Overview 
Depressive disorders are a significant and increasing burden on health and social 
care systems worldwide(1). Despite considerable impact on both quality of life, 
morbidity and mortality, depressive disorders are not only inadequately 
understood(2) but the therapeutic options available are limited and often lack 
efficacy(3).  
Ongoing research has increasingly associated inflammatory mechanisms with the 
pathogenesis of depression(4-8).  Animal studies have identified a role for pro-
inflammatory cytokines in the generation of sickness behaviours, behaviours that 
share many phenotypic similarities with the symptoms of depression in humans 
(5, 9-11). In addition, animal models looking at stress and depressive behaviours 
have begun to identify alterations in inflammatory status associated with 
behavioural changes(12). 
In human studies, a number of findings provide strong evidence for the 
involvement of the immune system in depressive illness; (i) treatment with 
interferons (IFNs) in hepatitis C infection results in a depressive disorder in 25-
40% of patients undergoing treatment(13, 14); (ii) alterations in both immune 
molecules and cells are present in depressed patients when compared to healthy 
controls(15-20); (iii) treatment of patients with anti-inflammatory medications 
can alleviate depressive symptoms(21, 22) and (iv)  response to anti-depressants 
has been associated with reductions in inflammatory biomarkers (16, 23). 
Taken together, these data provide convincing evidence that the immune system 
plays an important role in depressive disorders, although the mechanisms 
underlying this remain to be fully elucidated. The sickness behaviour hypothesis 
of depression proposes that sickness behaviours, manifested in response to 
immune alterations, may drive an underlying phenotype that predisposes to 
depressive disorder. 
Understanding the mechanisms that underlie the behavioural alterations of 
depressive disorder requires an appropriate model that can investigate these 
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responses and relate the findings back to human physiology. While it is 
impossible to accurately model human depression in a rodent, it is possible to 
aim to emulate aspects of inflammatory and psychological biology.  
Peripheral-central inflammatory models use a peripheral immune stimulus to 
examine the effects of peripheral inflammation on the central nervous system 
(CNS) and are commonly used to study the relationship between inflammation 
and CNS responses. One model that has been used previously to study this 
relationship within our laboratory is the Aldara model of psoriasiform 
inflammation (24, 25). This model uses Aldara cream as a topical dermatological 
immune stimulus that results not only in inflammatory changes within the brain 
but also changes in wellbeing as measured by burrowing in mice. Aldara cream 
generates a response through toll-like receptor (TLR) 7 agonism, a receptor that 
detects viral single stranded  ribonucleic acids (ssRNAs), and it is being 
investigated as an alternative to existing models of peripheral-central 
inflammation.  
Chemokines, or chemotactic cytokines, are known to be key regulators of 
immune cell infiltration and retention (26, 27). In addition, chemokines have 
important roles in development (28, 29) and are increasingly implicated in other 
CNS functions associated with behavioural change such as neurogenesis, 
hypothalamic-pituitary axis (HPA) function and neurotransmitter regulation (30-
32). The dual function of chemokines as modulators of both CNS and immune 
function makes them attractive candidates for study, particularly as they are not 
well characterised within the CNS. 
In summary, depressive disorders are a major burden on the health of 
populations around the globe. Ongoing research provides strong evidence for a 
link between the immune system and depressive illness, however the 
mechanisms that underlie this relationship are still incompletely understood. 
Given their role in co-ordinating immune responses and their increasing links to 
CNS biology the chemokine family of molecules provide an attractive candidate 
for study in the field of psychoneuroimmunology. 
The work presented in this thesis initially investigates the relevance of 
chemokine responses in human depression through a meta-analysis of the human 
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literature in this area. Alongside this, the Aldara model of psoriasiform 
inflammation was further characterised and validated with a particular focus on 
chemokine responses. This involved assays of chemokine expression in the 
peripheral tissues and CNS. As chemokines are strongly linked to cellular 
migration, it also examined changes in cellular populations associated with 
changes in chemokine expression. An overview of relevant areas of immunology 
and neuroscience, alongside key findings from related research is provided in the 
following sections in order to place the original work presented in this thesis in 
context. 
1.2 Immune System 
1.1.1 Overview 
The immune system is present throughout all organs of the body, although its 
precise function varies between tissues. It consists of a variety of cells that are 
responsible for normal immune homeostasis and response to inflammatory 
insults(33). In addition, many components of what is classically considered the 
immune system, appear to play important roles in non-inflammatory contexts, 
particularly within the CNS (34, 35). 
Anatomically, the immune system can be subdivided into primary and secondary 
lymphoid organs. The primary lymphoid organs are the bone marrow, where 
many immune cells are generated, and the thymus, where T cells mature. The 
secondary lymphoid organs are the lymph nodes, where antigen can be 
presented to B and T cells by antigen-presenting cells (APCs) to activate them 
and generate an immune response, and the spleen wherein the blood can be 
surveilled and white cells removed from the circulation when required.  
Lymphoid nodules are smaller sites of immune organization and include the 
tonsils, mucosa-associated lymphoid tissue and bronchus-associated lymphoid 
tissue. Finally, a system of lymphatic ducts and vessels drain lymph from tissues 
to the lymph nodes prior to re-absorption into the circulation(33). 
In normal physiological states the immune system is relatively quiescent, 
circulating white cells are minimal(36) and its primary functions are the 
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maintenance of immune homeostasis and surveillance of body tissues for 
pathological insults. 
In pathological states the immune system becomes activated through a variety of 
mechanisms including automatic recognition of damage- or pathogen-associated 
molecular patterns (DAMPs or PAMPs), or recognition of previously encountered 
antigenic motifs by memory T cells(33). Once activated, feed-forward pathways 
generate massive responses that, if uncontrolled, can rapidly become 
pathological in themselves(33, 37, 38). 
Immune responses are generally considered to be biphasic with the initial rapid 
and automatic activation of innate immunity being followed by a slower but 
more targeted adaptive response(33, 39). In addition, a final important stage of 
a normal immune response is resolution of the inflammatory state and a return 
to physiological immune homeostasis(40, 41). 
1.1.2 Innate Immunity and TLRs 
The innate immune system is the body’s first line of defence against immune 
insults such as wounds, pathogens and other noxious stimuli once barrier 
defences such as the skin have been breached. It primarily relies on pattern 
recognition receptors (PRRs), which include TLRs, RIG-I like receptors, NOD-like 
receptors and C-type lectin receptors(42). Another important component of the 
innate immune system is complement. These small circulating proteins can bind 
to bacterial surfaces and once bound they can either opsonize the surface to 
allow for efficient phagocytosis or they can attack the cell directly through the 
formation of membrane attack complexes that perforate the cell membrane(33). 
As the focus of this thesis is on work with a TLR7 agonist, the focus of the next 
section here is on the role and function of TLRs, and more specifically TLR7, 
within the innate immune system. 
PRRs are expressed by a variety of cells of the immune system including 
macrophages (resident tissue monocytes) and microglia (resident CNS immune 
cell). The TLR family of PRRs detects conserved molecular motifs that are 
associated with bacterial, viral, protozoal and fungal infection. Examples include 
TLR4, that detects lipopolysaccharide (LPS), a component of bacterial cell walls, 
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and other pathogenic proteins, TLR3 that detects double stranded ribonucleic 
acid (RNA) from viruses and TLR7 that detects ssRNA from viruses(42). 
Once TLRs are activated a cascade of downstream signalling occurs, initiated by 
the adaptor proteins TIR-domain-containing adaptor protein inducing IFN- 
(TRIF) and/or myeloid differentiation primary response gene 88 (MYD88) 
depending on the TLR. For example, TLR3 uses TRIF, TLR7 uses MYD88 and TLR4 
uses both adaptor proteins. These adaptor proteins initiate protein kinase 
pathways that generate IFN regulatory factor (IRF) and nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-B) responses(43) (Figure 1.1). 
 
Figure 1.1: Simplified TLR Signalling Overview 
Engagement of TLR receptors initiates signalling pathways from adaptor proteins TRIF and/or 
MYD88. Through the action of protein kinases these signalling pathways initiate IRF and NF-κB 
signalling that results in the production of ISGs and inflammatory cytokines respectively. 
Abbreviations: TLR – Toll-like receptor; MYD88 -  Myeloid differentiation primary response gene 
88; TIRAP – Toll-interleukin 1 receptor domain containing adaptor protein; TRIF – TIR-domain-
containing adapter-inducing interferon-β; IRF – Interferon regulatory factor; NF-κB – nuclear factor 
kappa-light-chain-enhancer of activated B cells; ISG – Interferon stimulated gene. Adapted from 
(25, 44, 45) 
IRF activation generates type-1/2 IFN responses(46) (Interferon-alpha (IFN)/ 
Interferon-beta (IFN)/Interferon-gamma (IFNγ)) characterised by IFN stimulated 
gene (ISG) induction, including several chemokines, most notably Cxcl9, Cxcl10 
and Cxcl11(47, 48). NF-B activation generates pro-inflammatory cytokine 
responses that include interleukin-1 beta (Il-1), interleukin-6 (Il-6) and tumor 
Chapter 1 28 
 
necrosis factor alpha (TNF)(49). In addition, NF-B can induce expression of the 
anti-inflammatory cytokine interleukin-10 (Il-10)(49).  
Another important effect of TLR signalling is induction of the NOD-like receptor 
family pyrin domain containing 3 (NLRP3) inflammasome(50). Downstream of NF-
B signalling, there is an increase in the expression of inactive NLRP3 protein, 
TLR signalling activates NLRP3 through de-ubiquitination. Once active NLRP3 
inflammasomes activate pro-caspase-1 to its active form caspase-1. This enzyme 
can then proteolytically cleave inflammatory proteins to their active form, for 
example cleaving pro-Il-1 to Il-1(51, 52). The tight regulation of this 
inflammation-promoting molecule, as demonstrated through not only its low 
constitutive expression but its production in an inactive form, provides an 
example of the complex mechanisms of control used by the immune system. 
Initiation of these molecular pathways leads to a variety of changes that 
promote cellular recruitment and immune activation. For example, upregulation 
of adhesion molecules and chemokines promotes cellular infiltration(26, 27, 33, 
53) while pro-inflammatory cytokines can induce both local changes such as 
vasodilation(54) and systemic changes such as fever and fatigue(9).  
Alongside resident macrophages, two other phagocytic cell types are key to 
innate immunity, particularly in the context of TLR activation; neutrophils and 
dendritic cells (DCs)(33). Neutrophils are rapidly recruited to inflamed tissues in 
response to TLR activation(55, 56) and can phagocytose target cells and 
bacteria, as well as releasing toxic granules into the surrounding tissue. DCs are 
APCs that migrate to draining lymph nodes. Once TLR signalling is initiated, 
CCR7 becomes upregulated(57), allowing DCs to respond to CCL19 and CCL21 in 
lymphatic vessels, interstitium and high endothelial venules (58). Subsequent 
CCR7 dependent migration to lymph nodes is often considered as the junction 
between innate and adaptive immunity as once DCs present antigen within the 
lymph node the adaptive immune system is engaged.  
Other cells of the innate immune system include natural killer (NK) cells and 
gamma/delta T cells. Natural killer cells are thought to play key roles in control 
of cancer development and defence against viral infections. They have two 
primary effector functions, firstly they can employ cytotoxic activity against 
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virus infected or tumor cells and secondly they can produce robust cytokine 
responses following activation (59, 60) NK cells use complex signalling 
mechanisms that balance both inhibitory (e.g. major histocompatibility complex 
(MHC)-class I) and excitatory (e.g. natural killer NKG2D ligands) stimuli (59, 60). 
Evidence for NK cell activation by TLRs appears significant. However, whether 
this is by indirect or both direct and indirect mechanisms is unclear. Despite 
this, it is clear that type I interferon signalling is a key pathway in NK activation. 
There is now reasonable evidence that for TLR7-mediated activation, accessory 
cells providing additional signals, such as Il-12 or IFN are required for full 
cytotoxic capabilities(61, 62). NK cells produce significant amounts of IFNy when 
in the presence of Il-12(61), and have also been shown to be producers of CCL3, 
CCL4 and CCL5 in response to the TLR7 agonist loxiribine in conjunction with Il-
12(63). In addition, mast cells, basophils and eosinophils form part of the innate 
immune system. However, they are generally associated with atopic reactions or 
parasitic infections. 
Recent developments in the study of innate immunity have shown that it is not 
as generalizable as previously thought and there may be some elements of 
memory involved. Innate immune memory appears to be mediated through a 
variety of mechanisms but epigenetic modifications and metabolic-
immunological interactions appear to be key(64). One of the simplest examples 
of innate memory is the process of tolerance, whereby pre-stimulation with 
lower doses of PAMPs can “tolerise” the immune system and ameliorate 
subsequent responses to larger stimuli of the same PAMP(65, 66). This process is 
particularly well characterised for the TLR4 agonist LPS. 
1.1.3 Adaptive Immunity 
The innate immune system is the primary focus of this thesis. However because 
of the complex nature of immune responses and the blurred line between innate 
and adaptive immunity it is worth also briefly reviewing the adaptive immune 
response. This is particularly true for early events of adaptive immunity such as 
the recruitment of T cells to sites of immune insult or injury.  
The adaptive immune system is a second line of immune defence that aims to 
mobilise specific defences against antigens if the innate immune system cannot 
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effectively clear an insult. Once APCs of the innate immune system reach the 
lymph nodes, they present antigen via MHC and co-stimulatory molecules to 
enable the activation of B and T cells(33). TLR activation in APCs, particularly 
DCs, promotes delivery of antigen to MHC(67) and upregulation of co-stimulatory 
molecules(68, 69) that are required for full activation of adaptive immune cells. 
Adaptive immunity is generally considered to be specific as, once presented with 
antigen, only those cells that have an ability to bind it will become activated 
and leave the lymph node to travel to sites of immune insult. Following 
activation via APCs, B cells can go on to become short-lived plasmablasts, that 
produce large amounts of circulating antibody, or longer-lived memory and 
plasma B cells. T cells can become a variety of different subclasses including 
CD4+ T-Helper (Th) cells, CD8+ cytotoxic T lymphocytes (CTLs), regulatory or 
suppressor T cells and memory T cells. Respectively, these cells act to co-
ordinate and promote immune responses, lyse and apoptose infected cells, 
prevent excessive immune reactions and remember foreign antigen to enable 
rapid immune mobilisation in the case of re-exposure(33). 
Once activated, a variety of signalling and other molecules act to direct these 
cells to sites of immune insult. These molecules include chemokines, 
leukotrienes and adhesion molecules that coordinate cellular arrest within the 
vasculature and subsequent migration through tissue parenchyma(26, 27, 53). 
Upon arrival at sites of interest these cells can execute their effector functions, 
which aim to clear immune insults and generate resolution of the inflammatory 
process. 
1.1.4 Inflammatory regulation and resolution 
Inflammatory resolution is a critical part of any immune response. It begins the 
moment an inflammatory insult is encountered and the innate immune system is 
engaged and continues until normal immune homeostasis is restored. Ongoing 
equilibrium between pro- and anti-inflammatory mechanisms drive inflammatory 
reactions, and aims to prevent excessive tissue damage and cellular death due 
to uncontrolled responses(40, 41). 
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Release of anti-inflammatory mediators such as Il-10(70, 71), and pro-resolution 
factors such as lipoxins, resolvins and protectins(72), are one mechanism for the 
control of these responses. Another resolutory mechanism is the role of 
macrophages and other phagocytes in clearing apoptotic leukocytes from 
tissue(73), a process known as efferocytosis. A recent study in CXCR2-/- mice 
provided strong evidence for macrophage interactions with apoptotic neutrophils 
as being an important step in the generation of anti-inflammatory mediators and 
the subsequent resolution of inflammation(74). Efferocytosis induces phenotypic 
switching, characterised by raised levels of mediators associated with resolution 
such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase(75). 
Atypical chemokine receptors (ACKRs) such as ACKR2 also appear to play a role 
in immune regulation, with ACKR2 deficient mice displaying exaggerated 
inflammatory responses in a variety of contexts(76, 77). This effect appears to 
be due to the role of ACKRs in scavenging chemokine molecules and limiting 
their signalling potential(76). While not exhaustive these examples provide 
significant evidence for the active nature of inflammatory regulation and 
resolution. 
Of interest, the brain appears to have challenges fully resolving some 
inflammatory insults. Two examples of this within the human population are 
Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE). In AD 
pathogenic proteins such as amyloid and tau are implicated in a chronic 
neurodegeneration that appears to be accompanied by an inflammatory 
pathology and an inability to clear these accumulating proteins. These proteins 
have the ability to trigger innate immune responses through PRRs and recent 
evidence suggests that the ongoing inflammation contributes to the pathology of 
AD(78, 79). CTE describes a condition that results from brain injury, originally 
described in boxers as dementia pugilistica. It has now been identified in 
athletes engaging in other high impact sports such as American football and 
those who have suffered from a traumatic brain injury. Inflammation is 
increasingly recognised as being associated with CTE and while some animal 
models have identified mechanistic links it is unclear whether it is a cause or 
consequence(80). In addition to these two human conditions, Qin et al. have 
identified altered immune responses within the CNS at up to 10 months post-
endotoxin exposure in an animal model, this work will be discussed in more 
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detail later(81). Overall these data suggest that mechanisms of inflammatory 
resolution within the CNS may be different when compared to the periphery, 
although the reasons for this remain to be elucidated. 
In summary, the innate and adaptive immune systems work together to initiate, 
co-ordinate and resolve inflammatory reactions and immune insults. A multitude 
of signalling pathways, molecules and cellular types can be rapidly engaged over 
time-courses spanning minutes to days to co-ordinate and fine-tune these 
responses. Specific relevant aspects of these pathways will be discussed below. 
1.1.5 Cytokines 
Cytokines are a broad class of cell signalling molecules that can act in an 
autocrine, juxtacrine, paracrine and/or endocrine manner and interact with 
their cognate receptors to alter cellular function. IFNs and interleukins are 
major classes of cytokines that drive many cellular responses. As the work 
discussed in this thesis examines the Type I/II IFN response and a limited number 
of other cytokines, these will be the focus of this section.  Chemokines, another 
large class of cytokine molecules specifically associated with chemotaxis, are 
discussed in more detail in the subsequent section as they are a primary focus of 
this thesis. 
Type I IFNs include, but are not limited to, IFN- and IFN-. These high-level 
signalling molecules are associated with antiviral responses but also play a role 
in response to bacterial infection as demonstrated by their induction in the 
presence of LPS, a bacterial cell wall component. Honda et al. demonstrated 
that IRF7, an IRF downstream of both TRIF and MYD88 is a key regulator of type-I 
IFN responses, and that many inflammatory gene responses are abrogated in 
IRF7-/- mice(82). In this study a lack of IFN induction resulted in an increased 
mortality in IRF7-/- mice exposed to viral infection, strongly supporting the 
theory that these responses are critical to effective immunity. 
Upon induction, Type I IFNs act to sustain and promote inflammatory responses, 
signalling through the interferon alpha/beta receptor (IFNAR) complex 
(IFNAR1/IFNAR2 heterodimer) (83). IFNAR signalling results in activation of many 
different molecular pathways, with microarray studies and data compilations 
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showing upregulation of over 1000 genes in response to IFN signalling (84, 85). 
Despite IFN-signalling appearing to be a key pathway shared between TLRs, 
IFNAR is not critical to the expression of major pro-inflammatory cytokines(86). 
This is probably because TLR signalling pathways also induce NF-B responses 
that drive the induction of the cytokines Il-1β, Il-6 and TNF, independent of 
IFNAR signalling. In addition to type I IFNs there is a single type II IFN, IFN, that 
can also be secreted downstream of TLR signalling(87). One of the main 
functions of IFN is to potentiate the action of macrophages(88, 89). 
The pro-inflammatory cytokines Il-1, Il-6 and TNF have both shared and 
unique features. They can be produced by a wide variety of cells, primarily 
through activation of the NF-B pathway. These cytokines are pleiotropic, with 
their exact function dependent on the inflammatory context in which they are 
produced. Despite, their general designation as pro-inflammatory, both TNFα 
and Il-6 have immunoregulatory and anti-inflammatory properties(90, 91). Il-1 
signals through the MYD88 pathway similar to some TLRs, Il-6 signals through its 
own receptor linked to the gp130 signalling receptor and TNF can signal through 
either TNF receptor (TNFR) 1, a ubiquitous receptor, or TNFR2, whose 
expression is restricted to a handful of different cell types. 
The full cascade of signalling events generates many downstream alterations. 
Both TNF and Il-1 promote NF-B signalling, showing evidence of positive 
feedback loops. However, there is some evidence they can also induce their own 
negative feedback loops. Examples include degradation or internalisation of 
TNFRs in response to TNF(92) and induction of interleukin-1 receptor antagonist 
(Il-1Ra) in response to Il-1 (93). Il6 can possibly inhibit the induction and 
actions of Il-1 and TNF (90, 94), while through production of soluble Il-6 
receptor (sIl-6R) it increases its own half-life and bioavailability (90) .  
Functionally these signalling events act to promote immune cell function through 
encouraging T and B cell activation and proliferation, induce the production of 
further inflammatory molecules such as chemokines, and promote the 
sustenance of inflammatory processes through various feedback loops.  
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Il-10, one of the most potent anti-inflammatory cytokines is produced by several 
immune cells including macrophages and DCs of the innate immune system and 
both B and T cells of the adaptive immune system(95). In innate immune cells, 
activation of extracellular signal-regulated kinases, downstream of TLR ligation, 
promotes Il-10 production(95). Studies have shown that absence of Il-10 during 
infection can result in an increased production of pro-inflammatory cytokines 
that is associated with a more severe immunopathology, although it can enhance 
bacterial and viral clearance(96). 
In summary, cytokine signalling is a balance of pro- and anti-inflammatory 
signals mediated by a variety of highly pleiotropic and overlapping mediators. 
The downstream effects of this signalling aim to simultaneously promote and 
restrain production of inflammatory mediators, activate and inhibit immune cell 
function and differentiation, and exert both positive and negative feedback on 
the original signal. As demonstrated by the dysfunction observed in cytokine 
knockout (KO) models, it is evident that induction of cytokine signalling is a key 
step in producing a co-ordinated, effective and resolvable inflammatory 
response.  
1.1.6 Chemokines 
Chemokines, originally named for their role as chemotactic cytokines are key to 
cell migration and homing during homeostasis, inflammation and development. 
In addition, since these first functional roles were discovered they have been 
shown to be involved in several other systems including angiogenesis (97, 98), 
neuroendocrine function (99, 100), neuromodulation (32, 101-103), neurogenesis 
(30, 104, 105), and tumorigenesis and metastasis (106, 107). Chemokines are 
structurally defined by their conserved cysteine motifs and signal through a 
group of 7 transmembrane G-protein coupled receptors (GPCRs). Four major 
classes of chemokines exist CC, CXC, CX3C and XC based on the cysteine residues 
present at their amino terminus and any intermediate amino acids (Figure 1.2). 
The CX3C group has only 1 member, CX3CL1 that plays an important role in 
neuron-microglia crosstalk and homeostasis within the CNS (105, 108). It is one 
of only 2 chemokines that exists in both a transmembrane and secreted form, 
the other being CXCL16 (109, 110).  
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Figure 1.2: Chemokine ligand structure 
Schematic detailing the basic structure of the chemokine ligands that are defined on the basis of 
conserved cysteine motifs present at the N-terminus of the chemokine polypeptide chain. Naming 
is based on both the number of cysteines and spacing between them. 
As previously mentioned, apart from the classical chemokine ligands and 
receptors, a family of ACKRs also exist. These are ACKR1-4 and they are 
primarily thought to act as non-signalling scavengers that help maintain immune 
homeostasis and prevent excessive immune reactions by internalising 
inflammatory chemokine ligands (77). These receptors are classified as atypical, 
due to their inability to initiate classical signalling pathways through G-protein 
receptor signalling. 
One feature of chemokines is that ligands can often bind multiple receptors, 
CCL5 can bind CCR1/3/5, and receptors can bind multiple ligands, CCR5 can bind 
CCL3/4/5/11 and other chemokine ligands(29). This promiscuity leads to a high 
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level of redundancy within the system. However, how much of this redundancy is 
true redundancy remains to be elucidated. For example, although CCL19 and 
CCL21 both bind CCR7 they can induce different downstream responses (111, 
112). This signalling bias in chemokine receptors is a relatively novel area of 
research and the full extent of the bias and its functional implications remain to 
be determined. Multiple lines of evidence suggest that induction of inflammatory 
chemokine ligands occurs downstream of both NF-B signalling and IFN signalling 
(49, 84, 113-116) that are characteristic of TLR activation.  
Functionally, chemokines have been implicated in multiple systems as discussed 
earlier and their potential roles in the CNS will be detailed later in this chapter. 
Here, only their role as chemotactic molecules in the context of inflammatory 
pathology will be discussed. Chemokines can attract a variety of different 
immune cells and upon receiving a chemokine signal cells undergo structural 
changes that aid cellular migration(117-120). These changes are linked to 
alterations in the cytoskeleton based on areas of higher chemokine 
concentration. It has been suggested through in vitro work that chemokine 
gradients are important for the migration and directionality of immune cells(58), 
and recent in vivo work by Lim et al. has suggested that neutrophil migration 
may be guided through trails of chemokines that are left within tissue 
parenchyma (121). 
Generally, chemokines are associated with the attraction of specific cell types, 
for example CCL5 and CXCL10 are strongly associated with T-cell migration 
through CCR5 and CXCR3 signalling respectively (122, 123), and the CCL2-CCR2 
axis is important in monocyte trafficking(124, 125). Further evidence of the 
promiscuity and redundancy of this system is demonstrated by the fact that 
CCL5 also appears to be able to attract monocytes (124, 125). As well as acting 
as inducers of cellular migration, chemokine ligand-receptor interactions are 
also responsible for homeostatic immune mechanisms. The CXCL12-CXCR4 axis is 
critical to the maintenance of haematopoietic stem cells within the bone 
marrow(126) and data suggests that down-regulation of CXCR4 allows egress of 
neutrophils, and possibly other leukocytes, to the circulation(127-129). The 
critical nature of CXCL12-CXCR4 in development is demonstrated by the 
perinatal lethality of CXCR4 and CXCL12 KO (130, 131). 
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An interesting area of development in chemokine biology is the idea of specific 
molecular “postcodes”. This concept suggests the need for cells of the immune 
system to have mechanisms for homeostatic trafficking and identification of 
sites of inflammation. This allows cells to both migrate to appropriate locations 
and to enact an appropriate response. The most compelling example of this is 
the CCL19/21-CCR7 axis that drives DC migration to the lymph nodes(58, 132). 
Alongside this, evidence also suggests that CCR4-CCL17 and CCR10-CCL27 are 
important in skin homing (133, 134), and CCR9-CCL25 are important for homing 
to the gut(135, 136). For the CNS the CCR6-CCL20 axis has been implicated in 
both humans(137) and mice(138, 139), and there is some evidence CXCR3-
CXCL10 may also be important in homing of leukocytes to the CNS and specific 
areas within it(139, 140). 
Overall the chemokine family is a structurally defined set of ligands that signals 
through GPCRs. They have diverse functions, not just in inflammatory contexts, 
but also in a variety of physiological and pathological states, including 
developmental processes. 
1.1.7 Cellular functions of the immune system 
Cells of the immune system are generally classified into innate immune cells; 
monocytes/macrophages, neutrophils, DCs, NK cells, eosinophils, basophils, mast 
cells and T cells, and adaptive immune cells; B and T cells. When looking at a 
conceptual overview of the immune system, it is worth considering the functions 
that immune cells fulfil. One primary function of all immune cells is 
immunological support either through cell-cell interaction or release of 
inflammatory mediators. The release of inflammatory mediators such as IFNs, 
cytokines and chemokines alters cellular functions through receptor-mediated 
alterations in transcriptional regulation as discussed above. Cell-cell interactions 
can promote activation of immune cells through antigen presentation and co-
stimulatory molecules, as described for DCs and T cells of the lymph node. Cell-
cell interactions can also involve engagement of Fas ligand to Fas receptor that 
induces apoptosis(141, 142), although this is primarily thought to be important in 
T cell homeostasis rather than acute inflammatory reactions. Another important 
example of cell-cell interactions is in immune cell-endothelial cell interactions, 
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where adhesion molecules expressed by vascular endothelium allow migrating 
immune cells to slow and adhere to endothelium before diapedesis occurs(33). 
While nearly all immune cells provide immunological support in some form, Th 
cells are unique in that this appears to be their primary function. Depending on 
the inflammatory environment Th cells can take on different lineages, including 
Th1, Th2 and Th17. In the context of TLR activation, CD4+ Th cells are thought to 
be driven towards the Th1 lineage, through DC derived Il-12 (143). More recent 
evidence suggests that this response may be differential depending on both the 
TLR activated and the extent of activation(144). TLR responses and Th1 
responses also appear to be a key step in the activation of NK cells by DCs (145). 
Neutrophils, monocytes/macrophages and DCs are all phagocytic cells of the 
immune system. Phagocytosis is a critical immune function that serves two 
purposes. Firstly, it allows APCs to scavenge and subsequently process antigens 
from the tissue environment and present them to other immune cells (146, 147). 
Secondly it allows for direct ingestion of bacteria followed by degradation using 
phagolysosomes (148). Phagocytosis occurs in DCs for the purposes of antigen 
presentation, neutrophils for intracellular destruction and macrophages for both 
antigen presentation and internal degradation. As discussed earlier macrophage 
phagocytosis also plays a role in inflammatory resolution through the uptake of 
apoptotic leukocytes. 
Neutrophils and macrophages can also release reactive oxygen species (ROS) into 
the surrounding tissue in what is known as a respiratory burst (149). These ROS 
can directly kill bacteria they encounter aiding the immune response, however 
they can also damage host cells and tissue, highlighting the need for controlled 
inflammatory responses. Alongside ROS other factors can be released into the 
tissue to damage bacterial cells and inhibit viral replication, these include the 
perforins and granzymes expressed by NK cells and CTLs(150) and, neutrophils 
can also undergo degranulation that releases a variety of antimicrobial 
peptides(151). 
Other cells of the immune system promote other responses; however, these are 
generally less related to TLR, anti-bacterial and anti-viral immunobiology. The 
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effector functions listed above demonstrate the diverse strategies the immune 
system can employ to combat foreign invaders. 
1.1.8 Summary 
Upregulation of cytokines, including chemokines, in response to stimuli are key 
early events in any immunological response and the subsequent activation and 
migration of diverse cell populations is critical to the resolution of inflammatory 
insults. The precise response to any insult is guided by molecular patterns and 
antigens that are encountered, and the nature of the insult itself. Co-ordinated 
immune responses utilise a variety of tools to combat the invader and if 
sustained provide immunological memory that allows for a rapid and effective 
response to future invasion. As discussed, in the context of TLR activation, NF-kB 
and IRFs drive transcriptional changes that promote antiviral and antibacterial 
immune responses. In addition, lack of co-ordinated immune responses with 
appropriate mechanisms for both positive- and negative-feedback can 
potentially fail to resolve resulting in ongoing inflammatory pathology in the 
absence of stimulus. 
The immune system is a highly complex system that has been extensively studied 
in a wide variety of contexts. The whole field of immunological knowledge is 
well beyond the scope of this Thesis. Despite this, I hope that the introduction 
to several key concepts and some specific aspects of immunity detailed above 
provides an appropriate context for approaching the work put forward in later 
chapters and demonstrates the functional relevance of those molecules and cells 
that are investigated. 
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1.3 Central Nervous System Immunity 
1.1.9 CNS Overview 
The CNS is composed of the brain and spinal cord. Its primary function is to 
integrate information transferred to it from the peripheral nervous system and 
environment, process this information and then relay responses back to the 
periphery. The processing of this information can be rapid and automatic such as 
in motor reflexes, or complex and conscious as is the case for higher brain 
functions such as problem solving. 
Anatomically the brain itself has been the subject of many different subdivisions 
based on function and/or anatomical criteria. Broadly speaking there are three 
main areas of the brain, the cerebellum, brainstem and cerebrum. In addition, 
the brain has a series of ventricles through which the cerebrospinal fluid (CSF), 
produced at the choroid plexus, flows before being reabsorbed into the vascular 
and lymphatic circulation(152, 153). The CSF acts as a both a mechanical and 
chemical buffer. Mechanically it acts to prevent pressure on the brain and 
provide buoyancy and chemically it acts as a system through which waste 
products and toxins can be removed (154, 155). The brain and spinal cord are 
also lined by three meningeal layers, the pia, arachnoid and dura mater and CSF 
flows between pia and arachnoid mater in the subarachnoid space after leaving 
the ventricular system of the brain. 
The CNS consists of neurons, the processing units of the brain that transfer 
electrical and chemical signals between each other through their synaptic 
connections, and non-neuronal cells. The non-neuronal cell population primarily 
consists of microglia, astrocytes, oligodendrocytes, radial glia and ependymal 
cells, a group of cells collectively known as glia (156, 157). Alongside the glial 
cells there are also endothelial cells, pericytes, epithelial cells and small 
numbers of peripheral immune cells present(158, 159). The endothelial cells of 
the CNS, along with astrocytes and pericytes form the blood-brain-barrier (BBB) 
a specialized barrier that helps maintain CNS homeostasis and, which is an 
important part of CNS immune control(158, 160). 
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This thesis will focus on the inflammatory molecules that are induced, 
particularly chemokines, and the cells that are recruited to and activated in the 
brain in response to inflammatory stimuli. The following sections will provide an 
overview of the cells present within the CNS and the immune reactions that 
occur within the CNS in response to inflammation. 
1.1.10 Cells of the CNS 
Given the multitude of cell types present within the CNS this section will 
primarily focus on microglia and astrocytes, as they are involved in immune 
function, and neurons, as they are involved in CNS function. Microglia are the 
resident immune cells of the CNS and astrocytes, while long considered to be 
relatively inert and mainly supportive in function, have become increasingly 
implicated in immune responses in recent years(161, 162). 
Microglia are resident immune cells that can be broadly considered as the 
macrophages of the brain. They are derived from the yolk sac early in 
embryogenesis, and there appears to be only a limited, if any, capacity for 
replacement through haematopoiesis (163). Activated microglia have historically 
been phenotypically subdivided into pro-inflammatory demyelinating ‘classically 
activated’ M1 microglia or pro-resolving remyelinating M2 microglia (164, 165), 
similar to macrophages of the peripheral tissues. Recently this dichotomisation 
has been challenged, and it is likely that microglia are highly plastic and exist on 
a continuous spectrum (166, 167). 
Despite this changing perspective, TLR responses in microglia are associated with 
inflammatory cytokine production that would previously be considered as 
characteristic of an M1 response (168-170). In addition, microglia clearly react to 
LPS stimulation and undergo reactive changes(171). The most characteristic 
change seen in activated microglia is morphological. Although opinion is divided 
prevailing theories suggest that, at first, as microglia attempt to survey the 
surrounding area and react to stimuli there is an increase in the number of 
ramified processes, also known as “hyper-ramification”. Once fully “activated” 
it is thought that microglia take on an amoeboid morphology(172). However it is 
likely that microglia are plastic and can change both their phenotype and their 
morphology depending on the precise environmental context(167). 
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Alongside their roles in immunity microglia also play key roles in synaptic 
development and in maintenance of neuronal homeostasis. Complement 
molecules of the immune system help guide synaptic pruning by microglia 
throughout development and adulthood (173, 174) and CX3CL1-CX3CR1 
interactions are key to neuronal survival and modulation of neurotoxicity(105, 
108). 
Astrocytes are key supportive cells in the CNS, they support the BBB through the 
encirclement of vessels with astrocytic end feet that allow for bidirectional 
interactions between astrocyte and endothelium(158). These interactions allow 
for modulation of BBB properties, including permeability and transport 
mechanisms, by astrocytes. In addition to their role at the BBB there is also 
evidence for their role at synaptic junctions. Tripartite synapses describe the 
three-piece suite of a pre-synaptic neuron, post-synaptic neuron and an 
astrocyte (175). The astrocyte acts to scavenge excess neurotransmitter and 
modulate synaptic properties. An example of this is the ability of astrocytes to 
take up glutamate from the synapse and thereby limit excitotoxicity (176). 
Alongside their supportive roles, astrocytes also participate in CNS immune 
function, they express a variety of TLRs, the IFNAR receptor and a variety of 
cytokine and chemokine receptors (177-181). In response to immune stimuli they 
have been shown to produce inflammatory mediators (179, 182) and undergo 
reactive changes characterised by increased expression of glial fibrillary acidic 
protein (GFAP) (183, 184).  
As we are interested in innate immune responses downstream of TLR signalling 
and particularly the chemokine response to this, it is interesting to note that 
there is evidence that both microglia and astrocytes express not only TLRs but a 
variety of chemokine receptors. In vitro work established that both microglia 
and astrocytes express CCR3-6 and CXCR1-5 at rest (177), with microglia 
expressing higher levels of CCR3 and CXCR3. It is interesting to note that in this 
study microglia, but not astrocytes, could readily migrate in response to CXCL10, 
probably mediated through CXCR3. Despite this, both TNFα and IFNγ significantly 
increased expression of CXCR3 in astrocytes, and stimulation with specific 
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concentrations of CXCL10 was able to promote astrocyte proliferation, 
implicating CXCL10-CXCR3 as having a role in astrogliosis. 
Neuronal cells of the CNS communicate through both direct electrical 
connections and the chemical release of neurotransmitters, although, direct 
electrical communication is rarer within the mammalian CNS(153). 
Neurotransmitters are the most common form of neuron-neuron communication. 
Once an electrical signal has reached the axon terminal of a neuron, vesicles 
release neurotransmitter from the pre-synaptic neuron, into the synaptic cleft. 
The neurotransmitter then binds to the postsynaptic neuron, either inhibiting or 
promoting activation of an electrical impulse. Neurotransmitters are often 
associated with specific psychological functions, for example dopamine is the 
neurotransmitter characteristic of reward pathways whereas serotonin is 
associated with mood(153). Many different molecules, as well as other neurons 
of the brain can influence the release of neurotransmitters from neurons and 
alter their electrical excitability. 
Neurons are generally considered to be non-replenishing cells, and death of 
neurons usually results in permanent loss that often causes functional deficits. 
While pre-natal and early life neurogenesis has clear developmental functions, 
there now appears to be a role for neuronal replenishment through ongoing 
neurogenesis in adults. However, this has been most extensively characterised 
for olfactory neurons in rodents (185) and, while there is strong evidence for 
ongoing neurogenesis in adult humans as well (186, 187), its functional purpose 
is equivocal. Despite this, some evidence suggests it plays a role in learning and 
memory (185). Despite these unknowns, reductions in hippocampal volume, 
thought to be due to decreased neurogenesis, are present in depressed 
populations (188-190) and increased neurogenesis has been implicated in the 
function of antidepressants (191-193). 
Like microglia and astrocytes, neurons can also express TLRs and chemokine 
receptors. While there is a clear role for chemokine receptors, particularly 
CXCL12/CXCR4, during neuronal development and guidance (194, 195), their role 
in the adult CNS is less well defined. Recent studies have demonstrated that 
chemokines may be able to modulate neuronal function, for example, in vitro 
electrophysiology demonstrated alterations in serotonergic neurons modulated 
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by CCL2 and CXCL10(102, 103). In addition, CCL2 appears to be important during 
pain sensitisation in animal models (196, 197). 
In summary astrocytes, microglia and neurons have overlapping functions within 
the CNS. Interactions between these cell types help maintain normal CNS 
function and allow for modulation of a variety of parameters in response to 
pathology. In addition, expression of TLRs and chemokine receptors by 
microglia, astrocytes and to some extent neurons, highlights the need for an 
understanding of the role they play in innate immune responses and CNS 
function. 
1.1.11 Immune “Privilege” in the CNS 
Due to the specialised barriers present in the CNS alongside the limited number 
of peripheral immune cells present, the CNS was previously considered to be 
“immune privileged” i.e. to be protected from normal immune reactions. Recent 
developments in CNS immunology suggest that this is not the case and that 
rather than being a site of “immune privilege” like the cornea, the CNS is much 
more likely a place of modified immune function (198-200). Despite this 
changing perspective, there is still a requirement to prevent parenchymal 
damage due to the largely non-replenishing nature of neurons. In addition, the 
swelling and oedema characteristic of inflammatory responses can be fatal 
within the enclosed compartment of the skull, and therefore several mechanisms 
exist to limit immunoreactivity within the CNS. 
One mechanism of protection is the extensive barrier function of the BBB and 
unlike other tissues of the body the capillaries of the CNS have a very limited 
“leakiness”. There is an absence of fenestrations, and nearly complete presence 
of tight junctions preventing easy ingress of many molecules and cells (157, 
201). In addition, while the ependymal cells of the choroid plexus have 
fenestrations and lack tight junctions, the choroid plexus epithelium itself does 
not, forming what is known as the blood-CSF barrier(201). 
Modified immune function is another mechanism through which the CNS is 
protected, this is particularly true for T cell responses. In contrast to peripheral 
tissues, foreign grafts into the CNS survive for longer(202), heat treated bacillus 
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calmette-guérin  injected directly to the CNS attracts monocytes but not T 
cells(203), and T cells specific against CNS antigens fail to initiate immune 
responses if no other stimuli are present(204). Although there is immune 
surveillance of the meningeal compartments lining the brain and a CD4+ T cell 
population in the CSF (159, 205), the parenchyma itself is subjected to very 
limited immune surveillance by T cells. Microglia are able to survey the brain 
parenchyma however they do not detect specific antigens, only conserved motifs 
that can be detected by their PRRs. 
If antigen is introduced to the periphery as well as the CNS, as would be the case 
in most real-world circumstances, the CNS can mount a true response(202) 
probably due to peripheral antigen presentation allowing for the activation and 
proliferation of antigen specific T cells that can then enter the CNS. The lack of 
T cell responses in the CNS is probably due to the lack of DCs in the healthy CNS 
parenchyma (159, 206). As there are no DCs to survey the area, it is unlikely that 
T cells would be presented with the antigen and co-stimulatory molecules 
required for full activation. Whether other cells drain to lymph nodes and 
present antigen is currently unknown.  
Another modification in the CNS, is that there is no lymphatic drainage of the 
parenchyma itself. Recent animal work has shown that there may be lymphatics 
present within the meninges (207), although whether these are present in 
humans as well as mice remains to be established. Despite this the CSF is 
reabsorbed back into the lymph and drains to the cervical lymph nodes (206). 
However, whether APCs can follow this route is unclear. 
In summary, a combination of specialized barriers, altered immune cell 
residency and surveillance, an anti-inflammatory environment and a deficit of 
draining lymphatics appear to be the underlying mechanisms through which the 
CNS displays differences in immune function. One of the main challenges facing 
study of CNS immune responses is the fact that much immunological research 
into peripheral tissues and organs is not clearly translatable to the CNS because 
of the differences in immunity highlighted above. While previously regarded as a 
site of immune “privilege” it is becoming clear that it is not in fact as privileged 
as originally thought and more analogous to an area of modified immune 
function. Original animal studies demonstrating immune privilege and a lack of 
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responses were limited by their use of pathological models that directly 
introduced stimuli to the CNS without peripheral interaction, a situation that 
would rarely be seen in real life. 
1.1.12 Immune Responses to Central Inflammatory Stimuli 
Although immune responses within the CNS have been studied in a variety of 
contexts, the focus of this section will be on viral, bacterial and TLR responses 
within the brain. Generally, these models, utilise either direct injection of 
stimuli intracerebroventricularly (i.c.v) or encephalitic pathogens that home to 
the CNS, for example West Nile Virus (WNV). 
After bacterial or viral invasion into the CNS, microglia can detect their 
presence through PRRs. Signalling through the TLRs generates distinct responses 
including the activation of NF-B and IFN as discussed earlier. One important 
thing to note is that in normal CNS infection, whereby inoculation occurs at a 
peripheral site, the immune system has already encountered the antigen and is 
therefore primed to respond (208). This allows the immune system to mount a 
more effective and prominent T cell response than if it had entered the CNS 
directly, as was the mechanism in some immune privilege studies.  
Viral or bacterial infection of the CNS results in dramatic upregulation of a 
variety of cytokines and chemokines including Il-1, TNF and Il-6 as well as the 
chemokines CCL2, CCL5, and CXCL10 (209-213). Alongside these molecular 
alterations there are changes in the activation state of microglia, death of 
neurons and an influx of peripheral immune cells. For example, in WNV there is 
an influx of both CD4+ and CD8+ T cells(214, 215), NK cells and monocytes(216, 
217). Alongside this, astrocytes and microglia become activated in response to 
the infection (218, 219).  
A number of studies have begun to highlight the role of CNS chemokines in co-
ordinating immune responses. Examples include the role for astrocytic CXCL10 
during viral encephalomyelitis(220), the increased susceptibility of patients with 
the CCR532 mutation to WNV (221) and the reduction in infiltrating monocytes 
seen in both Ccl2-/- and Ccl7-/- mice(222). In addition previous work within our 
laboratory identified upregulation of CCL2, CCL3, CCL5 and CXCL10 among other 
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chemokines in two models of viral encephalitis(213). This study also identified 
the chemokine receptors CXCR3 and CCR2 as being key to CNS inflammation and 
inhibition of these receptors improved host survival. Expression of CXC 
chemokines drives neutrophil infiltration in the JHM strain of mouse hepatitis 
virus (MHV) and aids neuroprotection. A further study of CNS MHV in CXCL10-/- 
mice resulted in increased viral load at 12 days post-infection that was 
associated with a decreased T cell infiltrate (223). CXCL12 appears to have a 
role in maintaining cells in the perivascular space (224), similar to its role in 
maintaining haematopoietic stem cells in the bone marrow niche. This cellular 
retention in the perivascular space of the BBB is often cited as an example of 
the altered immunity in the CNS. 
Alongside these findings in CNS infection, work has been done to understand 
innate immune responses in the CNS through direct introduction of a TLR ligand 
to the brain or through in vitro studies. TLR4 is the predominant TLR that has 
been studied and in vitro study of LPS agonism in neuronal cultures 
demonstrated upregulation of both chemokines, CCL5 and CXCL1, and cytokines, 
TNF and Il-6 (225). Using conditioned medium from these experiments 
indicated that these changes were associated with increased in vitro neutrophil 
migration across endothelium. 
A number of studies have demonstrated that LPS i.c.v increases expression of 
the pro-inflammatory cytokines Il-1β, TNFα and Il-6(226-228). These cytokines 
are directly associated with parenchymal alterations and Il-1ra antagonism of Il-
1β markedly reduced ventricular dilation following i.c.v LPS (226). Of note, 
many of these effects appear to be age dependent, with older mice exhibiting 
increased cytokine responses and prolonged behavioural changes (229). While 
not directly relevant to the work in this thesis it is worthwhile noting the 
importance of age-matching animals when performing investigations into 
inflammatory responses. 
These inflammatory responses are also associated with cellular changes 
characteristic of microglial reactivity and astrogliosis (226, 228, 230), suggesting 
that the innate immune responses of the CNS alter the phenotype of resident 
glial cells. Chemokine responses have been less extensively studied in this 
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model. One study in CCL2-/- mice demonstrated that although there were no 
obvious alterations in microglial and astrocytic responses to LPS, there were 
reductions in pro-inflammatory cytokine levels (228). The authors suggested two 
possible mechanisms for these changes. Firstly, absence of any CCL2 might mean 
that glial cells were under-primed for inflammatory responses. However this is 
not necessarily supported by the morphological data. The second mechanism 
proposed is that lack of monocyte recruitment due to the absence of CCL2 
reduces overall levels of inflammation. This study also demonstrated that in WT 
mice there is a significant upregulation of CCL2 in response to i.c.v LPS. 
Because of the limited number of in vivo studies examining chemokine 
responses, consideration of in vitro data on glial chemokine production in 
response to LPS is important. An array study of microglial responses to LPS 
observed significant transcriptional upregulation of multiple chemokine ligands 
including Ccl2, Ccl3, Ccl5, Cxcl2, Cxcl9 and Cxcl11(231). CCL2 and CCL5 protein 
were also found to be upregulated in an in vivo experiment to confirm these 
findings. The other chemokines were not studied in the in vivo model so 
confirmation of their expression is an area for further work. These chemokines 
have the ability to attract a wide variety of cells including monocytes, T cells 
and neutrophils, suggesting the ability of microglia to promote diverse immune 
cell infiltration in response to innate immune challenges. Similar to microglia, 
astrocytes have been shown to upregulate CCL2, CCL3, CCL5 and CXCL10, among 
other chemokines, in response to LPS (232-234). 
Although TLR4 has been most extensively studied, a limited number of studies 
have looked at the role of TLR7 in neuroimmune responses. As this is the agonist 
utilised in the model of inflammation presented in this thesis it is worth briefly 
discussing some key findings here. Butchi et al. found that i.c.v treatment of 
neonatal mice with either imiquimod (IMQ) (TLR7 agonist) or LPS induced 
significant increases in Ifnb1, Tnf, Ccl2 and Cxcl10 gene expression at 12 hours 
post inoculation (235). For IMQ this did not persist to time-points greater than 48 
hours, whereas for LPS this upregulation persisted up to 96 hours post 
inoculation for some transcripts. Despite this upregulation there was no 
significant upregulation of Cd3 messenger RNA (mRNA), that would be 
indicative of T-cell infiltration, in IMQ treated brains at any time-point, although 
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both meningitis and ventriculitis were observed. Despite the lack of immune cell 
infiltration there is an upregulation of GFAP at this time-point, suggesting 
astrogliosis in response to IMQ inoculation. This may reflect the fact that direct 
introduction of inflammatory stimuli to the CNS does not allow an effective T 
cell response until the antigen is encountered in the periphery as discussed 
earlier. A later study by Butchi et al. also found a similar upregulation of 
chemokine and cytokine proteins in response to TLR7 agonism at 12 hours(236). 
In addition to in vivo work Butchi et al. have also demonstrated in vitro TLR7 
expression in microglia and astrocytes using flow cytometry(237) and this has 
also been shown by in-situ hybridization in another study, where TLR7 expression 
was also observed in neurons(238). The in vitro study by Butchi et al. also 
demonstrated significant upregulation of CCL2, CCL3, CCL5, CXCL1 and CXCL10 
protein in response to stimulation with IMQ (237). A limitation of this data set is 
that all of the findings in relation to TLR7 response are from a single research 
group. 
Overall, CNS infection in physiological circumstances such as in viral models of 
encephalitis induces not only cytokine and chemokine responses within the brain 
parenchyma but also attraction of peripheral immune cells. In the case of direct 
TLR stimulation a similar pattern of upregulation is observed. While chemokines 
have been examined to a lesser extent than the major cytokines, there are a 
number of studies that demonstrate alterations in the immune response if 
chemokines are absent. This suggests that the chemokine family plays an 
important role in co-ordinating and promoting innate immune responses within 
the CNS. 
It appears that both microglia and astrocytes have the ability to promote pro-
inflammatory changes in response to TLR activation. Molecular alterations in 
mRNA and protein, and functional alterations demonstrated by changes in 
morphology and immunohistochemical staining are probably downstream of TLR 
activation. Alongside these alterations in glial cell function, infiltrating immune 
cells can contribute to the inflammatory milieu, particularly in the context of 
viral illness. The upregulation of chemokines that is observed in many of these 
models is likely to help mediate this immune cell influx. 
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1.1.13 CNS Immune Responses to Peripheral Inflammatory 
Stimuli 
In recent years, there has been an increasing focus on the role of peripheral 
inflammatory stimuli in driving CNS immune responses. These studies have 
largely concentrated on the TLR4 agonist LPS, but have also utilised the TLR3 
agonist polyinosinic:polycytidylic acid (PIC), other TLR agonists, and direct 
injection of pro-inflammatory molecules into the circulation. The majority of 
studies have used animal models as this allows for post-mortem tissue 
examination throughout a pre-determined time-course and closer investigation 
of the molecular and cellular response. Human studies have focused on lower 
doses of peripheral stimuli coupled with emotional/mood measures and imaging 
studies. 
In animal models, LPS has been most widely utilised. It is usually delivered 
intraperitoneally (i.p.) and has been demonstrated to induce upregulation of 
pro-inflammatory molecules within the CNS, including Il-1 and TNF (81, 102, 
239-242). Alongside these changes there is activation of microglia within the 
parenchyma itself (81, 240, 243). Studies aiming to quantify whether LPS 
reaches the brain itself have concluded that limited if any LPS crosses the BBB 
although it does associate with the endothelium (244), suggesting that its effects 
are not entirely mediated by direct access to the parenchyma. 
Alongside LPS, another immune stimulant that has been used is PIC. PIC is a 
TLR3 agonist, which mimics the dsRNA present in some viruses that TLR3 would 
normally detect. This provides an alternative to LPS that is considered to model 
bacterial TLR responses. Like LPS, upregulation of pro-inflammatory cytokines 
and chemokines has been observed in response to PIC (245-247). For both LPS 
and PIC the most commonly studied chemokine is CCL2, its upregulation has 
been observed in several brain areas as well as at brain-periphery interfaces 
such as the choroid plexus, other circumventricular organs (CVOs) and cerebral 
blood vessels(102, 248). Upregulation of the CCL2 receptor CCR2 has also been 
observed in response to LPS stimulation(102), providing further evidence for a 
potential functional role in the CNS. A longitudinal study performed by Qin et al. 
identified that even at 10 months after i.p. LPS administration there were 
alterations in brain TNF levels and alterations in substantia nigra neurons (81). 
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In addition, using i.p. TNF they demonstrated an increase in CCL2 in the brain 
that was associated with an upregulation of Il-1 and NF-B transcript. Overall 
this suggests that single systemic inflammatory stimuli can drive long-lasting 
alterations in CNS function that are at least in part driven by TNF. The concept 
that individual inflammatory insults can drive long-lasting changes within the 
brain is reinforced by an increasing body of human post-mortem literature. The 
primary example of this being the profound alterations observed in CTE and AD 
discussed earlier. 
LPS, delivered systemically, has also been shown to induce activation of 
astrocytes in a variety of brain areas in animal models (226, 249).  In another 
study infiltration of neutrophils and monocytes was observed in the CNS using 
flow cytometry, and alterations of microglial staining were seen using ionized 
calcium binding adaptor molecule 1 (Iba1) antibody (102). These alterations in 
microglial phenotype have also been observed using in vivo positron emission 
tomography  imaging in a non-human primate study, indicating that this response 
is not limited to rodents and is potentially translatable to humans (250). A 
recent study by Hao et al. found that after repeated administration of i.p. LPS 
there was no alteration in the number of CD3 cells present within the CNS 
parenchyma suggesting that peripheral T lymphocytes did not infiltrate into the 
brain at this point (251). Despite this NK cells and neutrophils were found to 
enter the CNS. Systemic NK cell depletion significantly ameliorated neutrophil 
entry into the CNS. Alongside this, microglia from NK depleted mice had 
significant reductions in some chemokine transcripts, particularly CXCL1 a key 
neutrophil chemoattractant. This finding highlights the interaction between 
resident and recruited immune cells in driving CNS immune responses. 
Earlier work within our group demonstrated that i.p. LPS not only upregulated a 
variety of pro-inflammatory cytokines but also generated a robust IFN response 
within the brain (25). This IFN response was associated with increased expression 
of the chemokine Cxcl10. Another experimental model used by our group, and 
studied in more detail in the work reported in this thesis, is the Aldara model of 
peripheral inflammation. In this model, animals are treated topically with Aldara 
cream, containing the TLR7 agonist IMQ. Work comparing the response to Aldara 
with the response to LPS identified the IFN pathway as a shared response 
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between the two TLR agonists (25). As discussed earlier, both TLR agonists drive 
MyD88 dependent activation of NF-B. However, TLR4 drives IFN responses via 
IRF3 downstream of TRIF adaptor protein signalling, whereas TLR7 drives an 
MyD88 dependent activation of IRF7. Further work into the Aldara model 
demonstrated that significant upregulation of chemokine transcripts was 
observed in the brain in response to Aldara stimulation and that this peaked 
after 3 days of repeated daily treatment. The upregulated chemokines included 
Ccl3, Ccl5, Ccl9, Cxcl9, Cxcl10, Cxcl13, Cxcl16 and the receptor Ccr5. Flow 
cytometry analysis of the brain tissues, demonstrated that this transcriptional 
upregulation was associated with infiltration of monocytes, CD4+ T cells, CD8+ T 
cells, NK cells and NK T cells(24). The multiple cell types attracted is probably 
due to the diverse chemokine upregulation seen. 
These data together provide evidence that peripheral inflammatory insults not 
only drive a systemic response but a CNS response that is associated with 
upregulation of chemokines and cytokines. Alongside these molecular 
alterations, cellular changes are observed in both resident CNS cells particularly 
astrocytes and microglia and infiltrating peripheral immune cells that include 
monocytes, neutrophils and T cells (Figure 1.3). 
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Figure 1.3: CNS response to peripheral inflammatory stimuli 
A variety of peripheral inflammatory stimuli delivered both i.p. and topically have been shown to 
induce inflammatory responses within the CNS. These responses include the upregulation of 
chemokine and cytokine ligands, alongside reactive changes in microglial and astrocytic 
populations and infiltration of peripheral immune cells. Abbreviations: top. – topical; IMQ – 
imiquimod; TLR – toll-like receptor; i.p. – intraperitoneal; PIC – polyinosinic-polycytidylic acid; LPS 
– lipopolysaccharide; NK – natural killer 
1.1.14 Peripheral-Central Immune Communication 
Despite a significant number of studies demonstrating that peripheral 
inflammation can drive a central response, the exact mechanisms that underlie 
this inflammatory crosstalk remain unclear. The two primary routes that are 
considered are the humoral or circulatory route whereby inflammatory 
mediators in the circulation drive changes in CNS function, and the neural route 
wherein nerves directly transmit information relating to systemic immune status 
to the CNS.  
Humoral routes drive CNS inflammation through a variety of mechanisms; (i) 
circulating mediators can activate BBB endothelium and/or perivascular cells 
transmitting signals to the CNS (181, 252, 253); (ii) the BBB can actively 
transport molecules into the CNS (253-256) and; (iii) mediators may activate 
cells of, or gain access through, the CVOs (252, 257, 258) .  
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Activation and alteration of the BBB by circulating mediators has been 
demonstrated in a variety of ways. Upregulation of adhesion molecules is a key 
step in inflammatory cell recruitment and i.p. LPS has been shown to increase 
adhesion molecule expression by brain endothelium (259). In the same study, KO 
of intracellular adhesion molecule 1 (ICAM-1) significantly reduced the influx of 
neutrophils into the brain parenchyma following peripheral LPS administration. 
In vitro studies of endothelial cells have suggested that LPS has the ability to 
upregulate chemokine and cytokine production by the BBB (260-262). In addition 
Blank et al. demonstrated increases in ISG15, an IFN response gene, in BBB 
endothelium after systemic infection with vesicular stomatitis virus (VSV) 
suggesting that IFN signalling can also drive endothelial production of 
inflammatory mediators(103). Alongside these mechanisms showing that 
systemic pathogens or PAMPs can drive changes in the BBB, work has also 
demonstrated the ability of Il-1β to induce prostaglandin synthesis in brain 
endothelium(252). Combined with the findings that KO of COX-2 ameliorates 
fever responses to circulating Il-1β(263) it is likely that these Il-1 responses play 
an important role in CNS immune function. 
It has also been suggested the BBB has the ability to actively transport cytokines 
such as Il-1β and Il-6 across the endothelium in a blood-to-brain manner(254). 
These cytokines would then be able to act on cells of the CNS and drive a 
downstream inflammatory response. These data all suggest that the BBB plays an 
important role in controlling CNS inflammation and allowing for information 
about inflammatory states to be relayed to the CNS. This probably occurs 
through active transport of molecular mediators, localized activation of the 
endothelium to promote immune cell influx and through production of 
inflammatory molecules at the endothelium itself. 
Alongside these BBB mechanisms it has also been demonstrated that cytokines 
and other immune molecules can cross into the CNS at the CVOs. Following 
intravenous (i.v.) injection of circulating cytokines there is an accumulation of 
these molecules at the CVOs(264). This is likely to be due to the altered 
composition of the endothelium at these sites and the increased ability of 
circulating mediators to diffuse across a more permeable barrier that has an 
altered tight junction composition(265). Although there is limited diffusion of 
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large molecules across CVOs compared to systemic organs(266), it has been 
shown that dextrans of molecular weights greater than 10kiloDaltons (kDa) can 
cross the vascular endothelium although they do not diffuse widely(267). This 
suggests that molecules such as TNFα (17kDa) and proteolytically cleaved Il-1β 
(17.5kDa) may be able to cross the endothelium at these sites and activate cells 
with the corresponding receptors. 
Neural routes are less well defined than the humoral routes probably because 
the concept of neural inflammatory communication is newer,  the increased 
complexity of studying neural routes using in vitro models, and difficulty in 
performing effective in vivo studies that can comprehensively remove neural 
pathways. It is generally difficult to completely remove innervation to an area 
and therefore much of the work has centred on the vagal nerve probably 
because of the relative ease with which vagotomy can be performed and its 
extensive innervation throughout the body. The other area in which work has 
primarily been done is in the study of pain where anatomical routes of nervous 
pathways are more clearly defined and therefore studying alterations in these 
pathways is an easier task (268). 
The inflammatory reflex has been both described and reviewed a number of 
times over the past 15 years (269-272). In brief it supposes that cytokines, 
particularly Il-1β activate afferent fibres of the vagus nerve that route to the 
brain. Descending efferent fibres can then release acetylcholine at peripheral 
lymphoid organs, particularly the spleen, which acts to suppress inflammatory 
responses. This mechanism has been demonstrated through both augmentation 
and abrogation of this pathway. Electrical stimulation of the efferent vagus 
nerve has been shown to inhibit TNF production in peripheral organs(270) and 
stimulation of the afferent vagus was recently shown to reduce 
neuroinflammation induced by LPS as measured by reductions in cytokines and 
microglial and astrocytic reactivity(273). Interestingly, a 2012 study by Bratton 
et al. did not find a neural connection between the vagus nerve and the splenic 
sympathetic neurons(274), suggesting that this may not be a direct reflex but 
that there are intermediate actors that are as yet undefined. These findings 
have led to a recognition of the need for reconsideration of the inflammatory 
reflex model(275). 
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The inflammatory reflex pathway is often described as anti-inflammatory(270-
272). However, there can also be release of noradrenaline and adrenaline in 
response to inflammatory stimulation, particularly in the context of pain. While 
these molecules do have anti-inflammatory properties, they can also promote 
inflammation and therefore it appears as though neural control of inflammation, 
much like humoral control, is a complex process that involves a balance of both 
pro and anti-inflammatory signals(276-278). 
Pain, while not a focus of this thesis, is an inherently inflammatory process as it 
is usually a response to an inflammatory insult be it trauma, infection or disease. 
It has been demonstrated that inflammatory mediators play an important role in 
sensitizing nerve fibres and promoting hyperalgesia (279, 280). In addition, 
increases in both cytokines and chemokines, particularly CCL2, have been found 
in the dorsal horn of the spinal cord in response to pain (281, 282). 
A further route with crossover between the neural and humoral pathways is the 
HPA where inflammatory mediators such as Il-1β can activate corticotrophin-
releasing hormone (CRH) neurons of the hypothalamus and drive secretion of 
glucocorticoids that then act to suppress inflammatory activity (283, 284). 
However, this route does not provide an explanatory mechanism for the 
induction of CNS inflammation in response to peripheral stimuli but rather a 
pathway through which systemic inflammation can be influenced through top-
down control. Despite this, it does provide further evidence supporting the idea 
that neurons can respond to inflammatory stimuli and be induced to promote 
effector responses. 
The mechanisms of communication between the periphery and CNS have begun 
to be elucidated (Figure 1.4). The critical role of the BBB in CNS inflammation is 
demonstrated repeatedly and in a number of different contexts. Circulating 
cytokines and PAMPs can drive changes in endothelial function and, in the case 
of cytokines, be directly transferred into the CNS itself. Neural routes also 
appear to contribute to immune homeostasis within both the CNS and the body, 
the vagal nerve clearly plays an important role in peripheral-central crosstalk 
and studies that aim to alter the function of this pathway identified alterations 
in inflammation associated with this. A challenge for this field is that currently 
the vast majority of work has been performed using LPS in murine models of 
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inflammation. While useful, this model is generally viewed as a model of sepsis 
that would be indicative of very severe systemic inflammation and therefore is 
not applicable in all human contexts. In addition, because of its i.p. 
administration LPS and the inflammation it induces will have immediate access 
to the vagus nerve due to its widespread gut innervation and this may influence 
the outcome of some models and therefore limit the generalisability of 
conclusions that are drawn. A final challenge is the marked difference in LPS 
reactivity observed between humans and mice. In vivo work in mice generally 
utilises doses of LPS in mg/kg whereas human work will use ng/kg doses. This 
100,000 fold difference in concentration may influence some of the observed 
effects and again limit the overall generalisability of these findings. 
Many challenges remain in the study of peripheral-central crosstalk. These 
include; (i) identifying the most appropriate in vivo models for its study; (ii) the 
need to perform complex mechanistic studies that target specific components of 
the immune system, for example the endothelial specific KO of IFNAR1 used by 
Blank et al. and; (iii) the need for improved in vitro models due to the 
challenges of in vivo mechanistic work, particularly when putative mechanisms 
are not well understood or even known. 
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Figure 1.4: Routes of peripheral-central immune communication 
Multiple routes have been identified through which peripheral immune responses can be 
communicated to the CNS. (A) Circulating immune molecules can activate brain endothelium or 
perivascular cells inducing them to secrete their own immune mediators. (B) Circulating immune 
molecules can be actively transported across brain endothelium. (C) Circulating immune molecules 
can gain access to the brain at CVOs where the blood-brain- barrier is less tightly sealed. In 
addition, they may also activate perivascular cells at CVOs. (D) Neural routes of communication 
appear to exist with the vagus nerve able to detect circulating immune molecules and subsequently 
communicate this to the CNS. 
1.1.15 Aldara Model of Psoriasis-like Inflammation 
The Aldara model of psoriasis-like inflammation that is described in this thesis 
uses the TLR7 agonist IMQ as its active component. Topical Aldara is applied 
daily where it induces psoriasiform inflammation characterised by epidermal 
hyperplasia and hyper-keratosis. It was originally described in 2009 by van der 
Fits et al. as a dermatological model for the study of psoriasis(285). Treatment 
of skin with Aldara cream has been shown to induce robust inflammatory 
responses at the local site and, as discussed earlier, IMQ has been shown to 
induce both cytokine and chemokine responses in the brain if injected i.c.v or 
applied to CNS cells in vitro(235-237). Alongside this other work has 
demonstrated the ability of IMQ to induce cytokines and chemokines in 
vivo(286). 
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Our own laboratory’s findings with the Aldara model have been discussed earlier 
in this section and included the finding that topical application of the cream to 
the dorsal skin of mice induced an IFN response within the CNS. This response 
was associated with upregulation of some chemokines and an influx of peripheral 
immune cells into the CNS parenchyma. 
The rationale for moving away from the LPS model of peripheral inflammation 
has been alluded to earlier. Firstly LPS is generally a severe insult that induces 
septicaemia-like inflammation and the Aldara model may be viable alternative 
to this for studying less severe peripheral immune insults and subsequent CNS 
responses. Secondly, LPS models generally use an i.p. route of administration 
that provides immediate and extensive access to vagal nerve innervation and can 
be rapidly disseminated into the body due to absorption through the 
peritoneum. Finally, although difficult to model and study, it does not appear as 
though differences in rodent and human responses to Aldara are of the same 
order of magnitude as for LPS. Aldara is routinely used in human clinical practice 
to treat actinic keratosis and warts. Induction of inflammation at these sites 
helps to promote immune responses against these benign growths. In some cases 
it is applied to the scalp, or large areas of the forearms. If the differences in 
responsiveness were similar to those observed in LPS this would almost certainly 
be fatal for human subjects. Overall therefore, it seems the Aldara model may 
be a good alternative model to the LPS model for studying peripheral-central 
immune responses.  
Nevertheless, there are a number of limitations of this model. Firstly, it has 
been shown that Aldara cream has a second active component that acts to 
promote skin inflammation through sterile inflammatory mechanisms; isostearic 
acid, the solvent used in Aldara, has the ability to activate the inflammasome 
and promote keratinocyte death in the absence of Aldara, indicating that not all 
findings using this model can be attributed directly to TLR7 agonism(287). This is 
particularly true for observations in the skin where the acid can act locally on 
keratinocytes. However a major limitation of this study is that while in vitro 
isostearic acid induced keratinocyte death, in vivo it did not significantly induce 
inflammatory-associated transcripts aside from interleukin-1 alpha, which was 
only raised by a factor of 2 compared to a factor of 10 for Aldara cream. In 
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addition, there was no apparent histological study of the skin in response to 
isostearic acid making it difficult to draw more complete conclusions. Another 
recently published study also identified a further potential limitation. Grine et 
al. reported that many of the effects of Aldara cream observed in mice are 
actually reliant on ingestion of the cream and subsequent activation of the 
gut(288). However, this study described a significant attenuation in skin 
inflammation associated with prevention of ingestion which does not entirely fit 
with the human literature. Humans are extremely unlikely to be ingesting Aldara 
in clinical practice yet still go on to develop psoriasiform lesions similar to those 
observed in mice(287) questioning the criticality of Aldara cream ingestion for 
development of inflammatory responses.  
Despite its potential limitations, overall the Aldara model provides a promising 
alternative to the LPS model of peripheral inflammation in studying peripheral-
central crosstalk. Earlier work has established that it can induce central 
responses, and now additional work must aim to further characterise the 
immune responses in this model, with a particular focus on the central response, 
and to ensure that it is an appropriate model for study, while keeping newly 
identified limitations in mind. 
1.1.16 Functional Consequences of CNS Immune Responses 
Following on from inflammation, associated changes occur that can be 
attributed to alterations in CNS function. These changes include alterations in 
behaviour, HPA axis function, neurogenesis and chronic inflammation and 
neurodegeneration. Certain inflammatory stimuli are also associated with 
demyelination, for example, experimental autoimmune encephalitis, a 
commonly used animal model of human multiple sclerosis, has profound impacts 
on CNS myelination(289, 290). Many of these responses are associated not only 
with direct CNS insults, but also the peripheral inflammatory insults that can 
drive immune changes in the brain as discussed above. 
Sickness behaviour describes a group of symptoms that are associated with 
response to illness and systemic inflammation. Behaviourally these changes 
include anhedonia or loss of pleasure, social withdrawal, fatigue and altered 
learning and memory. Physiological changes associated with sickness behaviour 
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include fever and altered HPA axis function. Examples of anhedonic sickness 
behaviours in animal models include reduced sucrose preference following on 
from LPS treatment(291, 292) and reduced burrowing, a measure of overall 
wellbeing, following on from Aldara treatment(24). Multiple reviews have now 
expanded upon the role of cytokines in generating sickness behaviours, with Il-1 
and TNF appearing to be the key molecular mediators of this response (4, 8, 
11, 293). These cytokines have been shown to rise in the hypothalamus and, as 
noted earlier, influence CRH neurons providing a mechanism through which 
inflammation can drive these changes. 
Other mechanisms include alterations in neurogenesis and neuronal signalling. 
Reductions in hippocampal neurogenesis have been observed in response to 
peripheral LPS treatment and decreased neurogenesis has been implicated in 
alterations of learning, memory and mood in rodents. Furthermore, cytokines 
have been implicated in neurotransmitter alterations, and a recent study using 
CCL2 demonstrated that CCL2 treatment could alter serotonergic neuronal 
function(102). Alongside this, there is evidence that the enzyme indoleamine 
2,3-dioxygenase (IDO) that can impact brain serotonin levels, through alterations 
in tryptophan catabolism, can be induced in the context of inflammation and 
plays a role in mediating depressive-like behaviours (294). 
Goshen et al. demonstrated the potential bi-directional nature of this 
relationship, wherein mice exposed to chronic mild stress (CMS), a model 
commonly used to induce depressive symptoms, were found to have increased Il-
1 in the hippocampus(295). Using interleukin-1 receptor (Il-1r) KO, and 
transgenic Il-1ra mice, they demonstrated that the behavioural alterations in 
CMS, reduced sucrose preference and social exploration, were mediated by Il-1. 
In addition, wild type mice had decreased neurogenesis and increased 
corticosterone levels compared to their Il-1r KO counterparts. This study drew 
together a number of threads in the sickness behaviour story and demonstrated 
the important role of Il-1 in mediating these effects. They also provided 
evidence to suggest that not only can inflammation drive psychological 
alterations but that psychological stress can itself drive immune alterations. 
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Blank et al. also demonstrated that in response to VSV there was a significant 
upregulation of the IFN stimulated chemokine CXCL10 by endothelial cells that 
appeared to be in response to circulating IFN-. When Cxcr3-/-, the receptor for 
CXCL10, or Cxcl10-/- mice were treated with VSV, depressive behaviours were 
significantly ameliorated compared to wild type mice(103). In addition, they 
demonstrated that CXCL10 could directly influence neuronal firing strongly 
implicating CXCL10 in psychological alterations. 
As we move forward to discuss human depression and the immune system, it is 
important to consider the potential mechanisms through which immune 
alterations may be able to drive psychological changes. The section above 
highlights several findings that suggest mechanistic links between altered 
inflammatory states and altered psychological function (Figure 1.5). 
 
Figure 1.5: Possible routes to psychological alterations and behavioural change in the 
context of stress and inflammation 
Immune insults or chronic stress can induce inflammatory changes and HPA axis activation within 
the CNS. These two systems appear to interact and there is evidence of a bidirectional 
relationship. Downstream of inflammation and HPA axis activation there appear to be alterations in 
neuromodulation, neurotransmitter levels and turnover and reductions in neurogenesis. These 
functional changes within the CNS have been associated with changes in behavioural phenotypes 
as evidenced by anhedonia, alterations in social behaviours and altered learning and memory. 
It is already well established that altered HPA axis function is a prominent 
feature in depressive disorders, as shown by the high rate of abnormal 
dexamethasone suppression tests in clinical settings (296). Newer evidence is 
suggesting a link between pro-inflammatory cytokines and depressive disorders, 
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and there is considerable overlap between the symptoms of depression including 
anhedonia, fatigue and altered learning and memory, and sickness behaviours. 
Altogether this suggests that, at least within a subset of patients, depressive 
illness may be driven by a low level sickness behaviour due to either 
inflammatory illness or immune dysregulation. 
1.1.17 Summary 
The CNS is a complex system that appears to extensively interact with the rest 
of the body in states of altered immunity. While the CNS has been shown to have 
a modified immune function, ideas surrounding immune “privilege” are now 
contentious and their relation to real world physiology unclear. 
Immune responses in the CNS are characterised by upregulation of a diverse 
range of cytokines and chemokines, particularly Il-1 and TNF and these 
molecular alterations are associated with reactive changes in resident cells, 
particularly those associated with inflammatory responses, microglia and 
astrocytes. Alongside resident cells, infiltrating immune cells invade the CNS, at 
least partly due to the upregulation of chemokines that is observed. These 
infiltrating immune cells are an important part of the inflammatory milieu and 
drive CNS inflammation while attempting to clear pathogenic insults. These 
immune changes appear to occur in response to both central and peripheral 
inflammatory stimuli, with i.p. LPS being the most commonly used model to 
study this peripheral-central crosstalk. 
Interestingly these immune responses are also associated with altered CNS 
function that is collectively known as sickness behaviour. Sickness behaviour is 
strongly associated with pro-inflammatory cytokines, particularly Il-1, that 
appear to drive the altered behavioural phenotype observed in these inflamed 
animals. 
Despite the large body of literature and considerable work that has gone into 
this extensive field, the pathways through which peripheral inflammation drives 
central responses remain unclear, although it is likely that both humoral and 
neural mechanisms play a role. Research has begun to demonstrate several 
potential mechanisms, but to understand the whole story more work is required. 
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1.4 Human Depression and the Immune System 
1.1.18 Overview 
Depression is a significant burden on the health of society and mental illness is a 
major burden of disease worldwide (1). Current treatment strategies in 
depression focus around the monoamine hypothesis of depression, in that mood 
is altered due to an imbalance in neurotransmitter systems(297, 298). As such, 
the majority of therapeutics aim to target these systems particularly the 
serotonergic and noradrenergic systems. Despite being efficacious in some 
patient populations, up to 30% of patients will receive no benefit from these 
treatments (3, 299). As a result, further research has attempted to better 
understand the pathogenesis of depressive disorders and a number of other 
potential mechanisms have been identified as potential drivers of illness. These 
include the HPA, the immune system and hippocampal neurogenesis. 
As discussed earlier, a number of strands of human research support the concept 
of inflammation as a potential driver of depressive disorders (13-16, 18, 21-23). 
While alone each of these observations is not conclusive, taken together these 
data provide convincing evidence for the ability of inflammation to drive 
alterations in mood within a human population. Research in the human 
population is increasingly supported by mechanistic studies in animals. As 
discussed earlier, inflammatory models, both peripheral and central, appear to 
have the ability to drive changes in CNS function that are associated with 
alterations in behaviour. 
While cytokines, have been extensively studied in human populations, 
chemokines are a newer field of research in relation to psychoneuroimmunology. 
Chemokines are attractive research targets for a number of reasons. Firstly 
chemokines are thought to be key co-ordinators of the immune response 
particularly with regards to cellular migration. As various subsets of immune 
cells become increasingly implicated in depressive disorders this has some merit. 
Secondly, chemokines are increasingly shown to be highly pleiotropic molecules. 
Research has shown that they have the ability to modulate both neuronal 
function and neurogenesis, systems that have been implicated in depressive 
disorders. Thirdly, while the pro-inflammatory cytokines are potential targets 
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they may not be appropriate in a therapeutic environment. Antagonism of the 
major pro-inflammatory cytokines has profound implications for whole body 
inflammatory responses. In contrast, chemokines have higher levels of 
redundancy and promiscuity within the immune system. This is a double-edged 
sword, as it may make them harder to target as individual molecules but could 
also allow for targeting of specific chemokines that have functions within the 
CNS while leaving the general chemokine system intact for immune purposes. 
 
Figure 1.6: Links between depressive disorder and inflammation in human populations 
Multiple associations have now been found that appear to mechanistically link inflammation and 
depressive disorders. Inflammatory components (red); psychiatric component (blue); Arrows 
(directionality); ? indicates unknown directionality. Abbreviations: IFN – Interferon. 
The following sections discuss key findings from meta-analyses of human 
biomarker studies and other human studies of note, and then attempt to 
introduce and revisit some of the mechanisms through which psychological 
alterations may occur. 
1.1.19 Human Biomarker Studies 
Systematic review and meta-analysis is considered the gold-standard of evidence 
within clinical research. It aims to synthesise data from many different studies 
and to provide an estimate of the overall effect size that exists within the 
population. In general, systematic and structured search strategies must be used 
in an attempt to avoid biases in searching and then data should be extracted 
from all appropriate studies where possible. 
During the course of the work undertaken for this thesis (2014-2017) several 
meta-analyses of cytokines and/or chemokines were published (15, 16, 300, 
301). Earlier work had already begun to study this area (17, 302, 303) and the 
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newer papers build on that earlier research. The primary findings of these meta-
analyses are summarised in Table 1.1. 
Paper Year Cytokines/Chemokines 
Examined (N of studies) 
Model 
Howren et al.(302) 2009 Il-1 (N=14) 
Il-1ra (N=9) 
Il-6 (N=62) 
RE; SMD 
Dowlati et al.(17) 2010 IFN-γ (N=4) 
Il-1β (N=9) 
Il-2 (N=5) 
Il-4 (N=5) 
Il-6 (N=16) 
Il-8/CXCL8 (N=4) 
Il-10 (N=6) 
TNFα (N=13) 
RE; MD 
Valkanova et al.(303) 2013 Il-6 (N=3) ME; SMD 
Haapakoski et 
al.(301) 
2015 Il-1β (N=14) 
Il-6 (N=31) 
TNFα (N=31) 
RE; SMD 
Goldsmith et al.(16) 2016 IFN-γ (N=2) 
Il-1β (N=4) 
Il-1ra (N=2) 
Il-2 (N=3) 
Il-4 (N=2) 
Il-6 (N=10) 
Il-10 (N=4) 
Il-12 (N=4) 
sIl-2R (N=5) 
sIl-6R (N=3) 
TNFα (N=8) 
FE; SMD 
Eyre et al.(300) 2016 CCL2 (N=8) 
Il-8/CXCL8 (N=7) 
RE; MD 
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Paper Year Cytokines/Chemokines 
Examined (N of studies) 
Model 
Köhler et al.(15) 2017 CCL2 (N=8) 
CCL3 (N=3) 
IFN-γ (N=17) 
Il-1β (N=22) 
Il-1ra (N=4) 
Il-2 (N=10) 
Il-4 (N=10) 
Il-5 (N=4) 
Il-6 (N=42) 
Il-8/CXCL8 (N=7) 
Il-10 (N=17) 
Il-12 (N=4) 
Il-13 (N=6) 
Il-17 (N=3) 
Il-18 (N=5) 
sIl-2R (N=10) 
sIl-6R (N=7) 
sTNFR2 (N=3) 
TNFα (N=42) 
TGFβ1 (N=3) 
RE; SMD 
Table 1.1: Summary of findings in meta-analysis of cytokines/chemokines in human 
depression 
Analyses in bold found the cytokines/chemokines highlighted to be significantly increased and 
analytes in italics were found to be significantly decreased. Abbreviations: RE – random effects; FE 
– fixed effects; ME – mixed effects; SMD – standardised mean difference; MD – mean difference 
 
The findings of these meta-analyses vary but it is worth focusing on some 
findings of note. All of the meta-analyses examining Il-6, aside from Valkanova 
et al. that only included three studies, found it to be significantly positively 
associated with depressive disorder. For the other major pro-inflammatory 
cytokines discussed in this introduction, namely Il-1β and TNFα, results were 
more equivocal with TNFα positively associated in 3 of the 4 studies examining 
it. In this case the discrepant study actually included a large number of studies 
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suggesting that there may still be work to be done in this area to provide a more 
conclusive idea of the role of TNFα. Il-1β and Il-1ra are closely related and some 
studies have chosen to measure Il-1ra as it can be easier to detect in the 
circulation. As such it is worth looking at both of these analyses in tandem. Il-1 
was found to be significantly associated with depressive disorder in an early 
meta-analysis by Howren et al.. However, since then, no meta-analysis has 
found it to be significantly associated with depressive disorder. Despite this the 
Il-1ra receptor has consistently been found to be associated with depressive 
disorder, suggesting that difficulties in measuring Il-1β may mean that it is an 
unsuitable biomarker for study in these generally physically healthy depressed 
populations.  
Other cytokines of note include Il-10, Il-12 and sIl-2R all of which were found to 
be significantly upregulated in depressive disorder in two meta-analyses. The 
mechanistic role these molecules play in depressive disorder is largely unclear. 
Interestingly patients treated with Il-2, the ligand for sIl-2R, often experience 
neuropsychiatric alterations including depressed mood(304), and very high doses 
of Il-2 have been associated with extreme psychiatric disturbances(305). 
Increased Il-10 contradicts the animal literature, where Il-10-/- mice were found 
to exhibit increased depressive behaviour that was reversible upon 
administration of Il-10(306). Raised Il-10 may simply be reflective of altered 
inflammatory status as it is usually increased in conjunction with pro-
inflammatory factors due to its role in inflammatory resolution and regulation. 
CCL2 one of the few chemokines examined in these meta-analyses was found to 
be significantly associated with depressive disorder in both the meta-analyses 
examining it. However, the more recent meta-analysis performed by Köhler et 
al. found that after removal of an outlying study this effect disappeared. In 
addition, there was considerable overlap between the two meta-analyses in the 
8 studies examined, with 5 studies being present in both. The other chemokine 
CXCL8 was not found to be significantly associated in any of the three meta-
analyses that included it. 
This work examining biomarkers provides new insight into potential pathogenic 
mechanisms in depressive disorder, although the nature of these biomarker 
studies means they rarely provide insight into the directionality of this 
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relationship. It is impossible to determine in case-control studies, particularly 
those that are looking at single time points, whether the alteration observed is a 
cause or a consequence of the disease being examined. As such, work looking at 
alterations in immune markers following on from anti-depressant treatment, and 
alterations in depressive status following on from anti-inflammatory treatment, 
are key to providing a clearer insight into this relationship.  
In their recent meta-analysis Goldsmith et al. also examined whether the 
biomarkers they had examined were changed following treatment. They 
identified Il-1β and Il-4 as being increased following treatment, while Il-6, Il-10 
and Il-12 were all decreased. This is in keeping with the data comparing acutely 
ill depressed patients with controls, as this demonstrates a reversal in 
directionality. For Il-1β directionality is more difficult to assess as there are no 
significant differences between controls and depressed patients at baseline. 
However the increasing levels may be reflective of anti-depressant treatment. It 
has been shown that anti-depressants can increase Il-1β, TNFα and Il-6 in in vitro 
studies of depressed patient’s cells (307). Interestingly this same study found no 
effect on Il-4 production following on from whole blood stimulation with anti-
depressants in contrast to the findings of Goldsmith et al. An earlier meta-
analysis examining just Il-1β, Il-6 and TNFα, found that for Il-6 there was no 
significant difference before, and after, treatment using a random effects 
model. However if a fixed effects model was used there was a small but 
significant decrease in the levels of Il-6(23). Interestingly they found this to be 
largely attributable to the effect of selective serotonin reuptake inhibitors, a 
specific class of anti-depressants, and the class that was examined in the in 
vitro study discussed above. In contrast, to the meta-analysis performed by 
Goldsmith et al., Hannestad et al. found that Il-1β was decreased in response to 
anti-depressant treatment. However, in keeping with Goldsmith et al, they 
found no significant alterations in TNFα. 
Due to the increased difficulty of assaying circulating cell populations, compared 
to circulating molecules, there is less research into cellular alterations in 
depressive illness. Despite this, links with circulating white cell populations and 
depressive symptoms have been identified(18-20). However, one study found 
that the directionality did not appear to support alterations in immune cells 
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driving depression but rather the other way around(19), and another study only 
found an association in men(18). Despite this, based on work around animal 
models and the limited findings available in human populations, microglia(308) 
and T-cells(309), both effector and regulatory, are now implicated in the 
immune pathogenesis of depression. 
Despite being the gold standard in clinical evidence, there are large variations in 
how these meta-analyses were conducted, from the number of studies included 
to the cytokines and chemokines studied. The number of studies included will be 
influenced by the rigor of the search strategy employed and the stringency of 
inclusion and exclusion criteria. This can be particularly difficult when studying 
chemokines which may have upwards of five alternative names before the 
nomenclature was standardised. In addition, analytical techniques can increase 
variation. The majority of studies used standardised mean differences (SMD) to 
generate effect size estimates. However, both Dowlati et al. and Eyre et al. 
used mean difference without standardisation and that may go some way to 
explaining heterogeneity of results. In addition the choice of random or fixed 
effects models will further influence outcomes. Random effects models should 
be used when heterogeneity between studies is expected to be high. Random 
effects provide a more conservative estimate of the result, generating a larger 
95% confidence interval. Finally some studies chose not to apply weighting to 
their studies, or applied weighting in differing ways. For example, Goldsmith et 
al. did not apply any weighting to their studies, while others used inverse 
variance, a common method for weighting studies. Inverse variance weights 
studies with higher variance less than those with lower variance, generally 
aiming to provide more weight to studies that found a more consistent effect. 
Inverse variance can cause issues if not using a SMD model. This is because 
studies that have higher assay readings, for example due to different 
measurement techniques, will be penalised for the greater standard deviation 
that generally is found with higher means, examples of this can be found in the 
Dowlati et al. meta-analysis(17). 
In addition to meta-analytical study of human biomarkers for depressive 
disorder, there has been an increasing focus on genome wide association studies 
(GWAS) as it has become easier and more cost-effective to engage in high 
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throughput sequencing techniques. This has led to a number of large GWAS 
attempting to identify single nucleotide polymorphisms (SNPs) that are 
associated with depressive disorders. Disappointingly to many in the field, these 
GWAS have at times failed to identify significant associations with depressive 
illness(310). Later analysis of this “mega-analysis” did yield a significant SNP 
association, rs7647854, in those who had later age of onsets of depressive illness 
(311). Although not contained within a particular gene it is flanked by a number 
of genes one of which is a mitogen activated protein kinase (MAPK) gene, 
MAP3K13, that may play a role in NF-κB signalling(312). A further GWAS study 
performed by the CONVERGE consortium in a Chinese population identified an 
SNP near the sirtuin 1 (SIRT1) gene that was particularly associated with a 
specific symptom of severe depressive illness known as melancholia(313). While 
not it’s only function, SIRT1 has been shown to antagonise NF-κB activity and 
alter both inflammatory transcription and responsiveness(314, 315). Meta-
analysis of two large multi-ethnic cohorts of GWAS, also identified a SNP in the 
signal transducer and activator of transcription (STAT) 1 gene as being 
associated with depression. This is of particular interest as STAT1 plays a role in 
type I and type II IFN signalling(316). A final large GWAS study, using the 
23andme cohort and meta-analysis of prior GWAS, failed to replicate the findings 
of the CONVERGE consortium yet did identify a number of other SNPs(317) most 
of which were not directly associated with genes. However, they did find that 
many of these SNPs were either in, or near to, genes associated with brain 
development. 
A more mechanistically-focussed study using immunoassay combined with in vivo 
imaging techniques identified a convincing link between TNF and the serotonin 
transporter (5-HTT)(318). Decreased serotonin availability is a hallmark of 
depressive disease and the monoamine hypothesis. This can be due to reduced 
release or increased uptake.  Krishnadas et al. studied both healthy and psoriatic 
patients and they found significant positive correlations between circulating 
TNF and brainstem 5-HTT, suggesting that altered immunity may drive 
alterations in neurotransmitter states that are associated with depression. Using 
Beck’s depression inventory (BDI), a depression research scale, they also found a 
significant indirect effect of TNF on BDI, suggesting that increases in TNF may 
induce depressive symptoms through effects on the 5-HTT (318). 
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Overall the findings presented here provide compelling evidence of an 
association between alterations in immunity and human depression. Although, 
there is variation between biomarker studies there does appear to be consistent 
alterations in immune status in the depressed population. GWAS studies 
identifying SNPs in or near to genes associated with inflammatory regulation also 
provide further evidence to support this, although the lack of consistency 
between GWAS studies does raise concerns. Despite this strong association, little 
work has been done to provide evidence of directionality in the human 
population and varying results regarding response to treatment do little to 
further clarify the issue. Even with more consistent results suggesting that Il-6 is 
raised in the depressed population, and has a tendency to be reduced following 
on from successful treatment of depressive disorder, it is difficult to ascertain 
the exact mechanism of this, particularly due to the often focused nature of 
biomarker studies. These alterations may be due to the fact that psychological 
alterations and stress can drive changes in circulating biomarkers, and that upon 
correction of these abnormalities immune homeostasis is restored. On the other 
hand, it may be that Il-6 itself drives depressive illness, and anti-depressant 
treatment acts to alter the regulation of this molecule in the periphery resulting 
in its reduction. Although this is not supported completely by the in vitro work, 
it is difficult to ascertain how drugs such as selective serotonin reuptake 
inhibitors that can alter the function of many different cells, will perform in 
more complex in vivo systems. Finally it is worth noting one of the main 
limitations of all the peripheral biomarker studies; by sampling the blood and 
assaying either plasma/serum you are examining a compartment that is not 
directly involved in the pathogenesis of psychiatric disorders. Whether 
plasma/serum values are an accurate marker of what is happening within the 
CNS remains to be ascertained, and sampling of CSF may provide a better 
window into the CNS. 
1.1.20 Other Studies of Inflammation and Depression 
To better understand the relationship between depression and inflammation, 
researchers have attempted to undertake more mechanistically focused studies 
in both human and animal populations. The challenge here is that depression is 
often a chronic disease that can persist for extended periods of time, whereas 
for practical purposes most animal models use relatively short time courses and 
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for ethical reasons most inflammatory human studies must be time limited and 
minimise risk exposure. 
Depression, as an illness, cannot be modelled in an animal. It is a complex 
disease with multiple symptomatologies that can vary from person to person. To 
overcome this challenge, specific aspects of depressive behaviour are often 
modelled or studied. These include anhedonia, altered memory and learning and 
social withdrawal. These behaviours demonstrate considerable overlap with 
sickness behaviours that have been discussed earlier. Studies will generally use 
one of two approaches. The first is to induce inflammation in an animal and 
observe downstream consequences that can be associated with depressive 
illness. These models have been discussed in ‘the functional consequences of 
CNS inflammation’ section, and outcomes include altered behavioural measures, 
changes in HPA axis function and alterations in neurogenesis. The second 
approach is to try to induce depressive behaviours through models of stress, a 
mechanism commonly implicated in human depression, and then to observe if 
there are changes in immune status associated with the depressive behaviours. 
Animal models of stress aim to understand the outcomes of stressful stimuli on 
CNS function in an attempt to model depressive behaviour. While not the focus 
of this thesis they are worth considering when examining potential mechanisms 
that may drive depressive behaviours. Briefly these models use different 
stressors to induce a “depressive” state, these include; chronic mild stress 
where mice are exposed to random but mild stressors, such as isolation or 
altered light-dark cycles for up to 3 months, and learned helplessness where 
mice are exposed to unpredictable and uncontrollable stressors, such as foot 
shocks.  
Many of the findings in these models have been highly equivocal. While some 
studies identify clear alterations in cytokine measures or microglial reactivity 
others do not find these same differences. A large review by Kubera et al. 
highlights this as it discusses that although alterations in Il-1, Il-6 and TNF 
have been observed in animal models of stress, other studies have failed to 
identify these (12). Alongside this, for papers with positive findings some papers 
find large differences in cytokine concentrations in specific brain regions, others 
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find very small but significant differences. Determining biological significance of 
these very small changes is difficult and further mechanistic work would be 
required.  Despite these challenges, some studies have presented stronger 
evidence to suggest that inflammation is a critical part of chronic stress models. 
For example, the study discussed earlier by Goshen et al. strongly implicates 
CNS Il-1 in the generation of depressive behaviours (295). One caveat is that 
they were able to mimic the effects of chronic stress through administration of 
corticosterone and this effect persisted in Il-1rKO mice suggesting that Il-1 may 
not drive behavioural changes directly but via indirect effects on the HPA.  
Other studies utilising the chronic stress model find alterations in neurogenesis, 
neurotransmitter systems and the HPA axis, associated with “depressive” 
behaviours(12, 319, 320). This aligns with findings from human depression and 
with data from inflammatory models studying sickness behaviours. One of the 
main challenges in terms of using these models for therapeutic development is 
that to validate a depressive behaviour many studies use reversibility upon anti-
depressant treatment. In many ways, this is almost the opposite of what should 
be striven for. Identification of models that generate depressive-like behaviours 
that are not reversible upon anti-depressant treatment is key, as these may 
mimic those seen in treatment-resistant depression better. Currently, these 
models appear to be studying, and identifying, depressive behaviours that we 
already have efficacious therapeutics available for. 
Other than animal models, human studies have also attempted to study the 
relationship of depression and inflammation in a more experimental manner. A 
common model for this is to administer endotoxin such as LPS at a low dose and 
then monitor changes in immune markers, mood and/or neuroimaging. 
Unsurprisingly administration of low doses of endotoxin induces innate immune 
responses in human subjects characterised by increases in Il-1, Il-6, TNF and 
Il-10 alongside increases in cortisol (321-323). In addition to immune changes, 
alterations in behavioural and mood measures are observed (323-325). While 
these studies identify clear alterations in immune parameters and mood in 
response to LPS administration, identifying direct links between changes in 
circulating immune mediators, mood and CNS function has been more 
challenging. Using fMRI changes in blood oxygen level dependent signal are also 
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detected(324), and these have been correlated to changes in Il-6 levels. 
Furthermore, studies have identified correlations with Il-6 in sub-groups 
stratified by either sex or dosage, with females and higher dose groups showing 
significant correlations and male and lower dosage groups not(323, 324), 
suggesting either that these links may only be valid in specific circumstances or 
that for the weaker correlations increased sample sizes may be required. 
1.1.21 Summary 
The data presented above provide strong evidence for an association between 
inflammatory alterations and human depressive illness. While, attempts have 
been made to mechanistically link immune alterations this has proved 
challenging within human populations, and animal models have provided 
equivocal results, particularly for direct effects. It is likely that inflammatory 
changes can induce HPA alterations and possibly reductions in neurogenesis. The 
Goshen et al. study suggests that Il-1β mediates its effect through the HPA. 
The field as a whole faces major challenges, these include the need to ensure 
that all studies follow rigorous methodology during both study design and 
statistical analysis. In addition synthesis of a complex, and often conflicting, 
literature is challenging. While many animal models strongly implicate Il-1β and 
TNFα in the generation of sickness or depressive behaviours, the human 
literature identifies Il-6 as the key biomarker. These disparate findings can be 
reconciled to some extent through the finding in some studies of links between 
TNFα and depressive disorders, or functional alterations associated with 
depression. In addition, the finding that Il-1ra is raised, may reflect the fact that 
although there are alterations in the Il-1 system, difficulties surrounding 
detection of Il-1β in the circulation have hindered research into associations. 
Finally it is worth noting that a major challenge for the whole field of 
biomarkers in psychiatric disease is the relevance of the peripheral circulating 
compartment to what is going on in the CNS. 
Aside from these challenges, there is increasing evidence of a role for 
chemokines in both human depressive disease and sickness behaviours. While 
this link will require further investigation to clarify it is an attractive area for 
research. This is due to the fact that modulation of major pro-inflammatory 
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cytokines is frequently associated with significant side effects, particularly an 
increased risks of infection that may make cytokine modulation unsuitable in a 
clinical setting. Chemokines, while important in co-ordinating immunity show 
high levels of redundancy and promiscuity within the immune system and 
therefore may be attractive targets if they have more specific roles within the 
CNS as Blank et al. suggest in their recent paper. 
There is a clear need for further work to try to establish the role of chemokines 
in human depression and to identify if changes are robust across multiple 
studies. This work has bidirectional implications, identification of molecules that 
are altered in human disease become attractive candidates for study in animal 
models. Alongside this, if animal models of stress or sickness behaviour have 
identified candidate molecules and meta-analytical techniques can associate 
these with human depressive illness, there is a strong case for further 
investigation. 
1.5 Justification and Thesis Aims 
Overall it appears that innate immune pathways drive a variety of downstream 
changes that can, at least, be associated with alterations in mood and behaviour 
and potentially mechanistically linked. Activation of PRRs, and particularly TLRs, 
is associated with IFN and/or NF-κB responses. These responses cause 
upregulation of a variety of molecules including, but not limited to, pro- and 
anti-inflammatory cytokines, such as Il-1β, Il-6, TNFα and Il-10, and chemokines, 
such as CCL2 and CXCL10. In the case of both peripheral and central immune 
challenges with TLR agonists, cellular changes in the CNS are observed alongside 
molecular alterations. Resident glial cells of the CNS, particularly microglia and 
astrocytes, become reactive and produce inflammatory mediators of their own, 
and alongside resident cell activation circulating immune cells are recruited 
from the circulation and enter into the CNS parenchyma where they can sustain 
and effect inflammatory responses. 
Immune responses of the CNS are increasingly associated with changes in CNS 
function. Alterations in neurotransmitter function, decreases in neurogenesis 
and HPA activation have all been identified within inflammatory models. These 
functional changes are linked with phenotypic changes characterised by mood 
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changes identified through behavioural studies. Mood changes include increases 
in anhedonia, decreases in social exploration and overall wellbeing, and altered 
memory and learning.  
These functional and phenotypic changes share many characteristics with 
depressive symptomatology and pathology that has been observed in human 
populations. This has led to a variety of hypotheses surrounding the pathogenesis 
of depressive behaviour. One of these, the sickness behaviour hypothesis of 
depression, supposes that immune alteration in the human population drives a 
sickness behaviour phenotype driven by the pro-inflammatory cytokines Il-1β and 
TNFα, alongside potentially unidentified mediators. This sickness behaviour 
phenotype predisposes people to depressive illness and it is thought that 
restoring normal immune homeostasis within the CNS may help to alleviate 
depressive symptomatology. 
Despite identification of these initial associations and the myriad of hypotheses 
arising from them, identifying and providing strong evidence for mechanistic 
links has been challenging. Well-designed multi-modal studies such as the study 
by Blank et al. that use more specialized techniques and specifically engineered 
mice that lack receptors only on cells of interest have begun to provide stronger 
mechanistic links between immune molecules and behavioural alteration. 
Finding animal models that mimic human biology and pathology as closely as 
possible is always a challenge, and use of a variety of methodologies and models 
is required for findings to be generalizable. As such identification, 
characterisation and validation of animal models that may be suitable for this 
purpose is a critical requirement in a field that has typically used the LPS 
endotoxin model of septicaemia as a ‘work horse’. Work in our laboratory has 
identified the Aldara model of peripheral inflammation as a potentially 
advantageous model for the study of these innate immune phenomena. 
Alongside animal work, human studies have begun to identify not only the major 
pro-inflammatory cytokines but also other immune molecules as being associated 
with depressive disorders. One class of molecules that is receiving increased 
attention, due to their pleiotropic functions that include cellular recruitment 
and possibly neuromodulation, are the chemotactic cytokines, or chemokines. 
Two recent meta-analyses have identified potential associations between CCL2 
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and depressive disease, however the role of other chemokines, such as CXCL10, 
remains unclear. Further work should aim to establish if this link exists for the 
other chemokines and to replicate evidence of pre-existing associations. 
Based on the existing information presented above, the work in this thesis aimed 
to test three major hypotheses at the outset. The first hypothesis was: 
“There is a significant association between circulating chemokine biomarkers, 
beyond CCL2, and human depression.” 
To this end a systematic review and meta-analysis of the role of chemokines in 
human depressive disorder, examining and synthesising the evidence presented 
in human biomarker studies to date was undertaken.  
The second hypothesis was: 
“TLR7 driven changes in ISG expression in the Aldara model of peripheral 
inflammation are accompanied by changes in cytokine and chemokine expression 
and cellular alterations” 
To test this the immune responses within the Aldara model of peripheral 
inflammation were further characterised, utilising a combination of gene and 
protein expression analysis and immunohistochemistry (IHC). It is acknowledged 
that this is a broad hypothesis and that much of the work done in this area was 
exploratory with the aim of characterising the Aldara model more completely. 
The third and final hypothesis was: 
“The Aldara model of peripheral inflammation is an appropriate tool for the 
study of peripheral-central inflammation” 
To investigate whether this was true peripheral responses were examined 
alongside the central responses, and this work attempted to ascertain 
mechanisms through which Aldara may be inducing a response within the CNS.
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Chapter 2 Materials and Methods 
2.1 Companies 
Full contact details of all companies listed within this Thesis are available in 
Appendix 1. 
2.2 Systematic Review and Meta-Analysis 
This study was performed by Dr. Sam Leighton (SL) and Louis Nerurkar (LN) in 
collaboration. All work for data collection and analysis was contributed to 
equally by both individuals. Any work presented in this Thesis was written by LN 
alone. 
2.2.1 Search Strategy 
Searches were performed within the EMBASE, PsycINFO and Medline databases 
up to March 5th 2016. To improve the scope of the review non-english language 
papers and conference abstracts were included, alongside full journal articles. 
The search strategy was based on the PICO framework: 
 Population – Humans 
 Intervention/Exposure – Depression 
 Comparison – No Depression 
 Outcome – Blood or CSF Chemokines 
Full details of final search strategies can be found in Appendix 2 
2.2.2 Study Selection 
Studies were selected for inclusion in the review based on the following criteria: 
 Original research study measuring blood or CSF chemokine concentration 
in depressed and non-depressed subjects 
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 Subjects had a formal diagnosis of depression or a validated depressive 
scale was used 
 Control subjects had sufficient information to allow for exclusion of 
depression 
Studies were excluded based on the following characteristics: 
 Subjects had comorbid or higher order psychiatric disorders (e.g. Bipolar 
disorder, schizophrenia) 
 In-vitro studies 
 Non-human studies 
 Studies looking at stimulated responses (e.g. following in vivo or ex vivo 
LPS stimulation) 
 Studies including pre-pubescent participants 
Note that studies including participants with a physical comorbidity were not 
excluded, if control subjects had comparable comorbidity (e.g. Heart disease (+) 
depression (-) vs Heart disease (+) depression (+)). Using subgroup analysis, 
differences between studies with healthy or physically comorbid patients were 
still examinable. 
Duplicate papers were excluded initially and titles were examined to exclude 
papers clearly not relevant to the current review. Subsequently, abstracts of all 
remaining studies were read. Those found to still meet inclusion criteria at this 
point were included for full text review and data extraction. If there were any 
ambiguities over inclusion or exclusion of a study, both reviewers discussed the 
study until a consensus was reached.  
2.2.3 Data Extraction 
Both reviewers (SL and LN) used a custom data extraction template (Available in 
Appendix 3) modified from the Cochrane Review criteria to extract relevant data 
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from studies. Where possible non-English studies were translated or data were 
extracted from English abstracts. For meta-analysis mean +/- standard deviation 
(SD) and N numbers were extracted from comparison groups. If the mean +/- SD, 
or raw data, were not available in the paper or supplemental materials, 
corresponding authors were contacted directly and allowed at least 28 days for a 
reply. If correspondence failed data were extracted from figures using Engauge 
data extraction software(326). Where only median +/- interquartile range was 
available data were converted using a previously published approximation 
method(327) to approximate mean +/- SD. If only raw data were available 
patients were dichotomised based on established cut-offs for depressive scales 
and calculated the mean +/- SD for the two groups. Finally for studies where SD 
was not available SD was inferred by using the pooled SD of all other studies for 
that chemokine. 
2.2.4 Quality Assessment 
To assess the quality of papers a combined approach was used to allow for the 
case-control nature of the studies assessed. To assess potential bias, the 
Cochrane collaboration guidelines(328) alongside modified Newcastle-Ottawa 
criteria(329) for observational studies were used. A selection of confounders 
previously shown to influence immune markers were also included. Finally two 
additional points were added to account for the need to extract data and 
whether the study was an abstract or complete article. This system generated a 
maximum possible score of 17 as below: 
 Newcastle-Ottawa Criteria (1 if present or 0 if absent, total 3 points) 
o Representative controls 
o Clearly state diagnostic criteria 
o Tissue sampled, measurement technique used and units stated 
 Cochrane (2 if low risk of bias, on1 if unclear, 0 if high risk, total 6 points) 
o Blinding of outcome assessment 
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o Incomplete outcome data 
o Selective reporting of outcome data 
 Confounders (1 if matched/adjusted, 0 if not mentioned or not 
matched/adjusted, total 6 points) 
o Body mass index (BMI) 
o Age 
o Sex 
o Smoking 
o Circadian [Time of blood draw] 
o Medications 
 Other (total 2 points) 
o Article (1 point)/Abstract (0 points) 
o No data extraction required (1 point)/Data extraction or inference 
required (0 points) 
All studies were included in the meta-analysis regardless of quality score 
however subgroup analysis was undertaken to assess only high quality studies 
≥12/17 where possible. 
2.2.5 Statistical Analysis 
All meta-analysis was performed in RevMan 5.3 Software(330) and effect sizes 
were replicated using R(331) with the metafor package(332). SMD was used 
rather than mean difference as the absolute values of results varied between 
different studies making direct comparison of mean differences inappropriate. 
An inverse variance random effects model was used to provide final estimates of 
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effect size and 95% confidence interval (CI). Inverse variance weights studies 
based on the variance observed, lower variance within a study results in greater 
weight for the study in the final model. Random effects should be utilised 
wherever heterogeneity may be high and it provides a more conservative 
estimate of effect size when compared to fixed effects models. 
Additional statistics were generated to allow for assessment of statistical 
robustness and meta-analytic characteristics. I2 values were calculated to 
provide an estimate of how much of the variance observed may be attributable 
to heterogeneity between studies, rather than sampling error. Publication bias 
was assessed using a combined approach of generating funnel plots and Egger’s 
regression test in the metafor package. Egger’s test provides a formal method 
for assessing funnel plot asymmetry. It is important to note that publication bias 
should not be considered absent if Egger’s test is non-significant while there is 
strong evidence of asymmetry from the funnel plot. Finally if significant 
publication bias was suspected or detected using Egger’s test, the trim and fill 
method of adjustment for publication bias was attempted in the R package. 
2.3 General Materials 
2.3.1 Plastics 
Unless stated otherwise all sterile filter tips, 0.2ml polymerase chain reaction 
(PCR) tubes and 2ml tubes were purchased from Starlab. 1.5ml, 15ml and 50ml 
tubes were purchased from Greiner. Cryovials were purchased from 
Alphalaboratories. 
2.3.2 Buffers and solutions 
Ethylenediaminetetraacetic acid (EDTA) (0.5M) (100ml) 
 18.61g EDTA 
 80ml double distilled (dd) H2O 
 Add NaOH until fully dissolved  
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 pH to 8.0 
 ddH2O to 100ml 
Li-Hep Phosphate buffered saline (PBS) (500ml) 
 500ml PBS 
 100KU Heparin-lithium salt from porcine intestinal mucosa (Sigma-Aldrich) 
10x Tris-buffered saline (TBS) (1L) 
 78.8g Tris-HCl or 60.6g Tris-Base (0.5M) 
 87.6g NaCl (1.5M) 
 800ml ddH2O 
 ≈30ml HCl 37% 
 pH to 7.5 
 ddH2O to 1L 
1x TBS (1L) 
 100ml 10x TBS 
 900ml ddH2O 
1x TBX (1L) 
 100ml 10x TBS 
 900ml ddH2O 
 250ul Triton-X 100 
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10x Sodium Citrate Buffer 
 29.4g Sodium Citrate Trihydrate (0.1M) 
 ddH2O to 800ml 
 pH to 6.0 
 ddH2O to 1L 
1x Sodium Citrate Antigen Retrieval Solution 
 100ml 10x Sodium Citrate Buffer 
 900ml ddH2O 
 pH to 6.0 
Scott’s Tap Water (STW) 
 3.5g Sodium Bicarbonate 
 20g Magnesium Sulphate Heptahydrate 
 1L Tap water 
Eosin Stain 
 500ml Putt’s Eosin Stain (CellPath) 
 500ml Tap Water 
1% Acid Alcohol 
 990ml 70% Ethanol (EtOH) 
 10ml Concentrated HCl 
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50x TAE Buffer 
 252g Tris-Base (2M) 
 650ml ddH2O 
 Dissolve Tris-Base completely 
 57.1ml Acetic Acid (Slowly add down side of bottle) 
 100ml 0.5M EDTA pH8.0 (50mM) 
 ddH2O to 1L 
1x TAE Buffer 
 100ml 50x TAE Buffer 
 4900ml ddH2O 
2% Agarose Gel 
 50ml TAE Buffer 
 1g Agarose 
 Heated in microwave until fully dissolved 
 2.5ul Ethidium Bromide 
2.4 Animals 
C57BL/6 mice were obtained from Harlan Laboratories/Envigo. CCR1/2/3/5KO 
also known as inflammatory chemokine receptor KO (iCCRKO) and IFNARKO mice 
were maintained at the Beatson Laboratories University of Glasgow and 
transferred to the Central Research Facility prior to experimental protocols. 
Mice were kept for a minimum of a week within the Central Research Facility to 
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allow for acclimatisation prior to commencement of procedures. Mice were 
maintained in specific pathogen free conditions. Mice were treated between at 
the age of 8-9 weeks and were all female unless otherwise stated. All 
experiments received local ethical approval and were performed under the 
authority of UK Home Office Licence 70/8377. 
2.5 Aldara Model of Inflammation 
2.5.1 Aldara Model of Psoriasiform Inflammation Overview 
Mice were treated with a quarter sachet (≈62.5mg) of Aldara™ (Meda AB) cream 
containing 5% IMQ or an equivalent volume of control cream (Boots Aqueous 
Cream/10% Vaseline Lanette Cream) at each treatment point. Cream was 
applied to shaved dorsal skin near the base of the tail (Figure 2.1). For 
experiments longer than 24 hours in length mice were weighed daily to ensure 
that there was no more than 20% body weight loss as per Home Office licence 
conditions. Mice were euthanised with an increasing concentration of CO2 after 
the completion of the experimental protocol. 
 
Figure 2.1 Image demonstrating treatment area on dorsal skin of mouse 
 
2.5.2 Three Day Aldara Model 
8.5 week old C57BL/6 female mice were treated daily with ¼ sachet Aldara 
(≈62.5mg) or an equivalent volume of control cream as described. Mice were 
euthanised 24 hours after the third application of cream. 
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2.5.3 Time-course Aldara Models of Inflammation 
8.5 week old C57BL/6J female mice were treated daily with ¼ sachet Aldara 
(≈62.5mg) or an equivalent volume of control cream as described. Mice were 
euthanised at 4 hours, 12 hours and 24 hours after the first treatment, or 24 
hours after the 3rd and 5th treatment (4h, 12h, 24h/1d, 3d, 5d groups 
respectively) 
2.5.4 Single Treatment Time-course Model of Inflammation 
8.5 week old C57BL/6J female mice were treated once with ¼ sachet Aldara 
(≈62.5mg) or an equivalent volume of control cream as described. Mice were 
euthanised 24 hours, 72 hours and 120 hours after the first treatment. (1d, 3d, 
5d groups respectively). 
2.5.5 Knockout Models of Inflammation 
IFNARKO (A129) or iCCRKO (C57BL/6N) mice were treated daily with ¼ sachet 
Aldara (≈62.5mg) or an equivalent volume of control cream as described. Mice 
were euthanised 24 hours after the 3rd treatment for IFNARKO or 4th treatment 
for iCCRKO mice. Details of these experiments are given in Table 2.1: 
Experiment Timepoint Mice Groups (total N) 
iCCRKO 1 
(Figure 5.2, Figure 
5.3) 
4d 8 wk 
C57BL/6N 
Female 
N=4-6 (16) 
[WT, HET, KO] 
iCCRKO 2 
(Figure 5.4, Figure 
5.5) 
4d 10 wk 
C57BL/6N 
Female 
N=5 or 6 (21) 
[Treated, Control] 
WT and KO 
IFNARKO1 
(Figure 5.9, Figure 
5.12, Figure 5.13) 
3d 8.5 wk 
A129 
Female 
N=4 (8) [Treated, 
Control] 
IFNARKO2 
(Figure 5.10, 
Figure 5.11) 
3d 10 wk, 11.5 wk 
[Treated, Control] 
A129 
Female 
N=4 (16) [Treated, 
Control] WT and 
KO 
Table 2.1: Details of animals used in KO experiments 
Figures listed under each experiments title are to direct reader to the corresponding gene 
expression data 
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2.6 Tissue Collection following Animal Models 
2.6.1 Peripheral blood leukocytes (PBL) collection for RNA 
Blood was collected from mice immediately after euthanasia using a syringe 
flushed with 0.5M EDTA. The pleural cavity was opened, the right atrium was cut 
and blood collected. PBL were obtained from blood by separating the plasma 
and cellular compartments of the blood initially using centrifugation at 300g for 
10 minutes. Plasma was removed from the top layer. PBL were obtained 
following red cell lysis treatment for 10 minutes with ammonium chloride 
(STEMCELL Technologies), and a series of washes in PBS. PBL were then re-
suspended in buffer RLT (Qiagen) prior to storage. Both PBL and Plasma were 
stored at -80°C. 
2.6.2 Tissue collection for RNA 
After opening of the right atrium, mice were perfused with 20ml PBS through the 
left ventricle to clear tissues of remaining blood. Following perfusion tissues 
(skin, lungs, liver, spleen, colon, right hemisphere of brain) were collected, 
placed in cryovials (AlphaLaboratories) and ‘snap frozen’ in liquid nitrogen (3 
day experiments and repeated treatment time-course experiment) or submerged 
in RNAlater (Thermo Fisher Scientific) at 4°C for 24-48 hours (all subsequent 
experiments). Tissues were then stored at -80°C until RNA extraction was 
performed. 
2.6.3 Tissue collection for Protein Analysis 
After opening of the right atrium, mice were perfused with 20ml PBS through the 
left ventricle to clear tissues of remaining blood. Following perfusion the left 
hemisphere of the brain was collected, placed in a cryovial and ‘snap frozen’ in 
liquid nitrogen. Tissue was stored at -80°C until protein extraction was 
performed. 
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2.6.4 Tissue collection for formalin-fixed paraffin embedded 
(FFPE) sections 
Brain (left hemisphere/whole brain) was collected from mice after euthanasia, 
with or without perfusion and placed into 10% neutral buffered formalin for 24-
48 hours before being transferred to 70% EtOH prior to tissue processing. 
2.6.5 Tissue collection for Mass Spectrometry 
After opening the right atrium whole blood was collected in syringes flushed 
with lithium-heparin PBS before being placed into a 1.5ml Eppendorf containing 
40ul lithium-heparin PBS (8U lithium-heparin). Following blood collection mice 
were perfused with 20ml lithium-heparin PBS and brains were collected, placed 
in cryovials and ‘snap frozen’ in liquid nitrogen. Plasma was immediately 
collected from whole blood by centrifugation at 10,000g for 5 minutes. 
Supernatant was then spun again at 10,000g for 5 minutes and plasma collected. 
Both plasma and brains were stored at -80°C until shipping on dry ice. 
2.7 Tissue Processing 
2.7.1 RNA Extraction 
Under RNase-free conditions, tissues were homogenized using the TissueLyser LT 
(Qiagen) in 1ml of Qiazol® (Qiagen). Following homogenisation, tissues were 
allowed to stand at room temperature (RT) for 5 minutes before 200ul of 
chloroform was added. Samples were then mixed and allowed to stand for a 
further 2 minutes. Qiazol/Chloroform homogenate was then spun at 12,000g for 
15 minutes at 4°C and supernatant drawn off. Supernatant was further purified 
and genomic deoxyribonucleic acid (DNA) removed using an RNeasy Mini Kit 
(Qiagen) with optional DNase I (Qiagen) on-column treatment as per 
manufacturer’s instructions. In brief, RNA was bound to silica membrane within 
RNeasy column and washed once with RW1 buffer. On-column DNAse treatment 
was performed for 15 minutes, after which a series of washes were performed 
and the column dried. Once dried 50ul of RNAse free water was added to the 
column and RNA was eluted. RNA quality for all time-course and knockout 
experiments was assessed using Agilent Bioanalyzer (Agilent Technologies), to 
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generate an RNA integrity number (RIN), at Glasgow Polyomics and details of this 
can be found in Appendix 4. 
2.7.2 RNA to complementary DNA (cDNA) conversion 
RNA was converted to cDNA using AffinityScript Multi-Temperature cDNA 
Synthesis Kit (Agilent) or High-Capacity RNA-to-cDNA Kit (Thermo Fisher 
Scientific) as per manufacturer’s instructions. RNA quantity was measured using 
Nanodrop 1000 (Thermo Fisher Scientific). An equal quantity of RNA (maximum 
amount recommended by kit or maximum amount possible from lowest 
concentration sample) was used to generate cDNA as per manufacturer’s 
instructions. For each batch of cDNA, a “–RT” control was generated where the 
reverse transcriptase was omitted from the PCR reaction to allow for assessment 
of genomic DNA contamination. 
2.7.3 Protein Extraction 
Protein was extracted using neuronal protein extraction reagent (N-PER) 
(Thermo Fisher Scientific) as per manufacturer’s instructions. In brief, Pierce 
mini protease tablets (Thermo Fisher Scientific) were added to N-PER reagent, 
homogenisation tubes were placed on dry ice and tissue was added. Tubes were 
transferred to wet ice to prevent lysis buffer freezing. Lysis buffer was added 
and tissue was homogenised using Tissue Lyser LT (Qiagen). Homogenate was 
then centrifuged at 10,000g for 10 minutes at 4°C and supernatant was 
collected, ‘snap frozen’ on dry ice and stored at -80°C prior to use. Protein 
concentration was determined using Pierce BCA Protein Assay Kit (ThermoFisher 
Scientific) as per manufacturer’s instructions. In brief, sample was added to a 96 
well plate with a set of bovine serum albumin standards, BCA reagent was added 
prior to incubation at 37°C for 30 minutes, the plate was then placed in the 
fridge for 2 minutes to stop the reaction. Optical density was then measured 
using a Sunrise plate reader (Tecan) and protein quantity was determined from 
the standard curve. 
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2.7.4 Tissue processing and paraffin embedding for FFPE 
sections 
After formalin fixation and storage in 70% EtOH, tissues were processed using 
KOS microwave HistoSTATION (Milestone SRL) using a 4mm tissue processing 
cycle and proprietary reagents. This system is Xylene free to help avoid 
excessive drying of tissues. For IFNARKO 2 (Figure 5.14, Figure 5.15, Figure 5.16) 
brains were processed using a Thermo Shandon Excelsior (Thermo Fisher 
Scientific) on an overnight processing cycle, this system was not Xylene-free. 
Tissues were then embedded in paraffin prior to storage at RT.  
2.7.5 FFPE sectioning 
FFPE Tissue were sectioned on a Shandon Finesse 325 Microtome (Thermo Fisher 
Scientific) at 5μm. Ribboned sections were floated on a water bath at ≈40°C and 
then collected onto SuperfrostPlus Slides (VWR). Slides were then placed onto a 
heated slide drier for >1 hour prior to storage at RT. 
2.8 Gene Expression Analysis 
2.8.1 Primer Design 
Primers were designed using primer3 software(333, 334) using the following 
conditions: 
 Between 18 and 23 base-pair (bp) length (20bp optimal) 
 Between 40 and 65% GC content (50% optimal) 
 Annealing temperature (Tm) of primers between 59.5C and 61C (60C 
optimal) 
 Max self-complementarity: 2 
 Max 3’ self-complementarity: 1 
 Amplicon size 50-150bp  
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 No more than two G or C bases in last 5 at 3’ end 
 No stretches of G or C >4 
 Use of rodent mispriming library 
In addition, where possible, primers were designed to be exon-spanning using 
information available from NCBI RefSeq Sequences to help avoid amplification of 
genomic DNA. 
Primers were checked for specificity using NCBI Primer Blast(335) for species Mus 
Musculus (taxid: 10090). Standard primers were designed using primer3 software 
as per the above specification with the following modifications: 
 Included region was defined as the quantitative real time PCR (qRT-PCR) 
amplicon region +20bp at both the 3’ and 5’ end 
 Amplicon size was extended to be 100-500bp 
If no standard primers could be designed using the above specifications the Tm 
range was widened to allow for greater flexibility in primer design. Once primers 
were designed they were ordered from Integrated DNA Technologies. 
Details of all designed primers can be seen in Table 2.2 and Table 2.3 for qRT-
PCR and standard primers respectively. 
Target qRT-PCR Primer 1 qRT-PCR Primer 2 
Ccl2 CTC ACC TGC TGC TAC TCA TTC A  CCA TTC CTT CTT GGG GTC A  
Ccl3 CAG CCA GGT GTC ATT TTC CT CAG GCA TTC AGT TCC AGG TC 
Ccl4 TGA CCA AAA GAG GCA GAC AGA T GCT GTG CCA CAT CTC TTG GT 
Ccl5 CTG CTG CTT TGC CTA CCT CT ACA CAC TTG GCG GTT CCT T 
Ccl9 CTC ACA ACC ACG GAC CTA CA CAC TGG GGA AGA CCA AAG AA 
Ccl11 GCA CCC TGA AAG CCA TAG TCT TGG GGT CAG CAC AGA TCT CT 
Ccl19 GTG CCT GCT GTT GTG TTC AC CAA GAC ACA GGG CTC CTT CTG 
Cxcl1 CCG AAG TCA TAG CCA CAC TCA AGG TGC CAT CAG AGC AGT CT 
Cxcl10 GCT CAA GTG GCT GGG ATG GAG GAC AAG GAG GGT GTG G 
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Target qRT-PCR Primer 1 qRT-PCR Primer 2 
Cxcl13 CAT ACC CAA CCC ACA TCC TT GCC TGT TCT CAA ATA GCC TTT C 
Cxcl16 TGC TGA CCC TTT GCC TCT AC GGC TGG CTT GGA CTA AAT AAC A 
Cx3cl1 CAA CTT CCG AGG CAC AGG AT AGA TGT CAG CCG CCT CAA AA 
Ccr5 TTT GTT CCT GCC TTC AGA CC TTG GTG CTC TTT CCT CAT CTC 
Il-1B CGC TCA GGG TCA CAA GAA AC  GAG GCA AGG AGG AAA ACA CA  
TNFa CAC CAC CAT CAA GGA CTC AA  GAG GCA ACC TGA CCA CTC TC  
Il-6 TTC CAT CCA GTT GCC TTC TT  ATT TCC ACG ATT TCC CAG AG 
Il-10 CAG AGA AGC ATG GCC CAG AA  GCT CCA CTG CCT TGC TCT TA  
Tbp TGC TGT TGG TGA TTG TTG GT AAC TGG CTT GTG TGG GAA AG 
Table 2.2: Primers for qRT-PCR 
 
Target Standard Primer 1 Standard Primer 2 
Ccl2 CAC CAG CAC CAG CCA ACT  GCA TCA CAG TCC GAG TCA CA  
Ccl3 CCA CGC CAA TTC ATC GTT TAT GCA GGT GGC AGG AAT GT 
Ccl4 CTA ACC CCG AGC AAC ACC AT CTG AAC GTG AGG AGC AAG GA 
Ccl5 CCC TCA CCA TCA TCC TCA CT TCA GAA TCA AGA GGC CCT CTA TCC 
Ccl9 GCC CTC TCC TTC CTC ATT CT CTT CAG ACC TTC CAG GCA TC 
Ccl11 TGC TGC TCA CGG TCA CTT C CTT AGG CTC TGG GTT AGT GTC AA 
Ccl19 GCC TTC CGC TAC CTT CTT AAT GA GCA CAG ACT TGG CTG GGT TA 
Cxcl1 ACA CTC CAA CAC AGC ACC AT AGC AGA ACT GAA CTA CCA TCG A 
Cxcl10 CGA TGG ATG GAC AGC AGA GAG CCT GAC AAG GAG GGT GTG GGG AGC A 
Cxcl13 AAC GCT GCT TCT CCT CCT G CCA TCT CGC AAA CCT CTT GT 
Cxcl16 CGC CTA CAG CAA GAG TGG A AAG AGT GTT CCC CAA GAG CA 
Cx3cl1 GCC TGA ATC CGC CAC ATT G CCT GAG GAG ATG GGG CTG TA 
Ccr5 ACC CAT TGA GGA AAC AGC AA CCT CTG AGG GGC ACA ACA AC 
Il-1B TGG GCT GGA CTG TTT CTA ATG C  CCA CAC GTT GAC AGC TAG GT  
TNFa TCT GTG AAG GGA ATG GGT GT  GGC TGG CTC TGT GAG GAA 
Il-6 TCC AGA AAC CGC TAT GAA GT  CTC CAG AAG ACC AGA GGA AA  
Il-10 TGC TAA CCG ACT CCT TAA TGC A GGC CTT GTA GAC ACC TTG GT 
Tbp GAG TTG CTT GCT CTG TGC TG ATA CTG GGA AGG CGG AAT GT 
Table 2.3: Primers for generation of standard curves 
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2.8.2 Standard Curve Generation 
Standard curves were generated using Expand Hi Fi master mix (Roche) or 
Phusion master mix (Thermo Fisher Scientific) as per manufacturer’s instructions 
using a positive sample of cDNA. Optimal Tms were calculated using New 
England Biolabs (NEB) Tm Calculator (Available at: tmcalculator.neb.com). A 
small aliquot was analysed by gel electrophoresis. If amplification was non-
specific the total PCR product was separated by gel electrophoresis and the 
specific band extracted using PureLink Gel Extraction Kit (Thermo Fisher 
Scientific), as per manufacturer’s instructions. 
The standard aliquot concentration was then quantified using triplicate 
nanodrop readings. To obtain an estimate of the number of DNA molecules 
present, molecular weight of the standard sequence was estimated using 
OligoCalc: Oligonucleotide Properties Calculator(336). The following formula was 
then used to obtain an estimate of the number of molecules present in the raw 
standard per μl: 
OR   
This was multiplied by 10-4 for input into the machine (first point on the 
standard curve) 
The raw standard was diluted 100 fold to generate a 10-2 stock prior to storage 
at -20°C. 
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2.8.3 Primer Validation PCR 
Primers for qRT-PCR were validated using SYBR Green PerfeCTa master mix, 
along with a positive sample: 
 5ul PerfeCTa 2x master mix 
 3.85ul RNase-free H2O 
 0.15ul primer pair 
 1ul cDNA sample 
PCR was performed for 40 cycles in a Veriti 96 well thermal cycler (Thermo 
Fisher Scientific) under the following conditions:  
 95°C – 3’  
 95°C – 3”  
 60°C – 30”  
The PCR product was analysed by gel electrophoresis with a 100bp ladder to 
confirm that there was only one specific product of the expected amplicon size. 
2.8.4 Gel Electrophoresis 
Gel electrophoresis of PCR product was performed using 2% agarose gel with a 
100bp ladder (New England Biolabs). Sample and ladder were loaded with 
BlueJuice Gel Loading Buffer (10x) (Thermo Fisher Scientific) and run at 80-100V 
until clear individual bands were visible. 
  
x 40 
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2.8.5 Quantitative Real-time Polymerase Chain Reaction qRT-PCR 
qRT-PCR was performed using 7900HT and QuantStudio7 (ThermoFisher 
Scientific), qRT-PCR machines. PerfeCTa SYBR Green FastMix with ROX reference 
dye (QuantaBio) was used: 
 5ul PerfeCTa 2x master mix 
 3.85ul RNase-free H2O 
 0.15ul primer pair 
 1ul cDNA sample 
Samples were run in triplicate on 384 Well PCR Plates (Starlab) and calibrated 
using a standard curve for either relative or absolute quantification. 6 point 
standard curves started at 10-4 dilution with a final point of 10-9. In the case of 
relative quantification, all standard curves were set at a range of 1,000,000 to 
10. A dissociation step was included at the end of thermal cycling to generate a 
melt curve so that product specificity could be assessed. Thermal cycles for the 
machines are shown in Table 2.4 
7900HT QuantStudio7 
A
m
p
lific
a
tio
n
 
95°C – 3’ 95°C – 20” 
95°C – 3” 
60°C – 30” 
95°C – 1” 
60°C – 20” 
D
isso
c
ia
tio
n
 
95°C – 15” 
60°C – 15” 
95°C – 15” 
95°C – 15” 
60°C – 1’ 
95°C – 15” 
Table 2.4: Thermal cycles of qRT-PCR machines 
 
x 40 x 40 
Chapter 2 99 
 
2.8.6 Analysis 
Raw cycle threshold (Ct) values and quantities were exported from the qRT-PCR 
software after checking that amplification had occurred and that standard 
curves, melt curves and negative controls were of sufficient quality. All 
subsequent analysis was performed in Excel 2013 (Microsoft)and statistical 
analysis was performed using GraphPad7 software (GraphPad Software). The 
analysis workflow was as follows: 
1) Assess coefficient of variation of Ct triplicates 
a) Any triplicates with a coefficient of variation >2.5% (SD = 0.5, @ Ct = 20) 
had an outlier excluded if it was >1.5 from median values 
2) Generate means of quantities calculated from standard curve 
3) If required subtract background levels from no template or no reverse 
transcriptase controls (whichever was highest) 
4) Calculate gene expression value relative to TATA-binding protein (Tbp) 
a) For absolute quantification this was the final value for gene expression 
presented as copies/103 Tbp 
b) For relative quantification, arbitrary value relative to Tbp was compared 
to the average of all control arbitrary values to generate a fold change 
compared to the control sample 
NB: For the first 3 day single time-point experiments in Chapter 2 (Figure 4.2, 
Figure 4.3, Figure 4.4) background subtraction was not performed.  
2.9 LegendPlex Protein Assay 
2.9.1 LegendPlex Protein Assay 
Protein expression was measured using the Legendplex assay (BioLegend) as per 
the manufacturer’s instructions. In brief, beads were incubated with protein 
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extract for 2 hours at 600rpm on a plate shaker. Beads were then conjugated 
with streptavidin-phycoerythrin (SA-PE) for 30 minutes and two washes were 
performed prior to sample reading using a BD LSR-II flow cytometer (BD 
Biosciences). Samples were differentiated on the basis of bead size and 
allophycocyanin fluorescence, while protein quantity was determined using SA-
PE fluorescence calibrated to a standard curve. 
2.10 Immunohistochemistry 
2.10.1 Haematoxylin and eosin staining 
FFPE sections were initially deparaffinised in Xylene and rehydrated in reducing 
concentrations of EtOH (100%, 90%, 70%). Sections were briefly washed in 
running tap water and then stained in Haematoxylin Z (CellPath) solution. 
Sections were washed again until the water ran clear. Haematoxylin stain was 
regressed in 1% acid alcohol and then blued in STW. Counterstaining in Eosin Y 
was performed prior to dehydration in increasing concentrations of alcohol and 
Xylene. Finally sections were mounted with DPX (Leica Microsystems). 
2.10.2 Chromogenic Immunohistochemistry  
Chromogenic immunohistochemistry was performed on FFPE sections after 
sectioning. Sections were de-paraffinised in Xylene before undergoing 
rehydration in decreasing concentrations of EtOH. Antigen retrieval was 
performed in boiling sodium citrate antigen retrieval buffer for 6 minutes in a 
microwave at full power. Slides were subsequently washed in TBX and 
endogenous peroxidase activity was quenched using 3% H2O2 in methanol for 20 
minutes or BLOXALL Endogenous Peroxidase and Alkaline Phosphatase Blocking 
Solution (Vector Laboratories) for 10 minutes. Prior to antibody incubation, 
sections were isolated on the slide using an ImmEdge Hydrophobic Barrier Pen 
(Vector Laboratories) and blocked in TBX + 10% serum for one hour @ RT. Serum 
was derived from the animal that the secondary antibody was raised in. Primary 
antibody or isotype was diluted in TBX + 2% serum at equal concentrations and 
then applied to sections overnight @4°C. 
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Following overnight incubation, sections were washed in TB, and secondary 
biotinylated anti-species antibody was applied to sections for 30 minutes @ RT.  
After washing in TB, ABC reagent (prepared >30 minutes in advance) with 
horseradish peroxidase (Vector Laboratories) was applied to sections for 30 
minutes @ RT. After a final wash in TB, 3,3’-diaminobenzidine (DAB) was applied 
to sections and allowed to develop for an appropriate amount of time. Sections 
were then washed in running water, counterstained with Haematoxylin QS, then 
dehydrated and mounted using DPX. 
All CD3 staining was performed by the Veterinary Diagnostic Services Core 
Facility at the University of Glasgow. (Vector Laboratories CD3 VP-RM01;Abcam 
CD3 Ab16669). 
Details of antibodies used can be found in Table 2.5 
Antibody 
Dilution (Final 
Concentration) 
Species Catalogue No. 
Primary Antibodies 
Iba1  1:2000 (0.25μg/ml) Rabbit 019-19741 [AlphaLabs] 
GFAP 1:2000 (1.3μg/ml) Rabbit Z0334 [DAKO] 
Secondary Biotinylated Antibodies 
Anti-Rabbit 1:4000 (0.375ug/ml) Horse 
BA-1100 [Vector 
Laboratories] 
Table 2.5: Primary and Secondary Antibodies used in IHC 
 
2.10.3 Image Analysis and Quantification 
Following immunohistochemistry slides were scanned at 20x resolution using 
Leica SCN400F (Leica Microsystems). Full scans of slides were then available to 
view in ImageScope software (Leica Microsystems). For each animal 2-3 sections 
were analysed for each stain. All image capture and analysis was performed on 
blinded slides. 
For Iba1 a single field of view was taken from both the hippocampus and cortex, 
for GFAP three fields of view were taken from hippocampus. Using ImageJ 
software an automated analysis algorithm was used to quantify percentage area 
stained. Briefly, background was subtracted in an automated fashion, images 
were separated into haematoxylin and DAB channels. Threshold was then set to 
Chapter 2 102 
 
a pre-determined value on the DAB separated image and the area above 
threshold quantified. Validity of analysis technique was confirmed by three 
independent individuals through the use of random image matching with a single 
dummy image. All individuals confirmed the six matched images were accurate 
representations and correctly identified the dummy slide in a blind fashion. 
For CD3 staining cell counts were performed, for hippocampus all CD3+ cells 
within the hippocampus were counted. For the cortex three fields of view were 
counted. 
2.11 Mass Spectrometry Analysis 
2.11.1 Mass Spectrometry Analysis 
Plasma and brain samples were sent to the Biomarker and Drug Analysis Core 
Facility at the University of Dundee (http://medicine.dundee.ac.uk/biomarker-
and-drug-analysis-core-facility) for mass spectrometry analysis. Briefly, samples 
were extensively homogenized prior to solid phase extraction using in-house 
strong cation exchange SpinTip. Eluents were vacuum dried and then 
reconstituted in 25μL elution solution. Liquid chromatography coupled with 
tandem mass spectrometry was performed using a HILIC colum (Intersil, GL 
Sciences) and a Thermo Quantum Ultra mass spectrometer (ThermoFisher 
Scientific). The lower limit of quantification was 1.57 ng/mL. 
2.12 Statistical Analysis 
2.12.1 Between group comparisons 
All statistical analysis was performed in Prism 7 software. Non-parametric data 
were log transformed prior to parametric tests. Student’s t-test, one-way 
analysis of variance (ANOVA) (with post-hoc tests) or two-way ANOVA (with post-
hoc tests) were used to test for significant differences between groups. If 
multiple genes or time points were tested in the same experiment Bonferroni’s 
multiple correction testing was applied to account for the increased probability 
of type I errors. For protein data, if samples were below the limit of detection 
they were set to the limit of detection for statistical analysis. A p-value of <0.05 
was considered significant.  
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2.12.2 Linear regression analysis 
For linear regression all non-normally distributed samples were log-transformed 
prior to analysis. Linear regression was performed in Prism 7 software. For 
protein and mRNA analysis all samples with an mRNA fold change <2 were 
excluded from analysis. A p-value of <0.05 was considered significant. 
2.12.3 Power calculation 
Power calculation for 5.3.2 was performed using normalised means obtained 
from both iCCRKO experiments and a pooled standard deviation from both 
groups. Power calculation was performed using 
https://www.stat.ubc.ca/~rollin/stats/ssize/n2.html 
104 
 
 
 
 
 
 
 
 
Chapter 3 
A Systematic Review and Meta-Analysis of 
Chemokines in Human Depression 
Chapter 3 105 
 
Chapter 3 A Systematic Review and Meta-
Analysis of Chemokines in Human Depression 
3.1 Introduction 
The burden of depression on health and social care systems, as well as affected 
individuals is great (1), yet current treatment options are limited(3). An 
association between depressive disorders and inflammation has been established 
through both individual biomarker studies and large meta-analyses of this field 
(15-17, 300-303). This has helped to support a growing field of research into 
psychoneuroimmunology and aided in the identification of potential molecular 
pathways to be investigated. Despite this growing body of research, there has 
been a paucity of reviews on the chemokine molecule family, aside from 
CCL2/MCP-1 and CXCL8/Il-8. As discussed earlier, chemokines are highly 
pleiotropic and increasingly associated with CNS functions (30, 101, 337) making 
them attractive candidates for study. 
This is likely due to two main reasons, firstly, chemokines are a newer field of 
study in psychoneuroimmunology particularly in a clinical context. Secondly, 
until standardisation of nomenclature most chemokines had multiple variant 
names making review of the literature challenging and many studies on 
chemokines can be difficult to identify(338). 
To fill this gap in the literature, SL and LN carried out a comprehensive review 
of the human biomarker literature examining chemokine expression in depressed 
individuals compared to controls. It is worth noting that throughout the course 
of this process two meta-analyses were published that looked at chemokines (15, 
300) however these only presented results for CCL2, CCL3 and CXCL8 and 
identified a relatively limited number of studies for each. 
This review used a broad approach, including grey literature (e.g. conference 
abstracts) where appropriate. Through use of a highly structured search strategy 
based on the PICO framework; Population was human; Intervention was 
depression; Comparison was no depression; Outcome was change in chemokine 
levels, and utilising multiple variant names for chemokine molecules this 
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analysis hopes to have overcome some of the challenges that review of the 
chemokine literature present.  
3.2 Results 
3.2.1 Search Results and Study Inclusion 
Systematic search of EMBASE, PsycINFO and MEDLINE databases up until 5th 
March 2016 identified a total of 8497 studies (Figure 3.1). Removal of duplicates 
resulted in 7440 unique studies. Exclusion based on title removed 4105 studies. 
Subsequently 3335 abstracts were reviewed, with 2981 studies excluded. 354 full 
texts were then reviewed with 72 meeting the criteria for inclusion in the meta-
analysis (339-410). 
 
Figure 3.1: PRISMA Flow Chart demonstrating study selection process for meta-analysis 
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3.2.2 Study Quality 
Assessment of study quality based on modified Cochrane collaboration and 
Newcastle-Ottawa criteria, combined with assessment for confounders, revealed 
large differences in quality between studies. Out of a total of 17 possible points 
a range of 3 to 17 was found within the identified studies (Table 3.1). Most 
studies were contained within a narrower interquartile range of 10 to 13. 
Study ID 
Study Design 
(Max. 3) 
Outcomes Confounders 
(Max. 6) 
Other Total 
Score (Max. 6) (Max. 2) 
Bai 2014 2 5 3 2 12 
Bai 2015 2 5 2 2 11 
Bazzichi 2007 2 5 3 2 12 
Blasko 2006 2 5 2 2 11 
Byrne 2013 3 5 3 2 13 
Cizza 2008 3 6 3 1 13 
Corwin 2015 3 5 6 1 15 
Dahl 2014 3 5 5 1 14 
Daniele  2015 3 5 1 1 10 
Dantoft 2014 2 5 1 2 10 
Dekker 2014 2 5 3 1 11 
Dong 2013 2 5 1 1 9 
Einvik 2012 3 5 4 1 13 
Eller 2008 2 5 5 2 14 
Fontenelle  2012 3 4 1 2 10 
García-Lozano 2008 3 5 1 0 9 
Gehi 2010 3 5 2 2 12 
Grassi-Oliveira 2012 2 5 3 2 12 
Gur 2002 3 5 1 2 11 
Halaris 2015 3 4 5 1 13 
Hallberg 2010 3 5 3 2 13 
Ho 2015 2 5 4 2 13 
Hocaoglu 2012 3 4 3 2 12 
Hüfner 2015 3 5 5 2 15 
Janelidze 2013 3 5 1 1 10 
Janelidze 2015 3 3 5 2 13 
Jonsdottir  2009 3 3 3 2 11 
Juengst 2015 2 5 4 2 13 
Kahl 2009 2 5 6 2 15 
Karege 2005 3 5 2 2 12 
Kelly 2015 2 5 2 1 10 
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Study ID 
Study Design 
(Max. 3) 
Outcomes Confounders 
(Max. 6) 
Other Total 
Score (Max. 6) (Max. 2) 
Kern 2014 3 5 2 2 12 
Kudoh 2001 3 1 1 2 7 
Kuijpers 2002 3 5 3 2 13 
Laake  2014 3 5 1 1 10 
Laghrissi-Thode 1997 3 4 3 2 12 
Lebedeva 2014 2 1 0 0 3 
Lee  2009 3 4 4 2 13 
Lehto  2010 3 4 4 2 13 
Lindqvist 2009 3 5 4 2 14 
Lindqvist 2011 3 5 3 2 13 
Lu  2013 3 5 5 2 15 
Mantur 2006 3 5 1 2 11 
Marksteiner  2011 1 5 1 2 9 
Mikova 2001 2 5 4 2 13 
Miller  2002 3 3 4 2 12 
Motivala  2005 3 5 6 2 16 
Musselman 2002 3 6 2 2 13 
Neupane  2015 3 5 0 1 9 
O'brien 2007 3 5 2 2 12 
Oglodek 2014 2 2 4 1 9 
Piletz  2009 3 6 6 2 17 
Pisetsky 2014 2 3 1 2 8 
Plourde 2011 2 5 0 1 8 
Podlipny 2010 3 4 3 1 11 
Pomara 2012 2 5 0 1 8 
Pomara 2013 2 5 0 1 8 
Rajagopalan  2001 2 6 4 2 14 
Rybka 2012 0 4 2 1 7 
Schins 2004 3 5 4 2 14 
Serebruany 2003 3 4 1 2 10 
Shelton 2015 3 5 1 2 11 
Simon 2008 2 5 3 2 12 
Song 1998 2 5 3 2 12 
Sutcigil  2007 2 2 3 2 9 
Tajfard  2014 3 5 2 1 11 
van Sloten 2014 3 5 2 1 11 
Weng 2004 2 5 0 1 8 
Whyte 2001 3 4 2 2 11 
Wong 2008 3 1 4 2 10 
Xiong 2015 3 6 1 1 11 
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Study ID 
Study Design 
(Max. 3) 
Outcomes Confounders 
(Max. 6) 
Other Total 
Score (Max. 6) (Max. 2) 
Zahn 2015 3 5 3 2 13 
Zhen 2015 3 5 1 2 11 
Table 3.1: Risk of bias scores from studies included in meta-analysis. Higher scores 
indicate lower risks of bias. 
 
3.2.3 CCL2 
For blood CCL2 21 studies with 4688 participants were identified. There was a 
significant increase in CCL2 concentrations in depressed compared to non-
depressed subjects (SMD 0.21; 95% CI 0.02, 0.40; p=0.03) (Figure 3.2). There was 
significant heterogeneity identified (I2=81%; p<0.00001). The funnel plot 
displayed evidence of asymmetry (Figure 3.3) and Egger’s test found significant 
evidence of this (p=0.0071). Despite this, trim and fill, did not impute any 
studies. Analysis of studies after manual removal of the funnel plot outlier 
Suticigil et al. 2007 did not retain significance (SMD 0.11; 95% CI -0.03, 0.25; 
p=0.12) 
Sensitivity analysis in studies with only healthy participants (n=17) retained 
significance (SMD 0.26, 95% CI 0.01, 0.51; p=0.04) however this significance was 
lost again once Suticigil et al. were manually removed. Sensitivity analysis of 
plasma and serum samples, demonstrated significant differences in serum (n=12) 
(SMD 0.33; 95% CI 0.09, 0.58; p=0.007) but not plasma, following manual 
removal of Suticigil et al. this difference was borderline significant (SMD 0.17; 
95% CI -0.00, 0.34; p=0.05). Final sensitivity analysis of only those studies with a 
low risk of bias (n=12) did not retain significance (SMD 0.18; 95% CI -0.05, 0.40; 
p=0.12) and this group did not contain the Suticigil et al. study. 
2 studies with 81 participants were also identified for CSF CCL2, there was no 
significant difference between depressed and non-depressed subjects (SMD -
0.20; 95% CI -0.66, 0.26; p=0.40), due to the low number of studies no further 
sensitivity analysis was performed. 
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Figure 3.2: (Previous page) Meta-analysis of blood CCL2 in depressed and non-depressed 
subjects.  
Forest plot of CCL2 meta-analysis generated in RevMan 5.3 software using random effects inverse 
variance model. SD = Standard Deviation, IV = Inverse Variance, CI = Confidence Interval. 
 
 
Figure 3.3: Funnel plot of blood CCL2 studies generated in R using metafor package. 
 
3.2.4 CCL3 
For blood CCL3 6 studies with 510 participants were identified. There was no 
significant difference in CCL3 concentrations in depressed compared to non-
depressed subjects (SMD 0.33; 95% CI -0.06, 0.71; p=0.10) (Figure 3.4). There 
was significant heterogeneity identified (I2=76%; p=0.0008). There was no 
evidence of asymmetry in the funnel plot (Figure 3.5) and Egger’s test was not 
significant. 
Sensitivity analysis in studies with only healthy participants (n=5) found a 
significant increase in blood CCL3 concentrations in depressed individuals (SMD 
0.48, 95% CI 0.20, 0.76; p=0.0007). Sensitivity analysis of plasma and serum 
samples demonstrated no significant differences. Final sensitivity analysis of 
only those studies with a low risk of bias (n=4) did demonstrate significant 
increases in blood CCL3 concentrations in depressed subjects (SMD 0.58, 95% CI -
0.35, 0.82, p<0.00001). 
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Figure 3.5: Funnel plot of blood CCL3 studies generated in R using metafor package. 
 
 
3.2.5 CCL4 
For blood CCL4 5 studies with 507 participants were identified. There was a 
significant decrease in CCL4 concentrations in depressed compared to non-
depressed subjects (SMD -0.31; 95% CI -0.49, -0.13; p=0.0007) (Figure 3.6). 
There was no significant heterogeneity identified (I2=0%; p=0.85). There was no 
evidence of asymmetry in the funnel plot (Figure 3.7) and Egger’s test was not 
significant. 
Sensitivity analysis in studies with only healthy participants (n=4) retained 
significance (SMD -0.32, 95% CI -0.54, -0.10; p=0.005).In addition, these studies 
all had a low risk of bias. Sensitivity analysis of plasma and serum samples 
demonstrated significant differences in serum (n=3) (SMD -0.33; 95% CI -0.54, -
0.12; p=0.002) but not plasma.  
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Figure 3.7: Funnel plot of blood CCL4 studies generated in R using metafor package. 
 
3.2.6 CCL5 
For blood CCL5 6 studies with 444 participants were identified. There was no 
significant difference in CCL5 concentrations in depressed compared to non-
depressed subjects (SMD -0.10; 95% CI -0.59, 0.40; p=0.70). There was significant 
heterogeneity identified (I2=82%; p<0.00001). There was some evidence of 
asymmetry in the funnel plot, however, Egger’s test was not significant. 
Sensitivity analysis in studies with only healthy participants or ill participants, 
using plasma or serum or examining only those studies with a low risk of bias did 
not achieve significance. 
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3.2.7 CCL11 
For blood CCL11 7 studies with 547 participants were identified. There was no 
significant difference in CCL11 concentrations in depressed compared to non-
depressed subjects (SMD -0.27; 95% CI -1.17, 0.62; p=0.55) (Figure 3.8). There 
was significant heterogeneity identified (I2=64%; p=0.02). There was some 
evidence of asymmetry in the funnel plot (Figure 3.9), however, Egger’s test was 
not significant. 
Sensitivity analysis in studies with only healthy participants (n=5) found a 
significant increase in blood CCL11 concentrations in depressed individuals (SMD 
0.44, 95% CI 0.20, 0.68; p=0.0003). Sensitivity analysis of plasma and serum 
samples demonstrated no significant differences. Final sensitivity analysis of 
only those studies with a low risk of bias (n=4) did demonstrate significant 
increases in blood CCL11 concentrations in depressed subjects (SMD 0.48, 95% CI 
0.22, 0.74, p=0.0003). 
 
Figure 3.9: Funnel plot of blood CCL11 studies generated in R using metafor package. 
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3.2.8 CXCL4 
For blood CXCL4 11 studies with 816 participants were identified. There was a 
significant increase in CXCL4 concentrations in depressed compared to non-
depressed subjects (SMD 0.93; 95% CI 0.17, 1.70; p=0.02) (Figure 3.10). There 
was significant heterogeneity identified (I2=96%; p<0.00001). There was evidence 
of asymmetry in the funnel plot (Figure 3.11), however, Egger’s test was not 
significant. Karege et al. 2005 had values for both serum and plasma, sensitivity 
analysis removing either of these retained significance. 
Sensitivity analysis in studies with only healthy participants or ill participants, 
using plasma or serum or examining only those studies with a low risk of bias did 
not achieve significance. 
 
Figure 3.11: Funnel plot of blood CXCL4 studies generated in R using metafor package 
  
Chapter 3 120 
 
 
F
ig
u
re
 3
.1
2
: M
e
ta
-a
n
a
ly
s
is
 o
f b
lo
o
d
 C
X
C
L
7
 in
 d
e
p
re
s
s
e
d
 a
n
d
 n
o
n
-d
e
p
re
s
s
e
d
 s
u
b
je
c
ts
.  
F
o
re
s
t p
lo
t o
f b
lo
o
d
 C
X
C
L
7
 m
e
ta
-a
n
a
ly
s
is
 g
e
n
e
ra
te
d
 in
 R
e
v
M
a
n
 5
.3
 s
o
ftw
a
re
 u
s
in
g
 ra
n
d
o
m
 e
ffe
c
ts
 in
v
e
rs
e
 v
a
ria
n
c
e
 m
o
d
e
l. S
D
 =
 S
ta
n
d
a
rd
 D
e
v
ia
tio
n
, IV
 =
 In
v
e
rs
e
 
V
a
ria
n
c
e
, C
I =
 C
o
n
fid
e
n
c
e
 In
te
rv
a
l. 
 
Chapter 3 121 
 
3.2.9 CXCL7 
For blood CXCL7 11 studies with 711 participants were identified. There was a 
significant increase in CXCL7 concentrations in depressed compared to non-
depressed subjects (SMD 0.63; 95% CI 0.10, 1.70; p=0.02) (Figure 3.12). There 
was significant heterogeneity identified (I2=90%; p<0.00001). There was some 
evidence of asymmetry in the funnel plot (Figure 3.13), however, Egger’s test 
was not significant. 
Sensitivity analysis in studies with only healthy participants (n=6) retained 
significance (SMD 0.54, 95% CI 0.30, 0.77; p<0.00001). Sensitivity analysis of 
plasma and serum samples demonstrated significant increases in plasma (n=9) 
(SMD 0.71; 95% CI 0.05, 1.37; p=0.04) but not serum. Final sensitivity analysis of 
only those studies with a low risk of bias (n=8) was borderline significant (SMD 
0.40, 95% CI -0.00, 0.80, p=0.05). 
 
Figure 3.13: Funnel plot of blood CXCL7 studies generated in R using metafor package. 
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3.2.10 CXCL8 
For blood CXCL8 40 studies with 3788 participants were identified. There was a 
significant increase in CXCL8 concentrations in depressed compared to non-
depressed subjects (SMD 0.26; 95% CI 0.06, 0.46; p=0.01) (Figure 3.14). There 
was significant heterogeneity identified (I2=84%; p<0.00001). There was 
moderate evidence of asymmetry in the funnel plot (Figure 3.15), however, 
Egger’s test was not significant. 
 
Figure 3.15: Funnel plot of blood CXCL8 studies generated in R using metafor package. 
 
Sensitivity analysis in studies with only healthy participants (n=29) retained 
significance (SMD 0.26, 95% CI 0.05, 0.46; p=0.01). Sensitivity analysis of plasma 
and serum samples demonstrated significant increases in plasma (n=17) (SMD 
0.57; 95% CI 0.17, 1.00; p=0.006) but not serum. Final sensitivity analysis of only 
those studies with a low risk of bias did not retain significance. 
We also identified 6 studies with 361 participants for CSF CXCL8, there was no 
significant difference between depressed and non-depressed subjects (SMD 0.19; 
95% CI -0.15, 0.54; p=0.40).  Funnel plot did not show evidence of asymmetry 
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and Egger’s test was not significant. Sensitivity analysis on healthy individuals or 
studies with a low risk of bias did not reveal significant differences.  
3.2.11 CXCL10 
For blood CXCL10 3 studies with 350 participants were identified. There was no 
significant difference in CXCL10 concentrations in depressed compared to non-
depressed subjects (SMD 1.17; 95% CI -0.26, 2.61; p=0.11). No further analysis 
was performed due to the low number of studies. 
We also identified 4 studies with 208 participants for CSF CXCL10, there was no 
significant difference between depressed and non-depressed subjects (SMD -
0.06; 95% CI -0.35, 0.22; p=0.66). Due to the low number of studies no further 
analysis was performed. 
3.2.12 CXCL12 
For blood CXCL12 2 studies with 121 participants were identified. There was a 
significant increase in CXCL12 concentrations in depressed compared to non-
depressed subjects (SMD 0.44; 95% CI 0.05, 0.82; p=0.03) (Figure 3.16). No 
further analysis was performed due to the low number of studies. 
3.2.13 Other chemokines 
A number of other chemokines (CCL7, CCL15, CCL18, CCL24, CCL27, CXCL1 and 
CXCL9) that had ≤3 studies and no significant results were also analysed. Details 
of effect sizes for these chemokines can be seen in Table 3.2. 
Chemokine Studies Participants Effect Estimate [95% CI] 
CCL7 3 156 0.07 [-0.65, 0.79] 
CCL15 2 100 0.09 [-0.31, 0.50] 
CCL18 2 100 0.15 [-0.26, 0.56] 
CCL24 2 105 -0.11 [-0.76, 0.53] 
CCL27 2 121 -0.21 [-0.78, 0.37] 
CXCL1 2 121 0.28 [-0.10, 0.66] 
CXCL9 3 161 -0.05 [-0.60, 0.49] 
Table 3.2: Non-signficant results from chemokines with ≤3 studies included in meta-
analysis.  
Effect size generated in RevMan 5.3 software. CI = Confidence interval. 
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3.3 Discussion 
3.3.1 Summary of results and concordance with existing 
literature 
Overall significant increases in CCL2, CXCL4, CXCL7, CXCL8 and CXCL12 were 
found. In addition, a significant decrease in CCL4 was identified when comparing 
depressed and non-depressed subjects (Table 3.3). Sensitivity analysis of studies 
with only healthy participants revealed further differences with both CCL3 and 
CCL11 being significantly increased in depressed compared to non-depressed 
subjects, and only CXCL4 losing significance. Interestingly, no significant 
differences were identified when examining only studies in which subjects had 
physical comorbidities. This suggests that in the context of illness likely to affect 
inflammation, immune markers are not a useful tool for discriminating 
depressive illness. This is likely due to the fact that biological noise in already 
raised markers will mask the smaller increases expected from depressive illness.  
Chemokine Overall Health Illness Plasma Serum Low Bias 
CCL2 Increase Increase NS NS Increase NS 
CCL3 NS Increase NS Increase NS Increase 
CCL4 Decrease Decrease NS NS Decrease Decrease 
CCL11 NS Increase NS NS NS Increase 
CXCL4 Increase NS NS NS NS NS 
CXCL7 Increase Increase NS Increase NS Increase 
CXCL8 Increase Increase NS Increase NS NS 
Table 3.3: Significant results and sensitivity analysis in chemokines with >5 studies 
identified and a significant difference.  
Italics indicates borderline significance (=0.05). NS = Not significant. Significance indicated by 
p<0.05 in a random effects model using inverse variance weighting. 
 
Further to this, examining differences in only plasma or only serum did not 
reveal any particular pattern. Analysis of only studies considered to have a low 
risk of bias also did not reveal a particular pattern. A number of studies lost 
significance within this context suggesting a role for poorer study design in the 
earlier identification of differences. However for both CCL3 and CCL11 
significance was gained. This is likely a reflection of the fact that there was 
considerable overlap between the studies in healthy participants and those with 
a low risk of bias and this may have supported identification of these changes. 
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The significant differences identified within this study strongly support the idea 
of peripheral alterations in circulating chemokines in depressive disorder. 
However, it should be noted that CCL2’s significance was largely due to a single 
study by Sutcigil et al. with a very large effect size (SMD=3.42) 
Both CXCL9 and CXCL10 are IFN stimulated genes and CXCL10 was recently 
identified as a key mediator of sickness behaviour in a study by Blank et al. (103) 
Despite this study, and the strong association of IFNs with depressive 
disorder(14), CXCL9 and CXCL10 were not significantly altered in depressed 
subjects. This may be a reflection of the lower number of studies available for 
these analytes. However only blood CXCL10 showed a trend and both blood 
CXCL9 and CSF CXCL10 did not appear to show any suggestion of significant 
effects. 
When comparing our findings to those observed in other meta-analyses by Eyre 
et al.(300) and Köhler et al.(15) significant increases in CCL2 were found, similar 
to these studies. However, unlike Eyre and Köhler increases in CXCL8 were also 
identified in this study. It is worth noting that Köhler et al. did not retain 
significance for CCL2 after exclusion of a study by Shen et al.(411). The paper by 
Shen et al. had been identified in this study, however, it was excluded prior to 
the meta-analysis due to a very high risk of bias and an inability to contact the 
authors. In addition, when examining studies with only a low risk of bias both of 
these analytes were not found to be significantly different in our meta-analysis. 
This suggests that more poorly designed studies may contribute to the significant 
alterations identified. Finally although Köhler et al. did not identify alterations 
in CCL3, the study in this chapter indicated the presence of significant increases 
that were retained even when considering only those studies with a lower risk of 
bias. Another possible explanation for the differences in CCL2, CCL3 and CXCL8 
findings between our study and the other meta-analyses is that a much greater 
number of studies were identified for inclusion, possibly due to the use of a 
more complete search strategy. 
Interestingly, Pantazatos et al. identified reductions in CCL4 at a transcriptional 
level in a post-mortem study of depressive disorder. This suggests that 
peripheral alterations observed here may also manifest within the CNS(412). 
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3.3.2 Biological relevance 
Although not widely studied in the context of behavioural and CNS alterations, 
work has shown that some of the chemokines above appear to be able to alter 
CNS physiology. CCL2 has been shown to be associated with, an influx of CCR2+ 
monocytes to the CNS following LPS challenge and liver injury(102, 413) and, 
activation of resident microglia(414). This association with microglial activation 
also links with emerging theories that depression and other CNS diseases may in 
part be microglial pathologies(308). Overexpression of CCL2 has also been 
associated with elevation of Il-1β and Il-6 cytokines that have been implicated in 
animal sickness behaviours (295) and human depression respectively (15-17, 301, 
302).  
Direct application of CCL2 to seroternergic neurons has been associated with 
decreases in action potential frequency and spontaneous discharge due to 
hyperpolarization and reductions in membrane resistance(102). Alongside these 
CCL2-associated electrophysiological alterations, CCL3 has been shown to alter 
hippocampal neuron firing and long-term potentiation effects that were linked 
to behavioural alterations in learning and memory. These effects could be 
reversed through co-administration of maraviroc a CCR5 antagonist(415). The 
finding that maraviroc blocked the effects of CCL3, suggests that the effects of 
CCL2 and CCL3 may be mediated through different receptors as CCL2 does not 
signal through CCR5 as CCL3 does(29). Alterations of chemokines may not 
necessarily be detrimental and could represent protective responses in stressed 
neurons. KO of CCR5 in a mouse model of nerve injury accelerated motor neuron 
death suggesting that CCR5 may be protective in the context of neurotoxicity 
(416). There is limited evidence currently available for CCL4 and a recent 
systematic review did not identify studies that implicated it in psychiatric 
disorders(417). Despite this, CCL4 has been associated with Treg cells (418) that 
have themselves been associated with depression (419). 
Villeda et al. found CCL11 to be mechanistically associated with reductions of 
hippocampal neurogenesis and impaired learning and memory(420), both of 
which have been associated with depressive disorders. Interestingly, this study 
also identified CCL2 as a factor that correlated with reductions in neurogenesis 
similar to CCL11. 
Chapter 3 130 
 
CXCL4 and CXCL7 are predominantly known for their role as platelet 
chemokines. Of the chemokines identified within this meta-analysis CCL2, CCL3, 
CXCL8 and CXCL12 are also thought to be platelet chemokines or associated with 
platelet activation (421, 422). Other platelet chemokines were either not part of 
this study due to insufficient studies (e.g. CCL17, CXCL5) or found to not be 
significantly altered within a very small number of studies (e.g. CXCL1 [n=2]). 
The only exception being CCL5 that had a similar number of studies, and 
participants, to other chemokines examined. This suggests there may be a 
potential association of platelet dysfunction with depressive disorder. This is 
supported by work showing that there is increased platelet activation in 
depressed patients (423, 424), and that this activation is decreased following 6 
months of cognitive and/or pharmaceutical therapy (423). 
CXCL4 alone has also been shown to be expressed by microglia in response to LPS 
in vitro and to induce their migration, in addition it was able to suppress the 
synthesis of nitric oxide (NO) in BV-2 cells but not primary microglia, and 
microglial phagocytosis was reduced in the presence of CXCL4(425) suggesting 
that it may have protective effects with regards to neurotoxicity similar to CCL3. 
These possible protective responses suggest that elevation of these chemokines 
may not be a driving factor in depression but rather a protective response to 
neuronal stress. 
It is harder to identify mechanistic links between CXCL8 and depressive 
behaviours as mice and rats do not have CXCL8, however CXCL1 is closely related 
to CXCL8(29). CXCL1 administered peripherally but not centrally was found to 
drive sickness behaviour responses in adult Wistar rats(426) suggesting that 
peripheral alterations may play a role in depressive phenotypes. Although 
alterations in CXCL1 were not found, there were only two studies and these did 
trend towards an increase in peripheral CXCL1. A recent study by Aguilar-Valles 
et al. identified neutrophils as mediators of sickness behaviour in the LPS model 
of inflammation(427), as CXCL8 is a neutrophil chemoattractant this suggests a 
possible mechanism through which elevated CXCL8 could contribute to 
depressive behaviours. 
CXCL12 has been shown to have effects on serotonergic, gamma-aminobutyric 
acid, glutamate and other CNS systems(428, 429). In addition, CXCR7 a receptor 
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for CXCL12 has been found to be rapidly upregulated on endothelial cells in 
response to TNFα treatment,(430) another molecule that has been linked with 
depression(318). Evidence has also suggested that CXCL12 can modulate 
neuroendocrine systems(337) and neurogenesis(30). Dysfunction of these CNS 
systems is implicated in depressive pathology (431, 432).  
Overall these data provide equivocal, and at times conflicting, evidence for a 
mechanistic role of identified chemokines in depressive behaviours. There is 
evidence that many of these chemokines can contribute to cellular recruitment 
and activation during neuroinflammation and promote alterations in CNS 
function associated with depressive behaviour such as reduction in neurogenesis, 
changes in neuronal function and HPA axis alteration. These lines of evidence 
promote the idea that raised chemokine levels are mechanistically associated 
with psychological disturbances. On the other hand, there is also evidence that 
some of these chemokines may have neuroprotective roles, while not mutually 
exclusive to the data presented above this would suggest a more reactionary 
rather than mechanistic role for chemokines in the context of depressive 
pathology. 
3.3.3 Limitations and Strengths of Study 
Throughout the course of this study a number of limitations within the human 
literature were identified. First and foremost, nearly all of the analytes assessed 
were taken from blood. This is a peripheral compartment and may not 
necessarily reflect what is observed in the brain. Differences in CCL2 and CXCL8 
that were observed in the blood of depressed subjects were not replicated in the 
CSF compartment. Although this may be partly due to the lower number of 
studies examined, it casts some doubt on the direct biological relevance of these 
findings. 
Secondly, there is large variability in the number of confounders that people 
account for. Evidence suggests that age(433), gender(434), BMI(435), 
smoking(436), circadian rhythms(437) and medications (e.g Nonsteroidal anti-
inflammatory drugs) can all influence immune status. When looking for the small 
differences anticipated in conditions like depressive disorder, accounting for 
these confounders is incredibly important. In addition, depressive disorder is 
Chapter 3 132 
 
also associated with nearly all of these confounders; depressive prevalence 
varies by age (438); depressive prevalence is greater in women(438); depressive 
prevalence varies based on BMI (439, 440), partly due to anti-depressant 
treatments(441); depression is associated with higher rates of smoking and lower 
rates of smoking cessation(442, 443); depression is associated with disturbances 
of circadian rhythmicity (444); and anti-depressant medication is associated with 
immune alterations as discussed in the introduction (16, 307). These associations 
between depression and inflammatory confounders increase the likelihood of 
confounding when effective matching does not occur. Unmatched confounders 
can easily lead to bias, particularly when there is non-reporting of these clinical 
demographics making it impossible to assess whether they are likely to be 
influencing perceived outcomes. 
Thirdly, small outlying studies can have large effects on meta-analysis results. In 
our study Sutcigil et al. provided an excellent example of this as removal of it 
from the analyses caused the significant difference in CCL2 to be lost, despite an 
overall n = 21. This is a challenging area to navigate as, if the study shows a high 
level of rigour and is conducted appropriately, it should be included in a meta-
analysis. However this can be difficult to ascertain particularly for older studies 
where online supplemental material may be lacking and identification of 
immune confounders was less advanced, meaning that there may be more 
limited reporting of demographics. 
Alongside these limitations, it is worth noting two major strengths of this study. 
Firstly the use of a comprehensive search strategy allowed for the inclusion of 
many more studies and chemokines than have previously been examined and 
allowed for more in depth sensitivity analysis. This identified alterations in 
chemokines that have not previously been reported in earlier meta-analyses. 
Secondly through the use of a more conservative random effects model it is 
possible to have increased confidence in the significant results identified, 
particularly from a statistical perspective. 
3.3.4 Conclusion 
Overall this study has demonstrated that there is significant evidence across 
multiple studies for peripheral alterations in circulating chemokine 
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concentrations. Despite this, there are methodological concerns when examining 
human biomarker studies. These include the relevance of peripheral biomarkers 
to CNS immunology and the role of unseen confounders in these studies, 
particularly emerging confounders such as circadian rhythm and the role of anti-
depressive medication in altering immune profiles. In addition, mechanistic 
conclusions are nearly impossible to draw from cross-sectional studies such as 
those examined in this meta-analysis. 
Moving forward it would be beneficial to encourage future studies to try to 
account for more of these confounders. When it is challenging or impossible to 
accurately match groups, efforts should be made to provide complete 
demographic reporting and attempt adjustment for potential confounding 
factors. In addition, with the increasing availability of affordable proteomic 
arrays, where possible these should be employed particularly in exploratory 
studies. This allows for an increased range of analytes and helps to prevent over 
interpretation of results with a narrow scope and to provide increased data 
availability for future analyses. Examining the differences between healthy and 
ill populations suggests that looking for alterations in peripheral immune 
biomarkers in depressed populations with comorbidities is unlikely to be very 
successful. As mentioned, this is probably due to the fact that when peripheral 
immune biomarkers are already raised, biological noise would mask the smaller 
effect size expected between a depressed and non-depressed population. 
Finally while it is possible to link these findings to mechanistic animal models 
and emerging theories of depression, it is worth noting that due to the highly 
complex nature of depression and the numerous theories surrounding its 
pathophysiology it is possible to link a very large number of molecular targets to 
depressive disease. While this does not preclude these associations being true it 
does shed some doubt on the mechanistic relevance of every finding. Rigorous 
mechanistic studies in animal models of depressive behaviours and more 
methodologically sound human cross-sectional studies combined with 
prospective longitudinal studies may help to overcome these issues and provide 
evidence of which molecules appear to be most mechanistically relevant to 
human depression. Despite this doubt, the work here clearly supports further 
research into the chemokine family as potential mediators of depressive disease.
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Chapter 4 Initial characterisation of the Aldara 
Model 
4.1 Introduction 
It has previously been established that peripheral inflammatory stimuli using TLR 
agonists can result in immune alterations within the CNS. TLR3, TLR4 and TLR7 
agonists administered to a peripheral site either topically, i.p. or i.v. result in 
the central upregulation of ISGs, chemokines and cytokines(24, 25, 81, 245, 246, 
248, 445). 
Previous work within our laboratory has established that the Aldara model of 
psoriasiform inflammation utilising the TLR7 agonist imiquimod results in 
upregulation of ISGs and some chemokines (24, 25) from 24 hours post-
treatment. This has been associated with an influx of T cells, reductions in 
neurogenesis and alterations in behavioural measures (24, 446). Recent work, 
has shown that this inflammatory response is associated with an influx of, not 
just T cells, but also other peripheral immune cells, into the CNS (24). Alongside 
this, work by other laboratories has demonstrated that both the liver and lungs 
may become inflamed in response to Aldara treatment, however, these organs 
were studied in isolation (447, 448). Earlier data from our laboratory have also 
suggested that the PBL and brain responses are temporally distinct (24, 446). 
This chapter aims to address several questions surrounding the Aldara model 
that have been identified from these data: 
1. What is the transcriptional response with regards to cytokines and a 
broader range of chemokines? 
2. How rapidly does the brain response become evident? 
3. How does the response within the brain compare to the response within 
the peripheral organs? 
4. Are transcriptional alterations evident at a protein level? 
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5. Are transcriptional responses associated with changes in glial populations 
of the CNS (microglia and astrocytes) and/or changes in a recruited 
cellular population (T-cells)?” 
To address these questions and to better understand the characteristics of the 
Aldara model, we aimed to perform a more widespread analysis of 
transcriptional responses that included a broader range of chemokines and some 
major cytokines, examining both the brain and the periphery. In addition to 
studying transcriptional responses, associated changes were assessed through 
assay of protein levels and immunohistochemical examination of cellular 
alterations. To assess the temporal nature of the response and the speed at 
which brain responses occur earlier time-points than have been previously 
examined were investigated. Together these data will form the foundation of an 
immunological characterisation of the Aldara model in both the periphery and 
CNS, and provide additional insight into functional changes within the brain 
itself. 
Based on current conceptions surrounding brain immunology, which suppose that 
the brain is a site of modified immune function (198-200), it was hypothesised 
that the brain response to Aldara would be distinct compared to the peripheral 
organs. In addition, based on the signalling pathways associated with TLR7 
activation, and the previous findings of ISG upregulation, it was hypothesised 
that various chemokines and cytokines that were previously unexamined would 
also be upregulated, and that this upregulation would be associated with 
increases in protein levels within the CNS. Considering the evidence from other 
models of TLR activation, and studies examining viral responses within the CNS, 
it was also hypothesised that this upregulation would be associated with 
alterations in microglial and astrocytic populations of the CNS. 
To this end, this chapter will present initial systemic data examining the peak 
response point of 3 days identified in earlier studies, followed by a more 
extensive time-course characterisation. To assess the functional implication of 
altered immunity it will next be determined, if transcriptional changes become 
evident at a protein level and, whether there are altered cellular responses to 
this peripheral stimulus using immunohistochemical techniques.  
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4.2 Results 
4.2.1 The effect of repeated cutaneous treatment with Aldara on 
mouse weight and skin thickness after 3 days 
Initially, changes in weight, and the skin response, up to 3 days of treatment 
were investigated. This time-point was chosen as it was the previously identified 
peak ISG transcriptional response point. Examining changes in weight from 
baseline identified that after 1 day of treatment mice treated with Aldara cream 
had significant reductions in weight compared to control mice (Figure 4.1A). This 
reduction continued for the 3 days of treatment. As Aldara treatment is 
characterised by changes in skin that are supposed to mimic psoriasiform 
inflammation we also examined skin histological changes using H&E. Examination 
of skin sections showed clear evidence of epidermal thickening and there were 
significant increases in epidermal:dermal ratios in mice treated with Aldara 
indicative of epidermal hyperplasia (Figure 4.1B/C). 
4.2.2 The effect of repeated cutaneous treatment with Aldara on 
systemic chemokine and cytokine transcription after 3 days 
Following the confirmation of a clear phenotype in treated animals the skin, 
lungs, liver and spleen alongside the brain were investigated at the 3-day time-
point. For all transcripts examined (Ccl2, Ccl3, Ccl5, Ccl9, Ccl19, Cxcl10, Cxcl13, 
Cxcl16, Ccr5, Il1b, Tnfa, Il6, Il1b) the brain demonstrated a significant 
upregulation when compared to control animals (Figure 4.2, Figure 4.3, Figure 
4.4). In contrast, peripheral tissues did not show universal upregulation. 
The skin did not demonstrate significant upregulation of any transcript after 
three days of Aldara treatment and this is in contrast to the histological changes 
that are clearly identifiable at this time-point. In the peripheral tissues, the 
lungs were the most significantly altered aside from the brain and there was 
significant upregulation of a number of chemokines and cytokines (Ccl2, Ccl3, 
Ccl5, Ccl9, Cxcl10, Cxcl13, Il1b and Il10) (Figure 4.2, Figure 4.3, Figure 4.4), 
although the magnitude of this upregulation was diminished when compared to 
that in the brain. Of all the transcripts examined Il10 was found to be the most 
consistently upregulated with significant differences identified in all tissues 
aside from the skin at this time-point. Minimal significant changes were observed 
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in the liver and spleen with only Tnfa and Il10 found to be significantly 
upregulated in the liver and only Il6 and Il10 being significantly upregulated in 
the spleen. Interestingly, Ccl19 was the only transcript found to be significantly 
down-regulated in any tissue and this downregulation was only present in the 
spleen.  
 
Figure 4.1: 3-day Aldara Model Weight Change and Skin Haematoxylin & Eosin.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin for 3-days. (A) Mouse weight change from baseline over 3 days of treatment (n=4, 1 
representative experiment of 2 shown) tested using One-way ANOVA and post-hoc Student’s t-test 
with Bonferroni multiple testing correction.  (B) Epidermis:dermis ratio as an average from 3 
sections per mouse (n=4) Tested using unpaired Student’s t-test. (C) Representative figures of skin 
H&E. *=P<0.05; ****P=<0.0001. Scale bars = 100μm. Bars represent mean ± SD. 
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Figure 4.2: 3-day Aldara Model CC Chemokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin for 3-days prior to perfusion and tissue collection. Arbitrary expression values from qRT-PCR 
were normalised to tbp housekeeping gene. Individual fold changes were calculated compared to 
average of controls for that tissue (n=9; 2 experiments shown, for Ccl5 n=4). Tested after log-
transformation using Two-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Figure 4.3: 3-day Aldara Model CXC Chemokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin for 3-days prior to perfusion and tissue collection. Arbitrary expression values from qRT-PCR 
were normalised to tbp housekeeping gene. Individual fold changes were calculated compared to 
average of controls for that tissue (n=9; 2 experiments shown). Tested after log-transformation 
using Two-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple testing correction. 
*=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Figure 4.4: 3-day Aldara Model Cytokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin for 3-days prior to perfusion and tissue collection. Arbitrary expression values from qRT-PCR 
were normalised to tbp housekeeping gene. Individual fold changes were calculated compared to 
average of controls for that tissue (n=9; 2 experiments shown). Tested after log-transformation 
using Two-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple testing correction. 
*=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
 
4.2.3 The effect of repeated cutaneous treatment with Aldara on 
mouse weight and skin thickness over a 5-day timecourse 
Following on from the identification of these changes after 3 days of treatment 
responses across a range of time-points were next examined to provide further 
information as to the time-course of the response. As had been done for the 
initial 3 day experiment, the skin and weight response of C57BL6/J mice to daily 
treatment of Aldara was examined. Similar to the 3-day experiment we found 
significant decreases in weight for treated animals when compared to controls 
(Figure 4.5A). After 2 days of treatment the mice appeared to begin to start 
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regaining weight. Despite this, significant differences in weight change persisted 
until 4 days after treatment. 
Although within the first 24 hours there were no significant alterations in 
epidermal thickening, after three days of Aldara treatment there were 
significant increases in the epidermal:dermal ratio that persisted until 5 days of 
treatment (Figure 4.5B). There was no significant difference in 
epidermal:dermal ratio between 3 and 5 days of treatment. By 24 hours post-
treatment there does appear to be some evidence of epidermal hyperplasia 
occurring (Figure 4.5C). However, this is not significant and is less obvious 
histologically than at 3 and 5 days post-treatment. 
 
Figure 4.5: Time-course Aldara Model Weight Change and Skin Haematoxylin & Eosin.  
Mice were weighed and then treated daily with 62.5mg Aldara cream (5% imiquimod) or control 
cream on the dorsal skin. Tissue was collected at 4, 12 and 24 hours and 3 and 5 days. (A) Mouse 
weight change from baseline over 4 days of treatment (n=4, weight change for 5 day mice shown) 
Tested using Two-way ANOVA and post-hoc Student’s t-test with Bonferroni multiple testing 
correction.  (B) Epidermis:dermis ratio as an average from 3 sections per mouse (n=4) Tested 
using One-way ANOVA and post-hoc Student’s t-test with Bonferroni multiple testing correction. 
(C) Representative figures of skin H&E. *=P<0.05; ****P=<0.0001. Scale bars = 100μm. Bars 
represent mean ± SD. 
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4.2.4 The effect of repeated cutaneous treatment with Aldara on 
chemokine and cytokine transcription in the brain over a 5-
day timecourse 
Following on from the finding of significant transcriptional upregulations within 
the brain after 3 days of treatment, it was asked how early these transcriptional 
responses manifested themselves within the brain and whether at a later time-
point (5 days) they persisted. Previous work had demonstrated that ISGs and 
some chemokines are upregulated after 1-5 days of treatment but did not 
examine earlier time-points. In addition to the transcripts assayed in the initial 3 
day time points we also investigated the expression of Ccl4, Ccl11, Cxcl1 and 
Cx3cl1 based on emerging evidence of their importance from both our own 
meta-analysis and other animal studies.  
Time-course data revealed that all transcripts examined (Ccl2, Ccl3, Ccl4, Ccl5, 
Ccl9, Ccl11, Ccl19, Ccr5, Cxcl1, Cxcl10, Cxcl13, Cxcl16, Il1b, Tnfa, Il6 and Il10) 
were significantly upregulated at 3 days post-treatment aside from Cx3cl1 that 
was not significantly altered at any time point(Figure 4.6, Figure 4.7, Figure 
4.8). The general pattern was that, by 1 day post-treatment, there was a 
significant upregulation of most transcripts, between 1 and 3 days post-
treatment there was a continuing increase in the level of transcript compared to 
controls, and by 5 days post-treatment this had begun to subside although 
generally it still remained significant. Aside from these broad patterns it is worth 
identifying other notable results from this time-course. A small number of 
transcripts were rapidly upregulated by 4 hours post-treatment (Ccl2, Ccl5, Ccl9 
and Cxcl10), interestingly both Ccl5 and Ccl9 were not found to be significantly 
upregulated after 12 hours and upregulation of Cxcl10 was ameliorated when 
compared to 4 hours (Figure 4.6, Figure 4.7). Aside from these rapidly 
upregulated transcripts, both Cxcl1 and Il1b were only upregulated at 3 days 
post-treatment (Figure 4.7, Figure 4.8). 
Figure 4.6: (Overleaf) Time-course Aldara Model Brain CC Chemokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Brain tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression 
values from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=4). Tested after log-
transformation using One-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Figure 4.7: Time-course Aldara Model Brain CXC Chemokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Brain tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression 
values from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=4). Tested after log-
transformation using One-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Figure 4.8: Time-course Aldara Model Brain Cytokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Brain tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression 
values from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=4). Tested after log-
transformation using One-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
4.2.5 The effect of repeated cutaneous treatment with Aldara on 
chemokine and cytokine transcription in the periphery over 
a 5-day timecourse 
After the finding of large differences between the brain and the peripheral 
organs at 3 days post treatment the peripheral tissues were next examined in 
the time-course analysis to determine if transcriptional differences between the 
brain and peripheral organs were due to a lack of upregulation at any time 
point, or due to temporal differences between the brain and periphery. In 
addition, to assess the circulating transcriptional profile, PBL gene expression 
was also examined alongside the previously mentioned peripheral organs. Due to 
technical issues the spleen was excluded from this time course analysis. 
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Figure 4.9: (Previous page) Time-course Aldara Model Skin CC Chemokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Skin tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression values 
from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=3-4). Tested after log-
transformation using one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
4.2.5.1 Skin and PBL chemokine and cytokine transcriptional responses 
Examination of the skin showed that there was a limited transcriptional response 
to Aldara treatment, although Ccl2, Ccl3, Ccl5 and Cxcl10 were significantly 
upregulated after 4 hours persisting until 12 or 24 hours post-treatment (Figure 
4.9, Figure 4.10). The remaining chemokines were not significantly upregulated 
at any time point. Examining the cytokine responses there was a transient 
upregulation of Il10 at 12 hours post-treatment and Il6 was significantly 
upregulated from 24 hours post-treatment until 3 days post-treatment returning 
to control levels by 5 days post-treatment (Figure 4.11). While striking that 
there was a lack of upregulation in some of the other transcripts RIN values 
(Appendix 4) indicated that the RNA was of adequate quality for qRT-PCR 
applications. 
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Figure 4.10: (Previous page) Time-course Aldara Model Skin CXC Chemokine Transcript. 
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Skin tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression values 
from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=3-4). Tested after log-
transformation using one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
 
 
Figure 4.11: Time-course Aldara Model Skin Cytokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Skin tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression values 
from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=3-4). Tested after log-
transformation using one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Next, the circulatory response was investigated as represented by the 
transcriptional response of PBL. Here, there was a more diverse upregulation of 
transcript when compared to the skin. Similarly to the skin, Ccl2, Ccl3, Ccl5 and 
Cxcl10 were significantly upregulated when compared to controls, in addition 
there were significant alterations of Ccl9, Cxcl13 and Ccr5 (Figure 4.12, Figure 
4.13). Alongside these changes in chemokine gene expression, there was also 
significant upregulation of all cytokine transcripts (Il1b, Tnfa, Il6, Il10) (Figure 
4.14). Although the precise pattern of upregulation varied between transcripts 
generally speaking by 4 hours post-treatment significant changes were present 
and these persisted for up to 3 days of treatment. An exception to this was Il1b 
that was only significantly upregulated at 4 hours (Figure 4.14). In addition, 
Cxcl13 and Ccl9 did not become significantly altered until 12 hours and 24 hours 
post-treatment respectively (Figure 4.12, Figure 4.13).  
Overall gene expression changes in both the skin and the PBL demonstrated a 
pattern of upregulation that was rapid and transient returning to control levels 
between the 24 hour and 3 day time-point for most transcripts. All measured 
transcripts returned to control levels after 5 days of treatment. In addition, for 
all transcripts that were significantly altered peak response points were within 
the first 24 hours aside from Il10 in PBL that showed a similar magnitude of 
upregulation at both 24 hour and 3 day time-points.  
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Figure 4.12: Time-course Aldara Model PBL CC Chemokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. PBL were collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression values from 
qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were calculated 
compared to average of controls for that time-point (n=3-4). Tested after log-transformation using 
one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple testing correction. 
*=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Figure 4.13: Time-course Aldara Model PBL CXC Chemokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. PBL were collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression values from 
qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were calculated 
compared to average of controls for that time-point (n=3-4). Tested after log-transformation using 
one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple testing correction. 
*=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Figure 4.14: Time-course Aldara Model PBL Cytokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. PBL were collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression values from 
qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were calculated 
compared to average of controls for that time-point (n=3-4). Tested after log-transformation using 
one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple testing correction. 
*=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
4.2.5.2 Liver chemokine and cytokine transcriptional responses 
Analysis of the liver showed a change in the pattern of upregulation when 
compared to the skin and PBL, with more prolonged alterations in a number of 
transcripts. Similar to the PBL there was a significant upregulation of Ccl2, Ccl3, 
Ccl5, Cxcl10 and Cxcl13 alongside the cytokines Tnfa, Il6 and Il10 (Figure 4.15, 
Figure 4.16, Figure 4.17). Like both the PBLs and skin, peak responses within the 
liver occurred within the first 24 hours including for Il10. In contrast, there were 
no significant alterations in Ccl9, Ccr5 or Il1b. Unlike the PBLs and skin a small 
number of transcripts remained elevated after 5 days of treatment in the liver 
(Ccl3, Ccl5, Cxcl13 and Il10), although the magnitude of upregulation was 
relatively small compared to peak response points. 
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Figure 4.15: (Previous page) Time-course Aldara Model Liver CC Chemokine Transcript. 
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Liver tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression 
values from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=4). Tested after log-
transformation using one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
 
 
 
Figure 4.16: Time-course Aldara Model Liver CXC Chemokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Liver tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression 
values from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=4). Tested after log-
transformation using Two-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Figure 4.17: Time-course Aldara Model Liver Cytokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Liver tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression 
values from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=4). Tested after log-
transformation using one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
4.2.5.3 Lungs chemokine and cytokine transcriptional responses 
Finally, the transcriptional response within the lungs was examined, this 
response was similar to other organs in that the chemokines Ccl2, Ccl3, Ccl5, 
Ccl9, Cxcl10, Cxcl13 and Ccr5 and the cytokines Il1b, Tnfa, Il6 and Il10 were 
upregulated (Figure 4.18, Figure 4.19, Figure 4.20). Unlike any of the other 
peripheral organs there were small but significant upregulations of Cxcl16 and 
Cx3cl1 after 4 hours, although these did not persist past this time point. The 
lungs, like the liver, demonstrated a more prolonged upregulation of a number 
of transcripts that persisted until 5 days of treatment. Alongside those found to 
be upregulated in the liver at 5 days (Ccl3, Ccl5, Cxcl13 and Il10) additional 
transcripts were still significantly altered (Ccl2, Ccl9, Cxcl10, Ccr5, Il1b and Il6) 
in the day 5 lung.  
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Figure 4.18: Time-course Aldara Model Lungs CC Chemokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Lung tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression 
values from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=4). Tested after log-
transformation using one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
 
 
Figure 4.19: Time-course Aldara Model Lungs CXC Chemokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Lung tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression 
values from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=4). Tested after log-
transformation using one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Figure 4.20: Time-course Aldara Model Lungs Cytokine Transcript.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Lung tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Arbitrary expression 
values from qRT-PCR were normalised to tbp housekeeping gene. Individual fold changes were 
calculated compared to average of controls for that time-point (n=4). Tested after log-
transformation using one-way ANOVA and post-hoc Student’s t-test with Bonferonni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
 
4.2.6 Comparison of the response between 1- and 3-days in the 
brain and periphery 
Considering the fact that nearly all peripheral transcripts peaked within the first 
24 hours and the brain response appeared to consistently peak at 3 days post-
treatment, temporal differences between the brain and periphery were next 
compared. To this end, the relative change in magnitude of response between 1 
day and 3 days post-treatment was examined. This clearly revealed that for all 
transcripts examined within the brain there was a continuing upregulation of the 
response whereas when looking at peripheral responses to Aldara treatment 
there was a return towards control levels in nearly all transcripts examined 
(Figure 4.21). The only major exception to this was Ccl19 in the PBL, but this is 
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likely attributable to the outlier present for this transcript at this time-point and 
removal of this sample abolished this effect. 
 
Figure 4.21: Time-course Aldara Model 1 day to 3 day relative gene expression change.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Tissue was collected at 24 hours and 3 days. Fold change values for 3 days were compared 
to 24 hours and relative fold changes calculated. 
4.2.7 The effect of repeated cutaneous treatment on chemokine 
and cytokine protein levels in the brain over a 5-day time-
course 
After identifying a significant upregulation of chemokine and cytokine gene 
expression within the brain following Aldara treatment, it was important to 
determine if this transcriptional response was translated to changes in protein 
levels and over what time period. Using a multiplex array approach that had as 
much overlap with our previously examined genes as possible we assessed 
protein levels in the brains of mice treated with Aldara.  
Protein assay showed that for all qRT-PCR targets that were included in the 
array there was significant upregulation at the protein level (CCL2, CCL3, CCL4, 
CCL5, CCL11, CXCL1, CXCL10, CXCL13, Il-1, TNF-, Il-6 and Il-10) (Figure 4.22, 
Figure 4.23, Figure 4.24). Alongside these upregulations another ISG CXCL9 was 
found to be significantly upregulated and both IFN and IFN were raised. The 
peak response point for all proteins was after 3 days of treatment which 
matches up with transcriptional data. Alongside this, many proteins were found 
to be significantly altered within 4 hours suggesting a rapid brain response to the 
peripheral immune stimulus. It is interesting to note that many of the 
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chemokines and cytokines examined appear to be constitutively expressed 
within the CNS as demonstrated by levels consistently above the limit of 
detection. Overall patterns of upregulation were similar to those observed at a 
transcriptional level, although for CXCL1 there appeared to be much more 
significant alterations in protein levels than in transcriptional responses (Figure 
4.7, Figure 4.24). 
 
Figure 4.22: Time-course Aldara Model Brain CC Chemokine Protein Expression. 
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Brain tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Biolegend LegendPlex 
assay was performed to generate absolute expression values. Tested using One-way ANOVA and 
post-hoc Student’s t-test with Bonferroni multiple testing correction. *=P<0.05; **=P<0.01; 
***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Figure 4.23: Time-course Aldara Model Brain CXC Chemokine Protein Expression.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Brain tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Biolegend LegendPlex 
assay was performed to generate absolute expression values. Tested using One-way ANOVA and 
post-hoc Student’s t-test with Bonferroni multiple testing correction. *=P<0.05; **=P<0.01; 
***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
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Figure 4.24: Time-course Aldara Model Brain Cytokine Protein Expression.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Brain tissue was collected at 4, 12 and 24 hours and 3 and 5 days. Biolegend LegendPlex 
assay was performed to generate absolute expression values. Tested using One-way ANOVA and 
post-hoc Student’s t-test with Bonferroni multiple testing correction. *=P<0.05; **=P<0.01; 
***=P<0.001; ****=P<0.0001. Bars represent mean ± SD. 
 
As the protein and gene expression assays had been performed on brains from 
the same animals it was possible to further investigate the relationship between 
fold changes in mRNA and fold changes in protein. Linear regression analysis on 
samples found to be above a 2 fold increase at an mRNA level revealed that 
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there were significant positive correlations between most analytes (CCL2, CCL3, 
CCL4, CCL5, CCL11, CXCL13, Il-1β, TNFα, Il-6 and Il-10) (Figure 4.25, Figure 
4.26, Figure 4.27). For Cxcl10/CXCL10 there was no significant correlation 
despite the large upregulation observed both transcriptionally and at a protein 
level. It is worth noting that for CCL5, TNFα and Il-10 there were samples where 
increased mRNA levels were actually associated with reduced protein (log2  fold 
change<0), as such, caution should be taken when interpreting this association, 
particularly at lower levels of transcriptional upregulation. Despite this, 
transcriptional responses appeared to account for much of the variation in 
protein readings as demonstrated by the high R2 values obtained. 
Figure 4.25: (Overleaf) Linear regression of Brain CC chemokine mRNA and protein 
expression values in Aldara treated mice.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Samples with a raw mRNA fold change compared to control >2 were used for analysis. Log-
transformed mRNA fold change compared to control and log-transformed protein fold change 
compared to control were assessed for relationship using linear regression analysis. P<0.05 for all 
analyses. 
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Figure 4.26: Linear regression of Brain CXC chemokine mRNA and protein expression 
values in Aldara treated mice.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Samples with a raw mRNA fold change compared to control >2 were used for analysis. Log-
transformed mRNA fold change compared to control and log-transformed protein fold change 
compared to control were assessed for relationship using linear regression analysis. P<0.05 unless 
stated. NS=not significant. 
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Figure 4.27: Linear regression of Brain cytokine mRNA and protein expression values in 
Aldara treated mice.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Samples with a raw mRNA fold change compared to control >2 were used for analysis. Log-
transformed mRNA fold change compared to control and log-transformed protein fold change 
compared to control were assessed for relationship using linear regression analysis. P<0.05 for all 
analyses. 
 
 
4.2.8 The effect of repeated cutaneous treatment with Aldara on 
cellular populations within the brain parenchyma 
Following on from the finding of chemokine and cytokine upregulation within the 
CNS it was investigated whether this was associated with cellular alteration or 
recruitment. At both 1 and 3 days post-treatment Iba1, GFAP and CD3 reactivity 
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were investigated within the brain. Iba1 is a marker of microglia/macrophages, 
GFAP is a marker of astrocytes and CD3 is a T-cell marker. 
4.2.8.1 Iba1+ staining of the hippocampus and cortex 
Iba1 staining revealed that after 1 day of treatment there were no significant 
alterations in the quantity of Iba1 staining observed in either the hippocampus 
or the cortex. However, after three days of treatment, in both the hippocampus 
and cortex, gross morphological changes were observed(Figure 4.28). These 
were apparent, primarily as, a thickening and shortening of dendritic processes 
protruding from the cell body, changes associated with microglia taking on a 
more amoeboid appearance. In addition, automated quantification of 3 day Iba1 
staining identified significant differences compared to both 1 day treated and 3 
day control mice. 
Figure 4.28: (Overleaf) Iba1 staining of brain in Aldara Model.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Brains were collected after 24 hours and 3 days. Formalin-fixed paraffin embedded sections 
were stained using Iba1 antibody and haematoxylin QS counterstain. (A, C) Representative images 
of 20x hippocampal (A) and cortical (C) fields of view used for automated analysis. Inset image 
shows 10x view of area with 20x area highlighted in green. (B, D) Automated analysis of Iba1 area 
was performed using ImageJ software to quantify hippocampal (B) and cortical (D) Iba1 staining 
(n=4, 2-3 sections per mouse). Tested using One-way ANOVA and post-hoc Student’s t-test with 
Bonferroni multiple testing correction. *=P<0.05; **=P<0.01; ***=P<0.001. Scale bars =100μm 
(main images), 200μm (inset images). Bars represent mean ± SD. Abbreviations: HPC – 
Hippocampus; CTX - Cortex 
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4.2.8.2 GFAP staining of the hippocampus 
Astrocytes are another important glial cell within the CNS. Due to their sparse 
distribution and the high background staining observed in the cortex GFAP 
reactivity was not assessed in this region. Despite this, in the hippocampus, a 
small but significant increase in GFAP staining was observed using the same 
methodology as for Iba1 (Figure 4.29). Gross morphological differences were less 
evident in this context than for Iba1. 
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Figure 4.29: GFAP staining of brain in Aldara Model.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Brains were collected after 24 hours and 3 days. Formalin-fixed paraffin embedded sections 
were stained using GFAP antibody and haematoxylin QS counterstain. (A) Representative images 
of 20x hippocampal fields of view used for automated analysis. Inset image shows 10x view of area 
with 20x area highlighted in green. (B) Automated analysis of GFAP area was performed using 
ImageJ software to quantify hippocampal GFAP staining (n=4, 2-3 sections per mouse). Tested 
using One-way ANOVA and post-hoc Student’s t-test with Bonferroni multiple testing correction. 
*=P<0.05. Scale bars =100μm (main images), 200μm (inset images). Bars represent mean ± SD. 
Abbreviations: HPC – Hippocampus; CTX - Cortex 
 
4.2.8.3 CD3+ cell counts of the hippocampus and cortex 
Finally, evidence of exogenous cell recruitment into the CNS was examined. 
Using CD3 staining, combined with whole hippocampal cell counts and multiple 
fields of view from the cortex, significant evidence of T cell infiltration was 
found in response to peripheral Aldara treatment (Figure 4.30). In all control 
mice, and 1 day treated mice, there was little evidence of T cell infiltration 
with minimal or no CD3+ cells observed. Following three days of treatment there 
was consistent evidence of an increased number of CD3+ cells in both the 
hippocampus and cortex. These were located both perivascularly and within the 
parenchyma itself. 
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Figure 4.30: (Previous page) CD3 staining of brain in Aldara Model.  
Mice were treated daily with 62.5mg Aldara cream (5% imiquimod) or control cream on the dorsal 
skin. Brains were collected after 24 hours and 3 days. Formalin-fixed paraffin embedded sections 
were stained using CD3 antibody and haematoxylin QS counterstain by Veterinary Diagnostic 
Services Laboratory at the University of Glasgow. (A, C) Representative images of 10x 
hippocampal (A) and cortical (C) fields of view. Expanded image is a 20x example of positive CD3 
staining in 3 day treated sample.  (B) Manual counting of all CD3+ cells in hippocampus (D) 
Manual counting of CD3+ cells in cortex, 3 fields of view were used per section (n=4, 2-3 sections 
per mouse). Tested using One-way ANOVA and post-hoc Student’s t-test with Bonferroni multiple 
testing correction. *=P<0.05; **=P<0.01; ***=P<0.001. Scale bars =100μm (main images), 200μm 
(inset images). Bars represent mean ± SD. Abbreviations: HPC – Hippocampus; CTX - Cortex 
4.3 Discussion 
4.3.1 Summary of results 
This chapter aimed to further characterise molecular responses to cutaneous 
Aldara treatment and their sequelae. To this end significant upregulation of a 
variety of chemokine and cytokine transcripts in the brain, skin, PBL and a 
number of peripheral organs was identified. Transcriptional data from the time-
course are summarised in Figure 4.31. In addition to upregulation of measured 
transcripts temporal differences between the brain and the periphery were 
found. Further to this it was confirmed that transcriptional changes identified 
within the brain were translated into protein. Finally, these molecular 
alterations were found to be associated with significant changes in astrocytic, 
microglial and T cell populations. 
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4.3.2 Transcriptional responses to cutaneous Aldara treatment 
The work presented here builds on earlier research performed in our laboratory 
that identified transcriptional alterations in many ISGs in the brain in response 
to cutaneous Aldara treatment. It was initially wished to extend this work to 
examine a broader range of chemokines, alongside previously unexamined 
cytokines. In addition, to expand our understanding of the Aldara model, 
transcriptional responses in several peripheral organs at multiple time-points 
were examined. 
To this end significant upregulation of a broad array of CC and CXC chemokines 
in both the brain and periphery at a variety of time-points was identified. 
Alongside this, there was significant upregulation of the pro-inflammatory 
cytokines that were examined. Within the brain there was a significant 
upregulation of all measured transcripts aside from Cx3cl1. These chemokines 
(Ccl2, Ccl3, Ccl4, Ccl5, Ccl9, Ccl11, Ccl19, Cxcl10, Cxcl13 and Cxcl16) are 
associated with the attraction of a broad range of cell types including 
monocytes(124, 125), neutrophils(449, 450) dendritic cells (451, 452), T cells 
(122, 123, 418, 453), eosinophils (454), B cells (455) and natural killer cells(456). 
Considering recent findings from our laboratory that many of these immune cell 
types are recruited to the CNS following cutaneous Aldara treatment (24), it is 
likely that the upregulation of these molecules is an important component of 
cellular recruitment. In addition a number of these chemokines have been 
implicated in sickness behaviours and/or neuronal modulation (102, 103, 457), 
suggesting one possible mechanism through which previously observed 
alterations in behaviour (24) may become manifest.  
As discussed in the introduction, the cytokines Il-1β, TNFα and Il-6 have diverse 
actions within the immune system (33, 458, 459). Within the CNS the role of 
these cytokines appears variable with data showing that they can interact with 
resident CNS cells and have both protective and detrimental effects dependent 
on context (460-464). In addition, they may also be important regulators of 
chemokine mediated cellular recruitment (465, 466). Alongside their immune 
roles Il-1 and TNF have been closely linked to sickness behaviours (5, 9) and 
alterations of CNS function in animal models, including changes in the expression 
of the 5-HTT (467) in neurons. Finally, Il-10 is one of the key regulators of 
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immune responses and has potent anti-inflammatory properties (71, 468). Its 
widespread upregulation throughout all tissues highlights the importance of 
active immune resolution in the context of acute inflammatory responses. These 
data provide significant evidence that following cutaneous Aldara treatment 
there are molecular alterations within the brain that can not only induce 
inflammatory changes but also influence cellular populations and CNS function. 
Considering that previous work has demonstrated that some of the chemokines 
examined here, and many ISGs, are upregulated in the brain after either 24 
hours or 3 days, earlier time-points were investigated to understand how rapidly 
changes in the brain became apparent. This showed that a limited range of 
chemokines (Ccl2, Ccl5, Ccl9 and Cxcl10) were significantly upregulated within 
the first 4 hours, suggesting that the beginnings of an inflammatory response are 
present even at this early time-point. In general the other transcripts were 
found to be upregulated at either 24 hours after treatment, or after 3 days of 
repeated treatment, and were largely sustained until 5 days. 
Earlier work in our laboratory had demonstrated that the brain and PBL 
responses differ temporally, and work in other laboratories, has identified 
changes in the lung(447) and liver(448) in response to Aldara. The data 
presented here demonstrate that changes in transcriptional state between 1 and 
3 days differ between the peripheral tissues and the brain. Between these two 
time-points the brain is continuing to upregulate its chemokine and cytokine 
transcriptional response, whereas the peripheral tissues are down-regulating and 
resolving their molecular inflammatory responses. This suggests that the 
peripheral response is rapid and transient in nature, particularly in the skin and 
PBLs, to some extent in the liver and to a lesser extent in the lungs. Whereas, in 
contrast to this, the brain response could be broadly considered to be slower but 
more sustained.  
4.3.3 Protein responses in the CNS 
While RNA samples are particularly useful for studies with a wider range of 
targets due to the minimal levels of starting material required, it is important, 
where possible, to assess if transcriptional changes are translated into protein 
responses. Protein array showed that for all transcripts included in the array 
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that were upregulated in the brains of Aldara treated mice, there were 
significant responses at a protein level. The high levels of association between 
mRNA and protein levels clearly suggests that translation for the studied 
molecules is closely related to transcriptional changes. This close association is 
also highlighted by the fact that, like the transcriptional responses, the peak 
response point for all of the measured proteins appeared to be after 3 days of 
treatment, with the majority of molecules studied appearing to down-regulate 
between 3 and 5 days. As part of the protein array both type I and type II IFNs 
(IFN/IFN) were also identified upregulated in the brain at these time-points. 
This supports earlier work identifying the IFN signalling pathway as an important 
component of Aldara responses (25).  
4.3.4 Cellular changes in the CNS 
Molecular changes provide insight into immune responses and allow us to 
speculate on outcomes based on previous research. Despite this, where possible 
it is best to directly assess if there are downstream consequences of molecular 
alterations. Therefore, whether observed molecular changes were associated 
with alterations in Iba1+, GFAP+ and CD3+ cellular populations was examined. 
Immunohistochemistry showed that after 3 days of Aldara treatment there were 
morphological changes associated with the Iba1+ microglial population with cells 
taking on a more amoeboid appearance. The functional implications of 
morphological changes in microglia are thought to be variable and depend on the 
context in which these changes occur, although they are consistently associated 
with enhanced phagocytosis (167, 469). Despite this it is reasonable to assume 
that morphological alterations are a reactive response to a stimulus, in this case 
cutaneous Aldara treatment. Astrocytes have been found to be a source of a 
number of chemokines and cytokines, particularly CXCL10 (182, 220) and, in this 
model, we did identify small but significant alterations of GFAP staining within 
the hippocampus. Upregulation of GFAP is characteristic of astrogliosis a 
response that is associated with many CNS inflammatory reactions(470). Thus, 
these changes may reflect a reactive response to cutaneous Aldara within the 
astrocyte population, similar to those observed within the microglial Iba1+ 
population. 
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Significant changes in astrocytes and microglia as measured by cellular staining 
do not become manifest until 3 days post-treatment. Despite this, the 
upregulation of both mRNA and protein observed within the CNS, at earlier time-
points, suggests that these cells can produce molecular responses prior to the 
appearance of gross morphological changes.  
Alongside reactive changes in brain resident cells, increases in CD3+ cells were 
identified in both the cortex and hippocampus after 3 days of cutaneous Aldara 
treatment, indicating significant increases in the T cell population. While these 
cells may contribute to the inflammatory response, their arrival also appears to 
coincide with the beginnings of immune regulation as evidenced by the rise in Il-
10 and subsequent down-regulation of immune transcripts. This may in part be 
due to the fact that recruitment of regulatory T cells is a critical event in 
resolution of brain inflammatory responses (471, 472). Whilst further work would 
be needed to characterise this cellular population, it is possible that a subset of 
recruited CD3+ cells are regulatory. 
4.3.5 Other findings of note 
Alongside the questions we had aimed to answer in this chapter as part of a 
further characterisation of the Aldara model, the data presented above 
highlighted some interesting findings that are worth consideration. 
Firstly, in this study we reported changes in skin histology at both 3 and 5 days 
yet we did not identify significant molecular alterations at either of these time-
points. Similarly, splenic enlargement has been reported after repeated 
treatments of Aldara (446, 473) however we did not identify significant 
molecular alterations in this tissue after three days of treatment. These findings 
suggest that phenotypic responses do not necessarily correspond to ongoing 
inflammation but rather represent downstream sequelae of inflammatory 
responses that may have already resolved at a molecular level. 
Secondly if we examine the magnitude of fold changes between tissues, the 
extent of upregulation within the brain appears to be greater than that observed 
in the peripheral tissues. While this is interesting, and at first glance may 
indicate that the brain may be responding more severely than the peripheral 
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organs, it is important to consider whether this increased magnitude is due to 
control levels in the brain being lower or whether it is a result of a more severe 
response within the brain itself (see Chapter 6). 
4.3.6 Summary 
Overall these data provide significant evidence that Aldara treatment and IMQ-
mediated TLR7 agonism induces a rapid response at the local site of treatment 
in the skin, in the circulating PBLs and in peripheral organs. Within the CNS 
there is a rapidly induced immune response that increases in both magnitude 
and molecular diversity over time and with repeated treatments. Importantly 
the temporal nature of the response appears to differ between organs but this is 
particularly apparent between the brain and the periphery. The chemokine and 
cytokine transcriptional response observed within the brain has the potential to 
attract a multitude of cell types and to dramatically alter CNS function. Indeed, 
there appear to be alterations in the resident cellular populations of the CNS 
when examining microglia and astrocytes and there is a recruitment of CD3+ 
cells into the CNS. This suggests that the Aldara model is a compelling model for 
exploring neuroinflammation in the context of a systemic response to peripheral 
TLR stimulus. 
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Chapter 5 Exploring mechanisms of Aldara-
induced brain inflammation 
5.1 Introduction 
In the previous chapter it was demonstrated that repeated applications of Aldara 
cream induce both peripheral and central inflammatory responses. CNS 
responses are of particular interest to our research, therefore, further 
investigation of potential mechanisms through which the CNS response may be 
induced was undertaken. 
Previous work, and the work presented so far in this thesis, has identified the 
upregulation of interferon simulated genes (24, 25) and a wide range of 
chemokines in the brain. This led us to ask two questions about the response to 
cutaneous Aldara treatment: 
What is the influence on chemokine and cytokine transcriptional responses, 
and associated microglial, astrocytic and T cell alterations of; 
1. Inflammatory C-C chemokine receptor knockout (iCCRKO)? 
2. Type 1 IFN knockout (IFNARKO)? 
To investigate the role that these pathways play in brain inflammation the 
response to Aldara treatment was investigated in two knockout models. The first 
of these models involved inflammatory C-C chemokine receptor knockout mice 
(iCCRKO). These mice do not express CCR1/CCR2/CCR3 and CCR5. As discussed 
previously, chemokines exhibit high levels of promiscuity and redundancy (29), 
therefore these multi-receptor knockout mice can be used to overcome the 
challenges of studying a highly promiscuous and redundant molecular family. As 
many of the chemokines that can signal through these receptors (Ccl2, Ccl3, 
Ccl4, Ccl5, Ccl9 and Ccl11) have been found to be altered in the brains of mice 
treated cutaneously with Aldara, exploring the influence of iCCRKO should 
provide insight into their role during CNS inflammation. The overlapping nature 
of signalling in the chemokines listed above is highlighted in Figure 5.1. 
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Chemokines are primarily associated with cellular recruitment and CCR5 is 
associated with T-cell recruitment(123). Therefore, it was hypothesised that 
iCCRKO would reduce the number of T cells that enter the brain. In addition, it 
was expected that decreases in cellular infiltration would lead to a reduced 
inflammatory burden, measured at both the transcriptional level and cellular 
level, through alterations in the microglial and astrocytic populations. 
 
Figure 5.1: CCL-CCR Overlapping Interactions 
Diagram illustrating the promiscuity of chemokine ligand and receptor interactions of those CC 
chemokines that were identified as raised in the initial time-course model and that signal through 
iCCRs. Based on (29) 
The second of the models investigated the role of type I IFN signalling using 
IFNARKO mice. As discussed previously, IFN responses appear to be a shared 
pathway between TLR induced brain responses (25). IFNARKO mice are unable to 
initiate type I IFN signalling and therefore downstream responses should be 
ameliorated. However, IFNARKO should not prevent NF-B responses. As such, it 
would be expected that ISG expression (e.g. Cxcl10) and the expression of other 
IFN associated genes such as Ccl2 would be reduced. Despite this, as the NF-B 
pathway remains intact pro-inflammatory cytokine responses would still be 
expected (49, 474), although these may be diminished due to the reduction of 
overall inflammatory stimulation. It was hypothesised that, reductions in type I 
IFN stimulated inflammation would reduce cellular infiltration, particularly due 
to reductions in Cxcl10. 
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Within this chapter and the following chapter a more focused analysis of the 
transcriptional response was undertaken. To this end Ccl2, Ccl3, Ccl5, Cxcl10 
and Ccr5 were chosen as chemokines of interest, alongside the cytokines Il1b, 
Tnfa, Il6 and Il10. The chemokines were chosen due to their association with our 
cells of interest, Ccl2 and Ccl3 are associated with microglia (231, 475, 476), 
Ccl5 and Cxcl10 are associated with T cells (122, 123), and Ccr5 is associated 
with both microglia (477, 478) and T cells (123, 479). In addition, astrocytes 
have been associated with the production of some of these chemokines, 
particularly Cxcl10 (232-234). The cytokines investigated have all been found to 
be altered in inflammatory TLR models and, particularly for Il1b and Tnfa, are 
consistently thought to be important mediators of CNS inflammatory reactions 
(226, 264) and subsequent behavioural changes (4, 9, 293). Finally, it is worth 
noting that for iCCRKO experiments, the animals were shared with others in the 
laboratory and therefore only the brain response could be investigated.  
5.2 Results 
5.2.1 The effect of iCCRKO on brain chemokine and cytokine 
transcriptional responses to repeated cutaneous Aldara 
treatment 
Initial investigation of brain responses in iCCR+/+ (WT), iCCR+/- (HET), and iCCR-/- 
(KO) mice, after 4 days of daily cutaneous Aldara treatment, revealed no 
significant differences in chemokine and cytokine transcription between the 
genotypes, aside from in Ccr5 (Figure 5.2, Figure 5.3). Reassuringly, significant 
reductions in Ccr5 were identified in iCCRKO mice and while WT and HET mice 
did not differ significantly in expression, mean expression in HET mice was 
roughly halved (1395 vs 617.8 copies/103 Tbp), indicative of haploinsufficiency. 
Although significant differences were not found in the other transcripts 
examined there did appear to be evidence of possible subtle differences. This 
was particularly true for Il1b where removal of the outlier present in the KO 
group did result in a significant difference between WT and KO mice.  
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Figure 5.2: 4-day iCCRKO Aldara Model 1 Brain Chemokine Transcript. 
iCCR+/+ (WT), iCCR+/- (HET) and iCCR-/- (KO) mice were treated daily with 62.5mg Aldara cream 
(5% imiquimod)  on the dorsal skin. Brain tissue was collected 24 hours after the 4th application. 
Absolute quantification was performed by qRT-PCR and values were normalised to housekeeping 
gene Tbp. N=4-6 per group. One-way ANOVA followed by Student’s T-test with Bonferroni multiple 
testing correction was used to determine statistical significance. ***=P<0.001. Bars represent mean 
± SD. 
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Figure 5.3: 4-day iCCRKO Aldara Model 1 Brain Cytokine Transcript 
iCCR+/+ (WT), iCCR+/- (HET) and iCCR-/- (KO) mice were treated daily with 62.5mg Aldara cream 
(5% imiquimod)  on the dorsal skin. Brain tissue was collected 24 hours after the 4th application. 
Absolute quantification was performed by qRT-PCR and values were normalised to housekeeping 
gene Tbp. N=4-6 per group. One-way ANOVA followed by Student’s T-test with Bonferroni multiple 
testing correction was used to determine statistical significance. A P value <0.05 was considered 
significant. Bars represent mean ± SD. 
To further explore possible differences between WT and KO mice a repeat 
experiment was performed with both treated and control groups for each 
genotype. This experiment reproduced the findings of the earlier experiment 
with no significant differences identified between WT and KO mice apart from 
Ccr5. For all other transcripts examined (Ccl2, Ccl3, Ccl5, Cxcl10, Il1b, Tnfa, Il6 
and Il10) there were significant differences between treated and control mice in 
the iCCRKO group (Figure 5.4, Figure 5.5). Il6 and Il10 did not differ significantly 
between treated and control WT groups, however there was still a mean 
increase in the treated group consistent with previous findings.  
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Figure 5.4: 4-day iCCRKO Aldara Model 2 Brain Chemokine Transcript 
iCCR+/+ (WT) and iCCR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% imiquimod) 
or control cream on the dorsal skin. Brain tissue was collected 24 hours after the 4th application. 
Absolute quantification was performed by qRT-PCR and values were normalised to housekeeping 
gene Tbp. N=5-6 per group. One-way ANOVA followed by Student’s T-test with Bonferroni multiple 
testing correction was used to determine statistical significance. ***=P<0.001. Bars represent mean 
± SD. 
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Figure 5.5: 4-day iCCRKO Aldara Model 2 Brain Cytokine Transcript 
iCCR+/+ (WT) and iCCR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% imiquimod) 
or control cream on the dorsal skin. Brain tissue was collected 24 hours after the 4th application. 
Absolute quantification was performed by qRT-PCR and values were normalised to housekeeping 
gene Tbp. N=5-6 per group. One-way ANOVA followed by Student’s T-test with Bonferroni multiple 
testing correction was used to determine statistical significance. ***=P<0.001. Bars represent mean 
± SD. 
5.2.2 The effect of iCCRKO on brain cellular responses to 
repeated cutaneous Aldara treatment 
5.2.2.1 Iba1+ staining of the hippocampus and cortex 
To understand the influence of iCCRKO on cellular populations, 
immunohistochemical staining of the Iba1+, GFAP+ and CD3+ cellular populations 
was performed. Iba1+ staining of iCCRWT and KO mice reproduced earlier 
findings of increases in Iba1+ staining in Aldara treated animals that are 
accompanied by changes in gross morphology (Figure 5.6A, C, D, F). There was 
no evidence of significant alterations in Iba1+ staining in iCCRKO mice compared 
to WT mice (Figure 5.6B, C, E, F) and morphologically both treated groups 
appeared similar (Figure 5.6A, D). 
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Figure 5.6: Iba1 staining of brain in iCCRKO Aldara Models 
iCCR+/+ (WT) and iCCR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% imiquimod) 
or control cream (A,C,D,F only) on the dorsal skin. Brain tissue was collected 24 hours after the 4th 
application. Formalin-fixed paraffin embedded sections were stained using Iba1 antibody and 
haematoxylin QS counterstain. (A, D) Representative images of 20x hippocampal (A) and cortical 
(D) fields of view used for automated analysis. Inset image shows 10x view of area with 20x area 
highlighted in green. Automated analysis of Iba1 area was performed using ImageJ software to 
quantify hippocampal (B, C) and cortical (E,F) Iba1 staining. Two separate experiments are shown; 
iCCRKO1 (B, E) iCCRKO2 (A, D, C, F) (n=4, 2-3 sections per mouse.) Tested using unpaired T-
test (B, E) or one-way ANOVA and post-hoc Student’s t-test with Bonferroni multiple testing 
correction (C, F). *=P<0.05; ****=P<0.0001. Scale bars =100μm (main images), 200μm (inset 
images). Bars represent mean ± SD. Abbreviations: HPC – Hippocampus; CTX – Cortex; FoV – 
Field of view. 
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5.2.2.2 GFAP staining of the hippocampus 
As noted previously, due to its sparse distribution and high background staining 
GFAP was not examined in the cortex (Figure 5.7). Examination of hippocampal 
staining between WT and iCCRKO mice did not reveal any significant differences 
between the groups (Figure 5.7B, C). Unlike in the original 1d/3d GFAP staining, 
no significant differences in GFAP area were observed between treated and 
control groups in either WT or iCCRKO mice.
 
Figure 5.7: GFAP staining of brain in iCCRKO Aldara Models 
iCCR+/+ (WT) and iCCR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% imiquimod) 
or control cream (A,C only) on the dorsal skin. Brain tissue was collected 24 hours after the 4th 
application. Formalin-fixed paraffin embedded sections were stained using GFAP antibody and 
haematoxylin QS counterstain. (A) Representative images of 20x hippocampal fields of view used 
for automated analysis. Inset image shows 10x view of area with 20x area highlighted in green. 
Automated analysis of GFAP area was performed using ImageJ on three fields of view software to 
quantify hippocampal (B,C) GFAP staining. Two separate experiments are shown; iCCRKO1 (B) 
iCCRKO2 (C) (n=4, 2-3 sections per mouse.) Tested using unpaired T-test (B) or one-way ANOVA 
and post-hoc Student’s t-test with Bonferroni multiple testing correction (C). *=P<0.05; Scale bars 
=100μm (main images), 200μm (inset images). Bars represent mean ± SD. Abbreviations: HPC – 
Hippocampus; CTX – Cortex; FoV – Field of view. 
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5.2.2.3 CD3+ cell counts in the hippocampus and cortex 
CD3+ cell numbers were examined in the hippocampus and cortex of iCCRKO and 
WT mice (Figure 5.8). Significant reductions in CD3+ cells were observed in the 
hippocampus but not in the cortex when comparing only treated WT and KO 
mice in the first experiment (Figure 5.8B, E). In the second experiment, 
although there were significant reductions in cortical CD3+ cell numbers, there 
was no significant difference within the HPC (Figure 5.8C, F). Reproducing 
earlier findings there were significant increases in CD3+ cells when comparing 
treated and control WT mice. Although not significant there was a mean 
increase in the number of CD3+ cells observed within the hippocampus and 
cortex of iCCRKO treated mice when compared to iCCRKO controls, and within 
the hippocampus this trended towards significance (p=0.062 after multiple 
testing correction) (Figure 5.8C, F). 
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Figure 5.8: CD3 staining of brain in iCCRKO Aldara Models 
iCCR+/+ (WT) and iCCR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% imiquimod) 
or control cream (A,C,D,F only) on the dorsal skin. Brain tissue was collected 24 hours after the 4th 
application. Formalin-fixed paraffin embedded sections were stained using CD3 antibody and 
haematoxylin QS counterstain by Veterinary Diagnostic Services Laboratory at the University of 
Glasgow. (A, D) Representative images of 10x hippocampal (A) and cortical (D) fields of view. 
Expanded images are 20x examples of CD3 staining in treated samples. (B,C) Manual counting 
was performed on all CD3+ cells within the hippocampus. (E,F) Manual counting of CD3+ cells in 
the cortex, 3 fields of view were used per section. Two separate experiments are shown; iCCRKO1 
(B, E) iCCRKO2 (A, D,C,F) (n=4, 3 sections per mouse.) Tested using unpaired T-test (B, E) or 
one-way ANOVA and post-hoc Student’s t-test with Bonferroni multiple testing correction (C, F). 
**=P<0.01; ****=P<0.0001. Scale bars =100μm (main images), 200μm (inset images). Bars 
represent mean ± SD. Abbreviations: HPC – Hippocampus; CTX – Cortex; FoV – Field of view. 
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5.2.3 The effect of IFNARKO on chemokine and cytokine 
transcriptional responses to repeated cutaneous Aldara 
treatment 
Following investigation of the iCCRKO response to cutaneous Aldara treatment, 
the effect of IFNARKO was explored in the brain, local site of immune 
stimulation, the skin, and, through examination of the PBL, the circulation. 
5.2.3.1 Brain chemokine and cytokine transcriptional responses 
Initial investigation of the brain, after 3 days of daily cutaneous Aldara 
treatment, revealed significant reductions in all measured chemokine and 
cytokine transcripts (Ccl2, Ccl3, Ccl5, Cxcl10, Ccr5, Il1b, Tnfa, Il6 and Il10) in 
IFNARKO mice (Figure 5.9). It is interesting to note that an archetypal ISG Cxcl10 
showed a much greater magnitude of reduction (≈1000x) when compared to 
genes that are more associated with NF-κB responses (e.g. Il1b and Tnfa), which 
showed differences of (≈10x). 
To further explore these differences a repeat experiment was performed using 
both treated and control groups for each genotype. This experiment reproduced 
the findings of the first experiment with significant reductions in the expression 
of all measured chemokine and cytokine transcripts (Ccl2, Ccl3, Ccl5, Cxcl10, 
Ccr5, Il1b, Tnfa, Il6 and Il10) in IFNARKO mice when compared to WT mice 
(Figure 5.10, Figure 5.11). As expected, in WT treated mice there were 
significant increases in measured transcripts as compared to controls. 
Interestingly in the IFNARKO treated mice there were significant increases in the 
majority of measured transcripts (Ccl2, Ccl3, Ccl5, Ccr5, Il1b, Tnfa, Il10) when 
compared to IFNARKO controls. However, both Cxcl10 and Il6 did not differ 
significantly, suggesting that following cutaneous Aldara treatment IFNAR is 
required for their induction in the brain at this timepoint. 
Figure 5.9: (Overleaf) 3-day IFNARKO Aldara Model 1 Brain Chemokine and Cytokine 
Transcript 
IFNAR+/+ (WT) and IFNAR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% 
imiquimod)  on the dorsal skin. Brain tissue was collected 24 hours after the 3rd application. 
Absolute quantification was performed by qRT-PCR and values were normalised to housekeeping 
gene Tbp. N=4 per group. Unpaired Student’s T-test with Bonferroni multiple testing correction was 
used to determine statistical significance. *=P<0.05; **=P<0.01; ***=P<0.001. Bars represent mean 
± SD. 
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Figure 5.10: 3-day IFNARKO Aldara Model 2 Brain Chemokine Transcript 
IFNAR+/+ (WT) and IFNAR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Brain tissue was collected 24 hours after the 3rd 
application. Absolute quantification was performed by qRT-PCR and values were normalised to 
housekeeping gene Tbp. N=4 per group. One-way ANOVA followed by Student’s T-test with 
Bonferroni multiple testing correction was used to determine statistical significance. *=P<0.05; 
**=P<0.01; ***=P<0.001. Bars represent mean ± SD. 
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Figure 5.11: 3-day IFNARKO Aldara Model 2 Brain Cytokine Transcript 
IFNAR+/+ (WT) and IFNAR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% 
imiquimod)  or control cream on the dorsal skin. Brain tissue was collected 24 hours after the 3rd 
application. Absolute quantification was performed by qRT-PCR and values were normalised to 
housekeeping gene Tbp. N=4 per group. One-way ANOVA followed by Student’s T-test with 
Bonferroni multiple testing correction was used to determine statistical significance. *P<0.05; 
***P<0.001. Bars represent mean ± SD. 
5.2.3.2 Skin and PBL chemokine and cytokine transcriptional responses 
Subsequent examination of peripheral transcriptional responses in the skin 
(Figure 5.12) and PBL (Figure 5.13) identified that in PBL alone, Ccl5 and Cxcl10 
expression were significantly reduced in IFNARKO mice. In the skin, no measured 
chemokine or cytokine transcripts were significantly altered, as was the case for 
the remaining PBL transcripts. Finally, it is worth noting that there was no clear 
trend in the skin to suggest either an upregulation or downregulation of 
inflammatory mediators in this tissue for IFNARKO mice, indicating that there 
was likely no effect of IFNARKO on skin chemokine and cytokine transcriptional 
responses after three days of cutaneous Aldara treatment. 
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Figure 5.12: (Previous page) 3-day IFNARKO Aldara Model 1 Skin Chemokine and Cytokine 
Transcript 
IFNAR+/+ (WT) and IFNAR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% 
imiquimod)  on the dorsal skin. Skin was collected 24 hours after the 3rd application. Absolute 
quantification was performed by qRT-PCR and values were normalised to housekeeping gene Tbp. 
N=4 per group. Unpaired Student’s T-test with Bonferroni multiple testing correction was used to 
determine statistical significance. A P value < 0.05 was considered significant. Bars represent 
mean ± SD. 
5.2.4 The effect of IFNARKO on cellular responses to repeated 
Aldara treatment 
5.2.4.1 Iba1+ staining of the hippocampus and cortex 
Initial Iba1+ staining of the hippocampus and cortex in treated IFNARWT and KO 
experiments demonstrated a significant reduction in hippocampal but not 
cortical, Iba1+ staining in KO mice (Figure 5.14B, E). In the repeat experiment 
this finding was not reproduced, and while there was no significant difference 
between treated WT and KO Iba1+ staining in the hippocampus, there was a 
trend towards a difference in the cortex (P=0.069 after multiple testing 
correction) (Figure 5.14C, F). Despite this lack of significance, morphological 
examination of Iba1 staining revealed that the clear changes in microglial 
appearance observed in treated WT mice do not appear to be as prominent in 
IFNARKO treated mice (Figure 5.14A, D).  
Figure 5.13: (Overleaf) 3-day IFNARKO Aldara Model 1 PBL Chemokine and Cytokine 
Transcript 
IFNAR+/+ (WT) and IFNAR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% 
imiquimod)  on the dorsal skin. PBL were collected 24 hours after the 3rd application. Absolute 
quantification was performed by qRT-PCR and values were normalised to housekeeping gene Tbp. 
N=4 per group. Unpaired Student’s T-test with Bonferroni multiple testing correction was used to 
determine statistical significance. *=P<0.05; ***=P<0.001. Bars represent mean ± SD. 
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Figure 5.14: Iba1 staining of brain in IFNARKO Aldara Models 
IFNAR+/+ (WT) and IFNAR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% 
imiquimod) or control cream (A,C,D,F only) on the dorsal skin. Brain tissue was collected 24 hours 
after the 3rd application. Formalin-fixed paraffin embedded sections were stained using Iba1 
antibody and haematoxylin QS counterstain. (A, D) Representative images of 20x hippocampal (A) 
and cortical (D) fields of view used for automated analysis. Inset image shows 10x view of area 
with 20x area highlighted in green. Automated analysis of Iba1 area was performed using ImageJ 
software to quantify hippocampal (B, C) and cortical (E,F) Iba1 staining. Two separate experiments 
are shown; IFNARKO1 (B, E) IFNARKO2 (A, D, C, F) (n=4, 2-3 sections per mouse.) Tested using 
unpaired T-test (B, E) or one-way ANOVA and post-hoc Student’s t-test with Bonferroni multiple 
testing correction (C, F). *=P<0.05.. Scale bars =100μm (main images), 200μm (inset images). 
Bars represent mean ± SD. Abbreviations: HPC – Hippocampus; CTX – Cortex; FoV – Field of 
view. 
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5.2.4.2 GFAP staining of the hippocampus 
Examination of hippocampal GFAP revealed a small but significant increase in 
GFAP staining in treated IFNARKO mice compared to WT (Figure 5.15B), however 
in the second experiment this was not reproduced and the mean GFAP area in 
treated WT mice was increased non-significantly compared to treated IFNARKO 
mice (Figure 5.15C). Alongside this there did not appear to be gross 
morphological differences between the groups (Figure 5.15A). 
 
Figure 5.15: GFAP staining of brain in IFNARKO Aldara Models 
IFNAR+/+ (WT) and IFNAR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% 
imiquimod) or control cream (A,C only) on the dorsal skin. Brain tissue was collected 24 hours after 
the 3rd application. Formalin-fixed paraffin embedded sections were stained using GFAP antibody 
and haematoxylin QS counterstain. (A) Representative images of 20x hippocampal fields of view 
used for automated analysis. Inset image shows 10x view of area with 20x area highlighted in 
green. Automated analysis of GFAP area was performed using ImageJ on three fields of view 
software to quantify hippocampal (B, C) GFAP staining. Two separate experiments are shown; 
IFNARKO1 (B) IFNARKO2 (C) (n=4, 2-3 sections per mouse.) Tested using unpaired T-test (B) or 
one-way ANOVA and post-hoc Student’s t-test with Bonferroni multiple testing correction (C). 
*=P<0.05; Scale bars =100μm (main images), 200μm (inset images). Bars represent mean ± SD. 
Abbreviations: HPC – Hippocampus; CTX – Cortex; FoV – Field of view. 
5.2.4.3 CD3+ cell counts in the hippocampus and cortex 
CD3+ cells were investigated in both the hippocampus and cortex of IFNARWT 
and KO mice (Figure 5.16). In both experiments there were significant reductions 
in CD3+ cells in the hippocampus of treated IFNARKO mice when compared to 
WT (Figure 5.16B, C). Alongside this in the first experiment there was a 
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significant reduction in cortical CD3+ cells and in the second experiment there 
was a trend towards significance (p=0.076 after multiple testing correction) 
(Figure 5.16E, F). In both the hippocampus and the cortex earlier findings of 
increased CD3+ cells in treated animals were reproduced in WT mice. In 
contrast, there was no significant difference in CD3+ cell numbers between 
treated and control IFNARKO mice. Together these data strongly suggest that 
there are reductions in CD3+ cell numbers in treated IFNARKO mice when 
compared to WT animals.  
Figure 5.16: (Overleaf) CD3 staining of brain in IFNARKO Aldara Models 
IFNAR+/+ (WT) and IFNAR-/- (KO) mice were treated daily with 62.5mg Aldara cream (5% 
imiquimod) or control cream (A,C,D,F only) on the dorsal skin. Brain tissue was collected 24 hours 
after the 3rd application. Formalin-fixed paraffin embedded sections were stained using CD3 
antibody and haematoxylin QS counterstain by Veterinary Diagnostic Services Laboratory at the 
University of Glasgow. (A, D) Representative images of 10x hippocampal (A) and cortical (D) fields 
of view. Expanded images are 20x examples of CD3 staining in treated samples. (B, C) Manual 
counting was performed on all CD3+ cells within the hippocampus. (E, F) Manual counting of CD3+ 
cells in the cortex, 3 fields of view were used per section. Two separate experiments are shown; 
IFNARKO1 (B, E) IFNARKO2 (A, D, C, F) (n=4, 3 sections per mouse.) Tested using unpaired T-
test (B, E) or one-way ANOVA and post-hoc Student’s t-test with Bonferroni multiple testing 
correction (C, F). *=P<0.05; **=P<0.01; ****=P<0.0001. Scale bars =100μm (main images), 200μm 
(inset images). Bars represent mean ± SD. Abbreviations: HPC – Hippocampus; CTX – Cortex; 
FoV – Field of view. 
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5.3 Discussion 
5.3.1 Summary of results 
The work presented in this chapter has investigated the role of inflammatory 
chemokine (CCR1, CCR2, CCR3 and CCR5) and IFNAR signalling in the induction 
of inflammation following cutaneous Aldara treatment. The data suggest that 
iCCRKO may influence CD3+ cellular response to cutaneous Aldara treatment, 
but does not have significant effects on transcriptional responses. In contrast, 
IFNARKO has significant effects on brain chemokine and cytokine transcriptional 
responses to cutaneous Aldara treatment that appear to be accompanied by 
changes in the response of Iba1+ and CD3+ cellular populations. Despite this 
IFNARKO does not appear to cause many significant differences in either the skin 
or PBL transcriptional response to 3 days of cutaneous Aldara treatment.  
Neither iCCRKO nor IFNARKO appeared to significantly influence the GFAP+ 
cellular population within the CNS in a consistent manner. 
5.3.2 Role of iCCRs in response to cutaneous Aldara treatment 
The data presented here suggest that, in contrast to our hypothesis, the iCCRs 
(CCR1, CCR2, CCR3 and CCR5) have no apparent effect on brain chemokine and 
cytokine transcriptional responses to cutaneous Aldara treatment. Despite this, 
there is evidence that there are reductions in the cellular CD3+ population. 
These data may be explained by a number of factors. Firstly iCCRs are most 
likely to influence cellular migration and recruitment(27), and, as such the 
responses of endogenous cellular populations such as microglia and astrocytes 
that are already present in the brain may not be significantly altered. This is 
particularly true when considering response to the type I IFNs and the cytokines 
examined here (Il1b, Tnfa and Il6). If the inflammatory signal from the periphery 
can be transmitted to the brain in the absence of cellular recruitment, for 
example, through circulating inflammatory mediators gaining access to the CNS 
parenchyma (254, 255, 257, 258), it would be unlikely that dramatic differences 
in the chemokine and cytokine response would be observed as the endogenous 
cells of the CNS would be able to respond to these signals and initiate an 
inflammatory response, independent of cellular recruitment. This would also 
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provide an explanation for the lack of consistent significant differences observed 
between iCCRKO and WT mice in the GFAP+ cellular populations. 
Another possible explanation is that although significant differences were not 
observed in this experiment, this was due to insufficient power rather than a 
lack of any difference. Based on the data generated here and using Il1b, which 
was reduced non-significantly in both iCCRKO experiments, power calculations 
indicated that for 80% power at an alpha of 0.05, 32 animals per group would be 
required. As these animals were in short supply this would have been difficult to 
achieve, however it does highlight a limitation of this work and a consideration 
for future experiments.  
A final possible explanation is that at this time-point transcriptional changes 
may not be present. Previous data from fluorescence-activated cell sorting 
(FACS) examination of recruited cellular populations in the brains of Aldara 
treated WT mice reveals that after 1 day there are limited changes with peak 
responses occurring at 3 or 5 days depending on the population(24). If 
recruitment begins to occur between 1 and 3 days, and there are deficits in this 
process in iCCRKO mice it is entirely possible that alterations in transcription 
may not become manifest until after the 4 day time-point examined here. 
A reduction in CD3+ cellular recruitment was expected in the context of iCCRKO, 
because, as mentioned earlier, CCR5 is an important receptor for T-cell 
recruitment (123, 479). Although not conclusive there does appear to be 
evidence of reductions in CD3+ cell numbers in the brains of iCCRKO mice. The 
reason for this equivocal outcome may be that, in the absence of CCR5, CXCR3 
will still be present in iCCRKO mice. The CXCR3-CXCL10 axis is also thought to be 
important for T-cell homing (122), particularly to the CNS (480, 481) and, as 
such, it might be expected that this redundancy would at least in part make up 
for deficits in CCR5. Increases in power or more quantitative methods such as 
FACS, may help to clarify the effect of iCCRKO on CD3+ cellular populations. 
5.3.3 Role of IFNAR in response to cutaneous Aldara treatment 
In line with our hypotheses IFNARKO resulted in significant reductions in brain 
transcriptional responses that were accompanied by changes in the Iba1+ and 
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CD3+ populations. The reductions in transcriptional response can be explained 
through the fact that IFNARKO mice should lack type I IFN responses. As type I 
IFN signalling is a potent inducer of inflammatory responses (85), it is not 
surprising that in its absence chemokine and cytokine transcriptional responses 
are attenuated.  
Two other, more interesting, findings from the transcriptional data are: (i) the 
extent to which all measured transcripts were downregulated (>10x) and; (ii) the 
fact that some (Cxcl10 and Il6) but not all transcripts were unchanged in 
IFNARKO mice in response to cutaneous Aldara treatment. Considering the first 
point, when examining genes that are more classically associated with NF-κB 
such as Il1b and Tnfa (49, 474) one might expect that, although there may be 
reductions in their expression due to reduction in overall inflammation in 
IFNARKO, their responses would be largely intact. The data presented here seem 
to suggest that this is not the case. While in the absence of IFNAR, many 
transcripts that are associated with NF-κB signalling are still significantly 
upregulated following Aldara treatment these data suggest that IFNAR signalling 
is critical to augmenting this response. The second point demonstrates that, 
while there is crossover between IFNAR and NF-κB signalling as discussed above, 
certain transcripts are strongly associated with specific signalling pathways. 
Cxcl10 is an archetypal ISG and therefore the fact that its response is completely 
abrogated in IFNARKO mice is not entirely surprising, although considering it was 
originally described as being induced by IFNγ a type II IFN, it is a little 
unexpected. However, without assessing the impact of IFNARKO on IFNγ in this 
model, it is difficult to know how unexpected this result is as conflicting data 
shows that IFNγ can be both decreased (482) and increased (483) in IFNARKO 
mice. Il6 is not an archetypal ISG, however, the data presented here suggest 
that, at least within the brain, in response to cutaneous Aldara, its induction is 
dependent on intact type I IFN signalling.  This conflicts with data from the same 
viral infection study (483) that demonstrated increase in IFN-γ, showing an 
increase in Il-6 in IFNARKO mice, although this may be accounted for by: (i) the 
fact that this model used a virus rather than a TLR ligand that may be able to 
activate other TLR signalling pathways; (ii) IFNARKO increases viral load and 
lethality, and additional damage associated with this may potentiate further 
inflammatory responses. 
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Having observed reductions in transcription it is unsurprising that the cellular 
responses observed in treated mice are attenuated. As discussed, significant 
reductions in Ccl5 and Cxcl10 would be expected to result in a reduced number 
of CD3+ cells within the CNS parenchyma. Alongside these significant reductions 
in inflammatory transcripts, it is not surprising that morphological alterations, 
associated with reactive changes, in Iba1+ cells would be reduced. Considering 
that these changes in microglia are most strongly associated with phagocytosis, 
(167, 469) these data suggest that IFNAR signalling is important for inducing 
morphological alterations associated with a phagocytic phenotype in microglial 
cells. However, whether this is due to the fact that IFNAR signalling is required 
for the induction of phagocytic activity, whether IFNAR is required for 
morphological changes following phagocytosis or whether IFNARKO limits damage 
that stimulates a phagocytic phenotype is not clear from this set of experiments. 
One challenge of the data presented above is that only two significant 
differences were identified in the chemokine and cytokine transcriptional 
responses of the skin and PBL. However, this would be expected, considering the 
fact that most transcripts in the time-course model appear to return to control 
levels by the 3 day time-point examined here. As such it is difficult to assess 
whether the reduction in inflammatory responses observed here is due to a 
reduction in the peripheral response that results in a reduction of CNS 
inflammation or is due to a brain specific role of IFNAR. A more complete time-
course in IFNARKO mice would help investigate this. 
5.3.4 Other findings of note 
Two other findings of note are worth briefly mentioning here. Firstly the data 
presented here supports earlier findings of increases in chemokine and cytokine 
transcription after repeated daily cutaneous Aldara treatment compared to 
control cream. In addition although not always significant, in experiments that 
compared WT control and treated animals there were consistent increases in 
Iba1+ and GFAP+ area, and CD3+ cellular numbers. The consistent nature of 
these findings across not just multiple experiments but also multiple genotypes 
(C57BL6/J in the time-course, C57BL6/N in the iCCRKO and A129 in the 
IFNARKO) provides substantial evidence that observed effects are real. 
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Secondly it is interesting that there did not appear to be changes in GFAP 
between the genotypes. This is likely due to the fact that compared to the 
changes in Iba1 and CD3; the changes in GFAP appear to be relatively small. This 
may reflect that quantification of DAB GFAP area is not sensitive enough. As 
such, immunofluorescence that may be more easily quantifiable or alternate 
assays of astrocytic function, such as examination of the astrocyte population 
after cell sorting, may be more appropriate. 
5.3.5 Summary  
Overall these data have provided insight into the role of iCCRKO and IFNARKO in 
brain responses to cutaneous Aldara treatment. iCCRKO has minimal impact on 
transcriptional and CNS resident cellular responses to cutaneous Aldara, but, 
does appear to significantly impact the recruitment of CD3+ T cells. In contrast, 
IFNARKO has significant impacts on CNS transcriptional responses, even those 
more classically associated with NF-κB. Alongside changes in the transcriptional 
response, IFNARKO also alters microglial responses as measured using Iba1 and 
reduces recruitment of CD3+ T cells into the brain. However, both of these 
studies raise questions that remain to be answered, particularly around the role 
of peripheral vs central mechanisms mediating these differences. In addition, 
much of the data presented here supported earlier findings from the Aldara 
model, allowing us to have greater confidence in findings of transcriptional and 
cellular alterations within the brain in response to cutaneous Aldara treatment. 
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Chapter 6 The effect of a single Aldara treatment 
over time and mass spectrometry of Imiquimod 
6.1 Introduction 
Earlier in this thesis a number of features of the response to Aldara were 
identified to be investigated further. Firstly, it appeared that the magnitude of 
fold changes in the brain was greater than in the peripheral tissues. Secondly, 
examination of the brain transcriptional response to Aldara identified that for all 
examined chemokines and cytokines, the peak was after 3 days of repeated 
treatments, and, that this was not the case for the peripheral tissues that 
generally peaked within the first 24 hours. Based on these two findings the 
following questions were asked: 
1. Is the absolute expression of examined chemokines and cytokines lower 
in the brain than in the periphery under control conditions thus 
accounting for the apparently greater fold change? 
2. In the case of only a single treatment of Aldara does the brain still 
manifest a peak chemokine and cytokine transcriptional response after 
3 days? 
To this end the Aldara model was repeated looking at 1 day, 3 day and 5 day 
time-points after a single treatment of Aldara at day 0. The use of absolute 
measures of gene expression allowed for tentative comparisons of control 
expression between tissues. Based on data from other TLR models of 
inflammation suggesting that single peripheral insults resolve relatively quickly 
(239, 245, 246, 484), it was hypothesized that a single treatment would result in 
an earlier peak response point at 1 day post IMQ application. 
In addition to the above findings, it was shown that there were profound 
systemic responses to Aldara treatment. Alongside this, human pharmacokinetic 
data shows that IMQ the TLR7 agonist present in Aldara can be absorbed into the 
circulation (485), and based on IMQ’s low molecular weight and lipophilic 
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nature(486), it may subsequently be able to cross the blood-brain barrier. 
Therefore, it was asked: 
3. Are the systemic and central responses to Aldara a consequence of 
imiquimod entry into the plasma and/or brain parenchyma? 
To investigate the possible role of systemic IMQ further the biomarker and drug 
analysis core facility at Dundee University conducted mass spectrometry on the 
plasma and brains from mice treated with Aldara cream at a variety of time 
points. 
Similar to the mechanistic investigations presented in the previous chapter the 
absolute expression of a select group of chemokines and cytokines identified as 
altered in the initial time-course investigations was investigated. In addition to 
the tissues studied in the time-course, the spleen was also examined as had 
been initially intended for the time-course experiment in Chapter 4. Alongside 
this, based on the paper by Grine et al. suggesting that Aldara’s effects may be 
mediated by oral intake and colon activation (288), it was deemed worthwhile to 
include colon tissue to examine if there were inflammatory changes that could 
be indicative of IMQ ingestion. 
6.2 Results 
6.2.1 Comparison of control levels of gene expression between 
tissues 
Due to the fact that a large quantity of absolute transcriptional data from 
control mice that had only been exposed to shaving was available, tissue specific 
expression levels were examined in these mice. The most striking finding from 
this analysis was that, for all chemokine and cytokine transcripts examined, 
absolute expression in the brain normalised to Tbp was either significantly lower 
or not significantly different from other tissues (Figure 6.1, Figure 6.2). For Ccl2, 
Ccl5, Il1b and Tnfa expression in the brain was significantly lower than all other 
tissues in control mice. For all transcripts except Il6 the skin, spleen and colon 
had significantly higher gene expression than the brain. 
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Figure 6.1: Chemokine transcription in control tissue 
Tissue was isolated 1, 3 or 5 days after mice were treated with control cream on the dorsal skin. 
Absolute quantification was performed by qRT-PCR and values normalised to housekeeping gene 
Tbp.  n=12. One-way ANOVA followed by Student’s T-test with Bonferroni multiple testing 
correction was used to determine statistical significance. *=P<0.05; ***=P<0.001. Bars represent 
mean ± SD. 
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Figure 6.2: Cytokine transcription in control tissue. 
Tissue was isolated 1, 3 or 5 days after mice were treated with control cream on the dorsal skin. 
Absolute quantification was performed by qRT-PCR and values normalised to housekeeping gene 
Tbp.  n=12. One-way ANOVA followed by Student’s T-test with Bonferroni multiple testing 
correction was used to determine statistical significance. **=P<0.01; ***=P<0.001. Bars represent 
mean ± SD. 
 
6.2.2 The effect of a single cutaneous treatment with Aldara on 
chemokine and cytokine transcription in the brain 
Following examination of control levels of gene expression, the brain response to 
a single treatment of Aldara was investigated. As was expected, all transcripts 
(Ccl2, Ccl3, Ccl5, Cxcl10, Tnfa and Il6) found to be raised after 24 hours in the 
repeated treatments time-course were also found to be significantly upregulated 
compared to controls 24 hours after a single treatment in this model (Figure 6.3, 
Figure 6.4). Those transcripts not altered 1 day after a single treatment (Ccr5, 
Il1b and Il10) did not become significantly different from controls at either 3 or 
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5 days. Examining the later time-points Ccl2, Ccl5, Cxcl10 and Tnfa all remained 
significantly upregulated at 3 days, however only Ccl5 remained upregulated 
after 5 days (Figure 6.3). Ccl5 was the only transcript that did not peak after 1 
day, but instead peaked 3 days after Aldara treatment. 
 
Figure 6.3: Brain chemokine transcript levels after a single Aldara treatment. 
Brain tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. **=P<0.01; ***=P<0.001. Bars represent mean ± SD. 
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Figure 6.4: Brain cytokine transcript levels after a single Aldara treatment.  
Brain tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. *=P<0.05; ***=P<0.001. Bars represent mean ± SD. 
 
6.2.3 The effect of a single cutaneous treatment with Aldara on 
chemokine and cytokine transcription in the periphery 
6.2.3.1 Skin chemokine and cytokine transcriptional responses 
Alongside investigation of the brain response, how the peripheral tissues 
responded to a single treatment was examined. Starting with the skin there was 
minimal upregulation of transcript at 1 day, with Ccl2, Ccl3, Il1b, Il6 and Il10 
being the only measured transcripts that were significantly upregulated (Figure 
6.5, Figure 6.6). Interestingly, in contrast to the repeated treatment model, 
Ccl3 was also upregulated after 3 days of treatment, although no other 
transcripts were significantly altered from controls at this point.  
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Figure 6.5: Skin chemokine transcript levels after a single Aldara treatment.  
Skin tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. *=P<0.05; ***=P<0.001. Bars represent mean ± SD. 
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Figure 6.6: Skin cytokine transcript levels after a single Aldara treatment.  
Skin tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. *=P<0.05; ***=P<0.001. Bars represent mean ± SD. 
 
6.2.3.2 PBLs chemokine and cytokine transcriptional responses 
Next, cytokine and chemokine expression was examined in PBL. There was 
minimal upregulation of measured transcripts with only Ccl3, Cxcl10 and Ccr5 
being significantly upregulated (Figure 6.7). No other chemokines or cytokines 
were significantly upregulated at any point, and it is interesting to note that in 
controls, and at later time-points, Il10 expression was not higher than negative 
control levels in a number of samples suggesting minimal to no expression 
(Figure 6.8). No transcripts were found to be significantly altered at either 3 or 5 
days after treatment. 
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Figure 6.7: PBL chemokine transcript levels after a single Aldara treatment.  
PBL were isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. *=P<0.05; ***=P<0.001. Bars represent mean ± SD. 
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Figure 6.8: PBL cytokine transcript levels after a single Aldara treatment.  
PBL were isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. Bars represent mean ± SD. 
 
6.2.3.3 Liver chemokine and cytokine transcriptional responses 
Analysis of the liver also revealed significant upregulation of a limited range of 
transcripts (Ccl2, Ccl3, Cxcl10 and Il10) after 1 day of treatment (Figure 6.9, 
Figure 6.10). There were no significant alterations at any other time point. 
Although significance was lost after multiple testing correction it is worth noting 
that Ccl5 also showed a trend towards upregulation (p=0.088). Liver Il6 was 
excluded from analysis due to high non-specific background resulting in positive 
expression in only 3 of 24 samples. 
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Figure 6.9: Liver chemokine transcript levels after a single Aldara treatment.  
Liver tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. *=P<0.05; ***=P<0.001. Bars represent mean ± SD. 
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Figure 6.10: Liver cytokine transcript levels after a single Aldara treatment.  
Liver tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. ***=P<0.001. Bars represent mean ± SD. 
 
6.2.3.4 Lung chemokine and cytokine transcriptional responses 
Investigation of the lung response revealed changes distinct from the other 
peripheral tissues. Expression of a wide range of transcripts was found to be 
significantly altered after 1 day (Ccl2, Ccl3, Cxcl10, Ccr5, Il1b, Il6 and Il10), 
with only Ccl5 and Tnfa showing no significant difference compared to controls 
(Figure 6.11, Figure 6.12). 3 days after Aldara treatment Ccl5 became 
significantly upregulated and, alongside this, Ccl2, Ccl3 and Ccr5 remained 
significantly raised at this time-point. For all of the transcripts examined there 
were no significant differences at 5 days after treatment. 
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Figure 6.11: Lung chemokine transcript levels after a single Aldara treatment.  
Lung tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. *=P<0.05; **=P<0.01; ***=P<0.001. Bars represent mean ± SD. 
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Figure 6.12: Lung cytokine transcript levels after a single Aldara treatment.  
Lung tssue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. *=P<0.05; ***=P<0.001. Bars represent mean ± SD. 
 
6.2.3.5 Spleen chemokine and cytokine transcriptional responses 
Investigation of the spleen demonstrated a significant upregulation of Ccl2 and 
Ccl3 after 1 day of treatment, similar to most of the other tissues examined 
(Figure 6.13). Expression of the cytokines Il6 and Il10 were also found to be 
significantly raised compared to control at this time-point (Figure 6.14). The 
only downregulation observed in this experiment occurred in the spleen, 3 days 
after Aldara treatment Il1b was found to be significantly downregulated. No 
other measured transcripts were significantly different from control at this time 
point. For all of the splenic transcripts examined there were no significant 
differences at 5 days after treatment.  
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Figure 6.13: Spleen chemokine transcript levels after a single Aldara treatment.  
Spleen tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. ***=P<0.001. Bars represent mean ± SD. 
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Figure 6.14: Spleen cytokine transcript levels after a single Aldara treatment.  
Spleen tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. ***=P<0.001. Bars represent mean ± SD. 
 
6.2.3.6 Colon chemokine and cytokine transcriptional responses 
Finally the colon response to Aldara treatment was investigated. The colon 
response appeared very similar to the spleen response with Ccl2, Ccl3, Il6 and 
Il10 all being significantly upregulated after 1 day (Figure 6.15, Figure 6.16). No 
measured transcripts were significantly altered 3 or 5 days after treatment. 
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Figure 6.15: Colon chemokine transcript levels after a single Aldara treatment.  
Colon tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp.  n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. *=P<0.05; ***=P<0.001. Bars represent mean ± SD. 
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Figure 6.16: Colon cytokine transcript levels after a single Aldara treatment.  
Colon tissue was isolated 1, 3 or 5 days after mice were treated with 62.5mg Aldara cream (5% 
imiquimod) or control cream on the dorsal skin. Absolute quantification was performed by qRT-
PCR and values normalised to housekeeping gene Tbp. n=4 per group. One-way ANOVA followed 
by Student’s T-test with Bonferroni multiple testing correction was used to determine statistical 
significance. ***=P<0.001. Bars represent mean ± SD. 
 
6.2.4 Mass spectrometry of plasma and brain imiquimod in the 
Aldara model 
To investigate the ability of IMQ, the TLR7 agonist present in Aldara, to enter 
the circulation and brain, mass spectrometry was performed at the University of 
Dundee. Initial investigation of IMQ levels after 3 days of Aldara treatment, the 
peak response point identified in earlier work, revealed that there was evidence 
that IMQ was not only present in the circulation but also within the brain (Figure 
6.17A). IMQ reaches molar concentrations of 0.33M (95% CI; 0.15-0.52) in the 
plasma with a total load of 0.76 nmol (95%CI; 0.31 – 1.21 nmol) in the brain after 
3 days of treatment. After demonstrating that IMQ was present at this later 
time-point, how early it gained access to both the circulation and brain was 
assessed. To examine this IMQ levels 4 hours, 12 hours and 24 hours after a 
single cutaneous Aldara treatment were investigated. Examination of the plasma 
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found significant IMQ concentrations at 24 hours but not the earlier time-points, 
however it is important to note that at both 4 and 12 hours IMQ concentrations 
were above limits of quantification for all treated samples and absent in all 
controls (Figure 6.17B). This strongly supports the idea that by 4 hours after 
treatment IMQ has entered the circulation. In the brain significant IMQ 
concentrations were detected at both 12 and 24 hours after treatment. In 
addition, although not significant at 4 hours, similar to the plasma, all treated 
samples had levels of IMQ above the limit of quantification with no IMQ present 
in the controls. 
Finally to assess if plasma and brain levels of IMQ were associated, linear 
regression analysis was performed. Linear regression revealed a strong 
association between plasma and brain levels (R2 = 0.8836, Figure 6.17C), in 
addition the residual plot did not show any clear pattern, indicating that this 
linear analysis was likely appropriate (Figure 6.17D). 
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Figure 6.17: Mass spectrometry of imiquimod in Aldara treated mice.  
Mice were treated with 62.5mg Aldara cream (5% imiquimod) or control cream. Brains and plasma 
were isolated from mice and frozen prior to mass spectrometry analysis at the University of 
Dundee. (A) Imiquimod concentrations in brain and plasma after 3 days of daily Aldara. N=8 per 
group (B) Imiquimod concentrations in brain and plasma 4, 12 and 24 hours after a single Aldara 
treatment. N=4 per group (C) Linear regression of brain and plasma imiquimod levels in all treated 
animals. (D) Residual plot of linear regression analysis. Student’s T-test with Bonferroni multiple 
testing correction (where required) was used to determine statistical significance between groups. 
Linear regression analysis was performed to look at relationship between brain and plasma 
imiquimod *=P<0.05; **=P<0.01. Bars represent mean ± SD. 
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6.3 Discussion 
6.3.1 Overview of results 
In this chapter, control levels of chemokine and cytokine expression in 
peripheral tissues were initially reported. This revealed that absolute expression 
of measured chemokines and cytokines normalised to Tbp was generally lower in 
the brain than other tissues investigated. The primary finding when examining 
the response to a single cutaneous Aldara treatment was that the brain 
chemokine and cytokine transcriptional response was at its peak after 1 day 
when compared to 3 and 5 days after treatment. This is in contrast to the 
repeated treatment model where the peak was after 3 days of daily treatments. 
Despite this, similar to the time-course experiment, 1 day after treatment the 
majority of examined transcripts were upregulated in the brain and lungs, and a 
summary heat-map of the transcriptional data is provided in Figure 4.31.  
In addition to the single treatment model, IMQ entry into both the circulation 
and the brain was investigated, to assess whether direct TLR7 agonism within 
tissues may contribute to observed inflammatory responses. Mass spectrometry 
analysis provided two main findings; (i) IMQ can enter both the circulation and 
the brain within 4 hours of cutaneous treatment; (ii) Plasma levels of IMQ 
correlate strongly with brain levels of IMQ;  
 
6.3.2 Control gene expression between tissues 
How control levels of genes varied between tissues was initially examined, to 
investigate whether large fold changes in the brain are due to an increased 
induction of transcriptional responses compared to other tissues or lower 
baseline levels. As mentioned, the brain generally had much lower absolute 
levels of expression of measured transcripts than many of the other tissues. The 
findings presented here suggest that, at least in part, the magnitude of fold 
change observed in the brain is due to lower baseline levels compared to other 
peripheral tissues. 
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6.3.3 Relevance of findings from single treatment model 
To investigate whether or not the 3 day peak in chemokine and cytokine 
transcriptional responses observed in the brain was a natural feature of the brain 
immune response, or a consequence of repeated treatments augmenting the 
brain response over time, a single cutaneous treatment model examining 1, 3 
and 5-day time points was performed. This showed that after a single treatment 
the peak brain response point shifted from 3 days to 1 day, strongly supporting 
the idea that sustained peripheral insults result in more sustained central 
responses. This suggests that the brain takes longer to induce immune-regulatory 
responses and/or to tolerise itself to immune stimuli. The idea of the brain 
taking longer to induce immune-regulatory responses is supported by data 
showing that after 1 day of treatment, unlike in other organs, Il10 was not 
significantly upregulated in the brain. 
There is reasonable evidence that pre-treatment with TLR7 agonists can diminish 
subsequent TLR7 responses. This has been demonstrated in vivo using models of 
experimental autoimmune encephalitis (487, 488) and in vitro in both 
macrophages(489) and microglia(488). Suggested mechanisms for this change 
include reductions in Tlr7(490) and reductions in phospho-interleukin-1 receptor 
associated kinase 1(489) that can activate NF-κB. These data support the idea 
that the lack of peripheral responses at later time-points in the repeated 
treatments model may be due to tolerisation. One unanswered point is still the 
question of why the brain does not appear to tolerise as quickly. A parallel 
hypothesis is that the slower rise in Il10 is what results in a more prolonged 
response, Il10 appears to be critical to suppression of LPS responses but not the 
tolerisation process itself (491, 492). Due to the complex nature of inflammatory 
responses it is entirely plausible that both reduced tolerisation and slower up 
regulation of anti-inflammatory mediators contribute to this response, 
particularly as the two may be linked. 
6.3.4 Importance of the mass spectrometry results 
As discussed, there was concern that the effects of Aldara treatment may be 
mediated by direct entry of the TLR7 agonist IMQ to the CNS. To this end, mass 
spectrometry identified IMQ in both the plasma and the brain of treated animals 
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from 4 hours after treatment. Microglia, astrocytes and neurons have all been 
shown to express TLR7 (238, 493), highlighting that direct IMQ agonism of TLR7 
within the CNS is a plausible mechanism for immune activation. This strongly 
suggests that, at least for the brain, if not the other peripheral organs, many of 
the observed effects are mediated by entry of IMQ to the brain parenchyma 
itself. This pathway of immune activation characterised by direct activation of 
resident immune cells of the brain suggests that the Aldara model is more akin 
to a model of systemic viral infection, particularly ssRNA viruses, (e.g. VSV and 
WNV) where the initial site of inoculation is the skin. This is in contrast to our 
previous conceptual model where Aldara was a peripherally restricted insult, 
and the resultant changes observed within the CNS were due to either humoral 
or neural routes of immune communication. Therefore, the responses observed 
in the brain are more likely to reflect changes expected in viral encephalitis. 
Examining chemokine and cytokine responses in models of ssRNA viral 
encephalitis, identifies upregulation of CCL2, CCL5, CXCL10, Il-1β and TNFα 
demonstrating considerable overlap with our own findings (209, 213, 494-497). In 
addition, reactive changes in microglia and astrocytes, alongside T cell 
infiltration are consistent findings in these models (216, 496, 498). These data 
highlight that the Aldara model is likely a useful tool for studying TLR7-mediated 
brain inflammation using a non-infectious and non-invasive model. However, it is 
not an appropriate tool for the study of neuroinflammatory responses to a 
localized peripheral inflammatory stimulus. 
Briefly, the fact that plasma levels of IMQ have strong linear associations with 
brain levels of IMQ suggests that IMQ is either transported rapidly across the BBB 
in a non-saturatable manner across the range of concentrations observed, or, 
that it is able to freely diffuse across the BBB. Based on its low molecular weight 
and high lipophilicity, it is probably that it is the latter. 
6.3.5 Summary and conclusions 
In this chapter it was demonstrated that a single treatment with Aldara 
generates a distinct response in the brain when compared to repeated 
treatments over a similar time-course. The finding that the peak response point 
is earlier in this model suggests that prolonged responses in the context of 
repeated treatments are due to delayed inflammatory dampening when 
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compared to peripheral tissues. While limited data are available on the 
mechanisms through which this occurs, the slower upregulation of anti-
inflammatory mediators, particularly Il10 examined here, is a compelling 
explanatory factor. Alongside this work, brief examination of control gene 
expression suggests that many of the inflammatory mediators examined in this 
thesis are expressed at lower constitutive levels in the brain than in other 
organs. This suggests that increased magnitude of fold changes in chemokine and 
cytokine expression observed in the brain are at least partly due to lower levels 
of baseline expression rather than increased absolute expression following 
cutaneous Aldara treatment. 
In addition to data from a single treatment model, IMQ entry into the circulation 
and brain, that may be responsible for observed changes, was examined. Mass 
spectrometry data provide strong evidence for entry of IMQ into the brain. It is 
therefore likely that many of the results obtained for brain responses reported in 
this Thesis are not driven by peripheral inflammatory responses but through 
central TLR7 agonism. While this does not prevent the Aldara model being used 
as a tool for studying neuroinflammatory responses, it strongly suggests that it is 
not an appropriate model for the study of peripheral-central crosstalk. 
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Chapter 7 Discussion 
7.1 Summary of Findings  
This thesis initially introduced the overlapping interactions between the immune 
system and the CNS (4, 5, 8, 499), and the subsequent effects on behavioural 
phenotypes (103, 295, 500). Research into these interactions identified 
associative links and had begun to point to putative mechanisms. However a 
number of gaps in the current literature were identified as areas for further 
research. As chemokines appeared to be a point of overlap between the immune 
system and CNS (32, 101, 501-504), and are a particular focus of our laboratory’s 
work, they were chosen as candidate molecules for further investigation.  
Chemokine molecules are increasingly being associated with immune-CNS 
interactions in the pre-clinical literature. However the role that these molecules 
play in psychiatric disease, specifically in depression, is somewhat unclear. To 
address this, a comprehensive systematic review and meta-analysis of the role of 
chemokines in human depressive disorder was undertaken. This work showed 
that, despite limitations of the human biomarker literature, alterations in a 
number of chemokines (CCL2, CCL3, CCL4, CCL11, CXCL4, CXCL7 and CXCL8) 
appeared to be associated with human depressive disorder. 
Previous work within our laboratory had identified the Aldara model of psoriasis-
like inflammation, which utilises the TLR7 agonist IMQ, as a compelling tool for 
studying peripherally induced CNS inflammation (24, 25). Cutaneous Aldara 
treatment was shown to induce inflammatory changes within the CNS that were 
associated with alterations of behavioural phenotypes. However, there were a 
number of gaps regarding the cytokine and chemokine response, CNS cellular 
responses, early time-points and the mechanisms of inflammatory induction. To 
this end we aimed to perform a more comprehensive examination of the 
inflammatory response in the Aldara model and to begin to investigate 
mechanisms of inflammatory induction. 
Work to further characterise the Aldara model showed that, in keeping with the 
initial hypotheses, a broad array of previously unexamined chemokines and 
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cytokines were induced in the brains of treated animals. These transcriptional 
changes were associated with alterations in cellular populations of the CNS. 
Reassuringly, these findings appeared to be consistent across a number of 
experiments and mouse genotypes. In addition, it was shown that the CNS 
response was temporally distinct from the periphery, taking longer to be fully 
induced and to resolve in response to repeated treatments. 
Subsequently, work was performed to examine potential mechanisms through 
which this response might occur. Using iCCRKO mice it was shown that absence 
of the iCCRs (CCR1, CCR2, CCR3 and CCR5) does not appear to result in 
significant deficits of transcriptional response or microglial reactivity. However, 
these receptors may play a role in the recruitment of CD3+ cells. In contrast, 
using IFNARKO mice, demonstrated that type I IFN signalling appears to be 
important to the induction of the CNS response to cutaneous Aldara treatment. 
This was shown through the identification of reduced transcriptional responses, 
alongside alterations in cellular reactivity and recruitment in Aldara treated 
IFNARKO mice. Use of a single treatment model helped to show that the 
prolonged response identified within the CNS requires repeated stimulation. 
Finally, through the use of mass spectrometry, it was shown that IMQ can enter 
into the circulation and CNS. As such, systemic effects of cutaneous Aldara 
treatment are likely driven through IMQ-mediated TLR7 agonism within tissues, 
although there may be a contributory role for inflammatory mediators produced 
at the site of stimulation. 
7.2 Discussion 
7.2.1 Human biomarker data 
Having initially identified evidence of raised chemokines in human biomarker 
studies of depression, it is important to explore possible links with the animal 
data presented in this thesis. Of note, CCL2, CCL3 and CXCL8 (mouse homolog 
CXCL1) that were raised in depressive disorder, were all raised following 
cutaneous Aldara treatment. While direct correlates are impossible to draw, 
particularly as IMQ appears to enter the brain and this is not a model of 
depression. It is interesting that, at least for Ccl2 and Ccl3, there was a 
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significant reduction in expression in IFNARKO mice. This links with human data 
suggesting that IFN responses can drive depressive disorders (14) and suggests 
that induction of these molecules in humans may be secondary to type I IFN 
signalling.  
Another finding of interest, is that although in the mouse in response to Aldara 
treatment there is a rise in Ccl4, in the human literature the opposite is found. 
This rise in CCL2 and CCL3 that is accompanied by decreases in CCL4 in humans 
appears paradoxical, yet, both Ho et al. and Lu et al. studied all three of these 
molecules in physically healthy depressed patients and found these paradoxical 
findings within the same groups of individuals (360, 379). Considering that CCL4 
is thought to be important for regulatory T-cell recruitment (418) and reductions 
in regulatory T-cells are associated with depressive disorder(419), this may have 
mechanistic significance. 
If these findings are robust and represent a true immunological alteration in the 
depressed population it would be interesting to compare the expression of these 
chemokines in individual patients. If within individual patients CCL2 and CCL3 
were raised, but, CCL4 was decreased this would suggest that dysregulation of 
CCL4 specifically may be important and warrant further investigation, possibly at 
a genetic or epigenetic level.  
7.2.2 IMQ in the brain 
Given the finding of IMQ in the brain it is difficult to draw any conclusions on the 
mechanisms through which peripheral immune alterations drive changes in the 
CNS using the Aldara model. In addition, this finding highlights how important it 
is to ensure that the models we use to study human disease are appropriately 
characterised and understood, so as to not draw false conclusions. 
Although the fact that IMQ enters the brain makes the model inappropriate for 
investigation of peripheral-central immune crosstalk, it does highlight a 
potentially novel use for this model. This work identifies the Aldara model as a 
tool for introducing a TLR7-specific non-infectious immune stimulus into the CNS 
in a non-invasive manner. This is particularly useful for a number of reasons; (i) 
it allows one to avoid the invasive nature of i.c.v injection that is at least mildly 
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traumatic to brain parenchyma(505); (ii) the fact that it is introduced through a 
peripheral route means it is probably closer to normal physiology; (iii) as a non-
infectious tool for studying neuro-inflammation it allows for investigation of 
more specific aspects of immune function, in this case TLR7 signalling. In 
addition, viral encephalitis in KO mice can result in raised and more rapid-onset 
mortality making study of later time-points challenging, whereas this does not 
appear to be the case for the Aldara model (216, 506). Work in our laboratory 
has shown that mice treated with Aldara for 4 days and left for an additional 7 
days do not develop any signs of terminal illness [personal communication] and 
data in this thesis has shown that recovery appears to begin around day 3. 
Alongside enhancing our understanding of the model, this finding of IMQ within 
the brain parenchyma helps to provide answers to a question raised in the iCCR 
and IFNARKO chapter. This was whether or not the effect of KO on peripheral 
responses was the critical mechanism that changed the brain response. The fact 
that IMQ can enter the brain and probably bind to TLR7 receptors that are known 
to be expressed by microglia, astrocytes, and neurons (487, 488), suggests that 
observed findings are due to the function of these receptors within the CNS. For 
IFNARKO this points to type I IFN signalling as being an important pathway within 
the brain for generating a chemokine and cytokine TLR7 response, whereas for 
iCCRKO it suggests that these receptors do not play a critical role. However, it is 
worth noting that diminished peripheral responses in KO mice may reduce the 
CNS inflammatory response and this would be an interesting area of investigation 
with the Aldara model. 
7.2.3 Cellular responses to TLR7 Stimulus 
Determining the relative contributions of the peripheral vs the central system 
requires assessment of the roles that exogenous cells play when compared to 
endogenous. Previous work within our laboratory has demonstrated an influx of a 
variety of cell types into the CNS in response to cutaneous Aldara treatment 
(24). The data in this thesis has demonstrated that CD3+ cells infiltrate into the 
hippocampus and cortex of Aldara treated mice and examination of endogenous 
CNS cells identified clear morphological changes in microglia, and evidence of 
astrogliosis in response to cutaneous Aldara treatment.  
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The role of microglia and astrocytes in CNS immune reactions is becoming 
increasingly clear and both cell types have been shown to produce chemokines 
and cytokines (182, 220, 231). Although clear morphological changes in Iba1+ 
cells that can be presumed to be predominantly microglia, and possible but not 
conclusive changes in the GFAP+ cell population presumed to be astrocytes were 
demonstrated, the effect on cellular function of these changes is not clear. As 
discussed, morphological changes in microglia do not necessarily correlate with 
specific changes in function (167, 469). However, based on the transcriptional 
and protein responses to cutaneous Aldara treatment reported in this thesis, 
alongside in vitro data from Butchi et al. demonstrating transcriptional 
alterations in astrocytes and microglia in response to IMQ (237), it can be 
hypothesised that, at least within the first 24 hours of cutaneous Aldara 
treatment when recruited immune cell populations appear to be sparse or 
absent (24), these endogenous cell types are the primary source of chemokines 
and cytokines within the CNS.  
The mechanisms through which inflammation resolves is of particular interest 
given the temporal differences in chemokine and cytokine responses between 
the periphery and CNS. Examination of the literature suggests that TLR7 
stimulation itself may be of particular importance for inflammatory resolution. 
In vitro work by Butchi et al. comparing TLR7, TLR9 and TLR7+TLR9 responses 
demonstrated that TLR7+TLR9 stimulation of microglia enhances Il10 expression 
and diminishes the expression of the interferon stimulated gene Cxcl10, 
compared to TLR9 stimulation alone (237), suggesting that TLR7 signalling in 
microglia promotes an anti-inflammatory phenotype when compared to TLR9.  
As discussed earlier in this thesis, the arrival of exogenous cell types within the 
CNS appears to coincide with the onset of inflammatory downregulation. In vivo 
work on TLR7KO mice infected with the neurotropic Langat ssRNA virus found 
that the absence of TLR7 actually increased Cd3ε and Cd8α expression but did 
not influence Cd4, suggesting that in the absence of TLR7 there is an increased 
recruitment of CD8+ cytotoxic T-cells but not CD4+ helper T-cells. In addition, 
this study found that while IFN responses appear to be enhanced in TLR7KO 
mice, there were significant decreases in the expression of Tnf, Ccl3, Ccl4 and 
Cxcl13 (507). This deficiency in Ccl4, which is associated with enhanced 
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inflammatory responses, provides further support to the hypothesis that this 
chemokine may be important in promoting T-cell regulatory responses. CXCL13 is 
thought to attract B-cells, which have previously been shown to promote Treg 
recruitment via CCL4 (418). Il10, found by Butchi et al. to be produced by 
microglia in response to TLR7, is also thought to be an important molecule for 
Treg function, acting to promote suppressive functions (508, 509), further 
supporting the idea that TLR7 may act to restrain inflammatory reactions. Work 
in this thesis has shown that cutaneous Aldara treatment stimulates the 
upregulation of Tnf, Ccl3, Ccl4, Cxcl13 and Il10 within the brain, complementing 
these earlier findings by others. It is worth considering that these alterations 
may be peripherally driven, however Nazmi et al. demonstrated that even in the 
case of brain specific TLR7 knock-down, increases in the inflammatory response 
were still present (510) and alongside Butchi et al’s. findings in in vitro 
microglia, this supports the suggestion that these changes are, at least in part, 
mediated by brain TLR7 and not just alterations in the peripheral immune 
response. 
The findings of these studies and the work presented in this thesis are 
challenging to synthesise primarily due to differing time-points, in vivo and in 
vitro work and some slightly contradictory data, particularly considering our 
findings of robust IFN stimulation in response to TLR7 triggering. However, a 
potential model for this could be that at early time-points TLR7 promotes the 
expression of CCL4 and CXCL13 that in turn promote recruitment of Treg cells and 
B cells. Concomitant induction of Il10 will also act to promote an anti-
inflammatory environment and enhance the function of these recruited cells. 
Subsequently these cells enhance the recruitment of further regulatory cells, for 
example through B-cell derived increases in CCL4, and promote the resolution of 
the inflammatory response. This resolution then results in the reduction or 
termination of interferon and other immune responses at later time-points. 
Alongside their immunological functions, recruited cells may act to influence 
behaviour. There is reasonable evidence that T-cells play important roles in 
modulating CNS function. Deficiency of T-cells results in cognitive impairment 
(506, 511), and a recent study by Filiano et al. demonstrated that T-cells appear 
to be important in modulating social behaviour through IFN-γ (500). This suggests 
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T-cell infiltration into the brain may play a role in the behavioural alterations 
observed in the Aldara model (24). However, even after a single day of 
treatment when T-cells appear to be largely absent from the CNS there are still 
decreases in burrowing behaviour in Aldara treated mice(24). This suggests that 
other factors may be responsible for this behavioural alteration. One possible 
cell type responsible for this effect are circulating monocytes that appear to be 
important mediators of behavioural and neuronal changes following peripheral 
inflammatory stimuli. This effect is thought to be mediated through their 
secretion of TNFα, as when signalling through TNFR, or when the production of 
TNF itself was knocked out these behavioural and neuronal responses to 
peripheral inflammation were absent (413, 512). Together these data suggest 
that signals from both innate and adaptive cells, present in both the periphery 
and brain parenchyma appear to be important for behavioural changes in 
response to immune stimulus and the relative contributions of each of these 
populations warrants further investigation. 
7.3 Conclusions 
The work in this thesis initially demonstrated that in a meta-analysis of human 
biomarker studies in depressive illness there was significant evidence of 
alterations in circulating chemokine levels. The primary caveats of these data 
were that: (i) the methodological quality of these studies was highly variable; 
(ii) there did not appear to be significant associations in depressed patients with 
comorbidities and; (iii) that due to the cross-sectional nature of the studies it is 
not possible to make inferences about directionality or mechanism. 
Following this review of human literature, characterisation and investigation of 
an animal model of peripherally induced neuro-inflammation, the Aldara model 
of psoriasis-like inflammation, was performed. This study showed that cutaneous 
Aldara treatment induces significant increases in chemokine and cytokine 
expression within the brain that are temporally distinct from peripheral 
transcriptional changes. In addition there is consistent evidence of reactive 
microglial changes and T-cell recruitment in the brain, and, while more 
equivocal, there is also evidence of astrogliosis. Study into IFNAR and iCCR 
function showed that IFNAR was important for the induction of inflammatory 
transcripts, morphological changes in microglia and the recruitment of T cells to 
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the CNS. In contrast, iCCR appeared to not influence transcriptional or microglial 
response but did seem to affect the recruitment of CD3+ cells. Subsequent mass 
spectrometry investigations revealed that these changes appear to be primarily 
mediated by IMQ, a TLR-7 agonist in Aldara cream, gaining direct access to the 
brain parenchyma. Whilst a series of interesting findings have been presented in 
this thesis, the data suggest that the Aldara model is not an appropriate tool for 
the study of peripheral-central crosstalk but is a useful model for the study of 
viral responses. 
Overall these data strongly support the investigation of chemokines as a 
molecular family in the context of both human psychiatric disease and neuro-
inflammatory responses. The Aldara model appears to be a useful, and possibly 
unique, tool for the study of neuro-inflammatory responses in vivo, particularly 
if interested in TLR7 or IFN signalling which both appear to play important roles 
in observed immune changes. 
7.4 Future directions 
A number of possible future directions can be taken based on the work 
presented here: (i) longitudinal epidemiological studies of human immune status 
and psychiatric disease, or more methodologically rigorous cross-sectional 
studies that record and assess the effect of confounders; (ii) further 
investigation of temporal differences between the brain and periphery and the 
mechanisms through which immune resolution occurs at these sites; (iii) further 
investigation of the role specific cells play in the induction of CNS inflammation 
and; (iv) further studies on the roles of chemokines and IFN signalling in the 
induction of CNS inflammation and behavioural change. 
While all are interesting this final section will focus on points (iii) and (iv). As 
discussed a number of questions remain to be answered with regards to the data 
presented here. These include, but are not limited to:  
 Are microglia and/or astrocytes the source of transcriptional and protein 
changes within the brain? 
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 Are recruited cells, specifically Treg cells, important for resolution of the 
inflammatory response? 
 What are the outcomes of behavioural change in iCCRKO and IFNARKO 
mice, and if changes are present what are the mechanisms through which 
this occurs? 
Experiments that can address each of these questions will be discussed in turn. 
Firstly to understand the role of microglia or astrocytes in the brain it is 
necessary to be able to isolate these cells either ex vivo or in vivo. It would be 
possible to isolate microglia or astrocytes ex vivo using cell sorting. Once 
isolated, cells could be rapidly fixed and then transcriptional and protein assays 
could be performed. Limitations of this approach would be the challenges of 
assessing the effect of isolation on these assays and, in addition, proteins that 
were rapidly secreted might not be identifiable in this manner. Other possible 
approaches would be to perform in-situ hybridization combined with 
immunohistochemistry to identify both cell types of interest and genes that were 
expressed by them. The major challenge of this approach is that with current 
techniques it would be challenging to identify more than one transcript and one 
cell type at the same time making this approach very low-throughput and 
perhaps more appropriate for the investigation of a specific molecule of 
interest. However, a major advantage over the use of cell sorting is that it 
would provide anatomical localisation within the CNS. A final approach would be 
to use specialised Cre/Lox mice that have cell-specific KO, for example, using 
TLR-7 floxed mice crossed to a GLAST-Cre/ERT2 background would abrogate 
TLR-7 signalling in astrocyte cells following treatment with tamoxifen (513) and 
provide insight into how they contribute to the neuro-inflammatory response to 
cutaneous Aldara treatment. In addition, due to this KO being tamoxifen 
inducible, it can provide temporal control over when this occurs. 
In this discussion a potential role for the chemokine CCL4 and Treg cells in the 
resolution of inflammatory response has been highlighted. It would be pertinent 
to initially confirm whether this subtype of T cells are present following 
cutaneous Aldara treatment and at what time-point they appear within the 
brain. Following this, depletion of Treg cells would allow for an assessment of 
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their role in inflammatory resolution and the production of anti-inflammatory 
mediators such as Il10. It would also be interesting to assess the role of CCL4 in 
Treg recruitment and, if possible, to assess the role of peripheral vs central Tregs 
in the modulation of the response to cutaneous Aldara treatment. Finally 
considering the tentative links to depressive disorder it would be worthwhile 
assessing the impact of Treg depletion on burrowing behaviour or other cognitive 
tests.  
Finally the behavioural response in either iCCRKO or IFNARKO mice could initially 
be investigated using the relatively simple burrowing task to look for gross 
deficits in wellbeing. Ideally more complex and controlled behavioural tasks 
would be performed such as the Morris water maze, to examine learning and 
memory, and the elevated plus maze to assess anxiety-based behaviours. In 
addition, use of controlling behavioural studies such as the open field test would 
help to confirm that these alterations were in fact psychologically based rather 
than mechanically. If behavioural deficits were observed it would then be 
interesting to use an approach similar to that used by Blank et al. to investigate 
this further(103). Use of cre/Lox mice, particularly those targeting neurons can 
begin to dissect if certain ligand-receptor relationships appear to mediate 
behavioural changes. 
In conclusion there is a wide range of directions that work following on from this 
thesis can take. An increasing number of tools are available to psycho-neuro-
immunologists to investigate the causes and mechanisms of behavioural 
alterations and the precise studies that people undertake will depend on their 
own specialist interests. 
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Appendices 
Appendix 1: Companies referenced 
in methods 
 
Agilent 
(Agilent Technologies, Cheshire, UK) 
Agilent Technologies LDA UK Limited 
Life Sciences & Chemical Analysis 
Group 
Lakeside 
Cheadle Royal Business Park 
Stockport, Cheshire SK8 3GR 
 
Alpha Laboratories 
(Alpha Laboratories, Hampshire, UK) 
Alpha Laboratories 
40 Parham Drive 
Eastleigh 
Hampshire 
SO50 4NU 
United Kingdom 
 
BD Biosciences 
(BD Biosciences, CA, USA) 
BD Biosciences 
2350 Qume Drive 
San Jose 
CA 95131-1807 
USA 
 
Biolegend 
(Biolegend, CA, USA) 
Biolegend 
9727 Pacific Heights Blvd 
San Diego 
California 
92121 
 
CellPath 
(CellPath, Newtown, UK) 
Cellpath Ltd. 
Mochdre Industrial Estate 
Mochdre 
Newtown 
SY16 4LE 
 
 
 
GraphPad Software, Inc 
(GraphPad Software, CA, USA) 
GraphPad Software, Inc. 
7825 Fay Avenue, Suite 230 
La Jolla, CA 92037 USA 
 
Greiner 
(Greiner Bio-One, Stonehouse, UK) 
Greiner Bio-One Ltd  
Brunel Way  
Stroudwater Business Park  
Stonehouse  
UK  
 
Leica Microsystems 
(Leica Microsystems, Milton Keynes, 
UK) 
Larch House, Woodlands Business 
Park, 
Breckland,  
Linford Wood 
Milton Keynes  
MK14 6FG  
United Kingdom 
 
 
Meda (Aldara) 
(Meda AB, Solna, Sweden) 
Meda AB 
Box 906 
SE-170 09 Solna 
Sweden 
 
Microsoft 
(Microsoft, WA, USA) 
Microsoft Corporation 
Corporate Headquarters 
One Microsoft Way 
Redmond, WA 98052-6399 
UNITED STATES 
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Milestone SRL 
(Milestone, Sorisole, IT) 
Milestone Srl 
Via Fatebenefratelli, 1/5 
24010 Sorisole (Bergamo) – Italy 
 
New England BioLabs 
(New England BioLabs, MA, USA) 
New England BioLabs 
240 County Road 
Ipswich 
MA 019838-2723 
USA 
 
Quantabio 
(Quantabio, MA, USA) 
100 Cummings Center 
Suite 407J 
Beverly, MA 01915 
 
Qiagen 
(Qiagen, Hilden, GER) 
Qiagen Str. 1 
40724 Hilden 
Germany 
 
Roche 
(Roche, West Sussex, UK) 
Roche Diagnostics Ltd 
Charles Avenue 
Burgess Hill 
West Sussex 
RH15 9RY 
United Kingdom 
 
Sigma-Aldrich 
(Sigma-Aldrich, Dorset, England) 
Sigma-Aldrich Company Ltd. 
The Old Brickyard, New Road 
Gillingham, Dorset 
SP8 4XT 
United Kingdom 
 
 
 
 
Starlab 
(Starlab, Milton Keynes, UK) 
STARLAB (UK), Ltd 
5 Tanners Drive 
Blakelands 
Milton Keynes MK14 5BU 
United Kingdom 
 
STEMCELL Technologies 
(STEMCELL Technologies, Cambridge, 
UK) 
STEMCELL Technologies UK Ltd. 
Building 7100 Cambridge Research 
Park 
Beach Drive 
Waterbeach 
Cambridge 
UK 
CB25 9TL 
 
Tecan 
(Tecan, Mannedorf, SWI) 
Tecan Group Ltd. 
Seestrasse 103 
8708 Mannedorf 
Switzerland 
 
 
Thermo Fisher 
(Thermo Fisher Scientific, MA, USA) 
Thermo Fisher Scientific 
168 Third Avenue 
Waltham, MA USA 02451 
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Appendix 2: Example search strategy used for meta-analysis of chemokines 
Search Query  
S1 chemokine*  
S2 
ccl1 or ccl2 or ccl3 or ccl4 or ccl5 or ccl6 or ccl7 or ccl8 or ccl9 or ccl10 or ccl11 or 
ccl12 or ccl13 or ccl14 or ccl15 or ccl16 or ccl17 or ccl18 or ccl19 or ccl20 or ccl21 or 
ccl22 or ccl23 or ccl24 or ccl25 or ccl26 or ccl27 or ccl28)  
S3 
(cxcl1 or cxcl2 or cxcl3 or cxcl4 or cxcl5 or cxcl6 or cxcl7 or cxcl8 or cxcl9 or cxcl10 or 
cxcl11 or cxcl12 or cxcl13 or cxcl14 or cxcl15 or cxcl16 or cxcl17)  
S4 (xcl1 or xcl2)  
S5 cx3cl1  
S6 (ccl or cxcl or xcl or cx3cl)  
S7 
(scya1 or scya2 or scya3 or scya4 or scya5 or scya6 or scya7 or scya8 or scya9 or 
scya10 or scya11 or scya12 or scya13 or scya14 or scya15 or scya16 or scya17 or 
scya18 or scya19 or scya20 or scya21 or scya22 or scya23 or scya24 or scya25 or 
scya26 or scya27 or scya28)  
S8 
(scyb1 or scyb2 or scyb3 or scyb4 or scyb5 or scyb6 or scyb7 or scyb8 or scyb9 or 
scyb10 or scyb11 or scyb12 or scyb13 or scyb14 or scyb15 or scyb16 or scyb17)  
S9 (scyc1 or scyc2)  
S10 sycd1  
S11 (scya or scyb or scyc or scyd)  
S12 chemokine receptor*  
S13 (ccr1 or ccr2 or ccr2b or ccr3 or ccr4 or ccr5 or ccr6 or ccr7 or ccr8 or ccr9 or ccr10)  
S14 (cxcr1 or cxcr2 or cxcr3 or cxcr3b or cxcr4 or cxcr5 or cxcr6 or cxcr7)  
S15 xcr1  
S16 cx3cr1  
S17 (ccr or cxcr or xcr or cx3cr)  
S18 (chemotactic cytokine* or chemokine*)  
S19 (i-309 or i309 or tca-3 or tca3 or sise)  
S20 
(monocyte chemotactic protein#1 or monocyte chemotactic protein-1 or mcp#1 or 
mcp-1 or small inducible cytokine a2 or gdcf#2 or gdcf-2 or hc11 or hsmcr30 or mcaf 
or cmc#cf or smc-cf)  
S21 
(macrophage inflammatory protein#1a or macrophage inflammatory protein-1a or 
mip#1a or mip-1a or g0s19#1 or g0s19-1 or ld78alpha or mip#1#alpha or mip#1-alpha 
or mip-1#alpha or mip-1-alpha or mip1a)  
S22 
(macrophage inflammatory protein#1# or macrophage inflammatory protein-1# or 
mip#1# or mip-1# or act2 or act-2 or at744#1 or g26 or g-26 or hc21 or lag-1 or lag1 
or mip-1-beta or mip1b or mip1b1)  
S23 
((regulated on activation, normal t cell expressed and secreted) or rantes or d17s136e 
or sis-delta or sisd or tcp228 or eocp)  
S24 (c10 or mrp#1 or mrp-1 or mrp#2 or mrp-2)  
S25 
(monocyte specific chemokine#3 or monocyte specific chemokine-3 or monocyte-
specific chemokine#3 or monocyte-specific chemokine-3 or mcp#3 or fic or marc or 
mcp-3 or nc28)  
S26 
(monocyte chemotactic protein#2 or monocyte chemotactic protein-2 or mcp-2 or 
mcp#2 or hc14)  
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S27 
(macrophage inflammatory protein#1#gamma or macrophage inflammatory protein-
1#gamma or macrophage inflammatory protein#1-gamma or macrophage 
inflammatory protein-1-gamma or mip#1#gamma or mip#1-gamma or mip-1#gamma 
or mip-1-gamma or macrophage inflammatory protein#1* or macrophage 
inflammatory protein-1* or macrophage inflammatory protein-related protein-2 or 
mrp#2 or mrp-2 or ccf18)  
S28 (eosinophil chemotactic protein or eotaxin-1 or eotaxin#1)  
S29 
(monocyte chemotactic protein 5 or mcp#5 or mcp-5 or mcp#1-related chemokine or 
mcp-1#related chemokine or mcp#1#related chemokine or mcp-1-related 
chemokine)  
S30 (mcp#4 or mcp-4 or ncc#1 or ncc-1 or ckbeta10 or scyl1 or ckb10)  
S31 
(hcc#1 or hcc-1 or mcif or ckb1 or ckbeta1 or ncc#2 or ncc-2 or hcc#3 or hcc-3 or 
scyl2)  
S32 
(leukotactin#1 or leukotactin-1 or mip#5 or mip-5 or hcc#2 or hcc-2 or ncc#3 or ncc-3 
or scyl3 or lkn#1 or lkn-1 or mip#1d or mip-1d or hmrp#2b or hmrp-2b)  
S33 
(lec or ncc#4 or ncc-4 or lmc or ckb12 or ckbeta12 or liver#expressed chemokine or 
liver-expressed chemokine or monotactin#1 or monotactin-1 or mtn#1 or mtn-1 or 
scyl4 or hcc#4 or hcc-4 or lcc#1 or lcc-1)  
S34 
(tarc or dendrokine or abcd#2 or abcd-2 or (thymus and activation regulated 
chemokine) or a#152e5#3 or a-152e5#3)  
S35 
(parc or dc-ck1 or dc#ck1 or amac-1 or amac#1 or ckb7 or ckbeta7 or mip#4 or mip-4 
or (pulmonary and activation-regulated chemokine) or (pulmonary and 
activation#regulated chemokine) or dendritic cell-chemokine 1 or dendritic 
cell#chemokine 1 or alternative macrophage activation-associated cc chemokine-1 or 
alternative macrophage activation#associated cc chemokine-1 or alternative 
macrophage activation-associated cc chemokine#1 or alternative macrophage 
activation#associated cc chemokine#1 or macrophage inflammatory protein-4)  
S36 
(elc or exodus#3 or exodus-3 or ckb11 or ckbeta11 or ebi1#ligand chemokine or ebi1-
ligand chemokine or macrophage inflammatory protein-3-beta or macrophage 
inflammatory protein#3#beta or mip-3-beta or mip-3b or mip#3b)  
S37 
(larc or exodus#1 or exodus-1 or ckb4 or ckbeta4 or liver activation regulated 
chemokine or macrophage inflammatory protein#3 or macrophage inflammatory 
protein-3 or mip#3#alpha or mip-3#alpha or mip#3-alpha or mip-3-alpha or mip-3a or 
mip#3a or st38)  
S38 
(slc or 6ckine or exodus#2 or exodus-2 or ckb9 or ckbeta9 or tca-4 or tca#4 or 
lymphoid-tissue chemokine* or lymphoid#tissue chemokine*)  
S39 (mdc or dc#b-ck or dc#beta-ck or dc-b-ck or abcd#1 or abcd-1 or stcp#1 or stcp-1)  
S40 
(mpif#1 or mpif-1 or ckb8 or ckbeta8 or mip#3 or mip-3 or macrophage inflammatory 
protein 3 or myeloid progenitor inhibitory factor 1)  
S41 
(eotaxin#2 or eotaxin-2 or mpif#2 or mpif-2 or ckb6 or ckbeta6 or myeloid progenitor 
inhibitory factor 2 or eosinophil chemotactic protein 2)  
S42 
(teck or ckb15 or ckbeta15 or thymus#expressed chemokine or thymus-expressed 
chemokine)  
S43 
(eotaxin#3 or eotaxin-3 or mip#4a or mip-4a or imac or tsc#1 or tsc-1 or thymic 
stroma chemokine#1 or thymic stroma chemokine-1 or macrophage inflammatory 
protein 4#alpha or macrophage inflammatory protein 4-alpha or mip#4#alpha or 
mip#4-alpha or mip-4-alpha or mip-4#alpha)  
S44 
(ctack or ilc or eskine or pesky or skinkine or eskine or il#11 r#alpha#locus chemokine 
or il-11 r-alpha-locus chemokine or cutaneous t#cell#attracting chemokine or 
cutaneous t-cell-attracting chemokine)  
S45 
(mec or mucosae#associated epithelial chemokine mucosae-associated epithelial 
chemokine or cck1)  
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S46 
(gro#a or gro-a or gro#alpha or gro-alpha or gro1 or nap#3 or nap-3 or kc or 
neutrophil#activating protein 3 or neutrophil-activating protein 3 or melanoma 
growth stimulating activity alpha or msga#alpha or msga-alpha or msga#a or msga-a)  
S47 
(gro#b or gro-b or gro#beta or gro-beta or gro#2 or mip#2a or mip-2a or macrophage 
inflammatory protein 2#alpha or macrophage inflammatory protein 2-alpha or 
mip2#alpha or mip2-alpha or growth#regulated protein beta or growth-regulated 
protein beta or gro oncogene#2 or gro oncogene-2 or gro-2 or mgsa#beta or mgsa-
beta or mgsa#b or mgsa-b or cinc#2a or cinc-2a)  
S48 
(gro#gamma or gro-gamma or gro#3 or gro-3 or mip#2b or mip-2b or mip#2beta or 
mip2-beta or gro3 oncogene or gro protein gamma or grog or macrophage 
inflammatory protein#2#beta or macrophage inflammatory protein#2-beta or 
macrophage inflammatory protein-2#beta or macrophage inflammatory protein-2-
beta or cinc#2b or cinc-2b)  
S49 (pf-4 or platelet factor#4 or pf#4 or platelet factor-4)  
S50 
(ena#78 or ena-78 or epithelial-derived neutrophil-activating peptide 78 or 
epithelial#derived neutrophil#activating peptide 78)  
S51 
(gcp#2 or gcp-2 or granulocyte chemotactic protein#2 or granulocyte chemotactic 
protein-2 or cka#3 or cka-3)  
S52 
(nap#2 or nap-2 or ctapiii or b-tg or beta-tg or b#tg or beta#tg or pep or beta-
thromboglobulin or beta#thromboglobulin or pro#platelet basic protein or pro-
platelet basic protein or ppbp or b#tg1 or b-tg1 or ctap#iii or ctap-iii or ctap#3 or 
ctap-3 or la#pf4 or la-pf4 or ldgf or mdgf or pbp or tc#1 or tc-1 or tc#2 or tc-2 or tgb 
or tgb#1 or tgb-1 or thbgb or thbgb#1 or thbgb-1)  
S53 
(il-8 or nap-1 or mdncf or gcp-1 or gcp#1 or il#8 or interleukin 8 or neutrophil 
chemotactic factor or lect or luct or lynap or mdncf ormonap or naf or nap#1)  
S54 (mig or crg-10 or monokine induced by gamma interferon or cmk or humig or crg#10)  
S55 
(ip-10 or ip#10 or crg#2 or crg-2 or interferon gamma-induced protein 10 or 
interferon gamma induced protein 10 or small-inducible cytokine b10 or small 
inducible cytokine b10 or c7 or ifi10 or inp10 or gip#10 or gip-10 or mob#1 or mob-1)  
S56 
(i#tac or i-tac or h#174 or h-174 or ip#9 or ip-9 or scyb9b or b#r1 or b-r1 or beta#r1 or 
beta-r1 or interferon inducible t cell alpha chemoattractant or interferon-inducible t-
cell alpha chemoattractant or interferon-gamma-inducible protein 9 or intergeron 
gamma inducible protein 9)  
S57 
(sdf-1 or sdf#1 or tlsf or tpar1 or pbsf or stromal cell-derived factor 1 or stromal 
cell#derived factor 1 or irh)  
S58 (b lymphocyte chemoattractant or bca-1 or bca#1 or blr1l or blc or angie#)  
S59 
((breast and kidney-expressed chemokine) or brak or njac or bolekine or kec or mip-
2g or mip#2g or bmac or ks1)  
S60 (lungkine or weche)  
S61 (sr#psox or sr-psox or cxclg16)  
S62 
(dmc or vcc#1 or vcc-1 or vegf co#regulated chemokine 1 or vegf co-regulated 
chemokine 1 or (dendritic cell- and monocyte-attracting chemokine-like protein) or 
(dendritic cell and monocyte attracting chemokine-like protein) or (dendritic cell and 
monocyte attracting chemokine like protein))  
S63 (lymphotactin or atac or ltn or lptn or scm#1# or scm-1#)  
S64 lymphotactin  
S65 
(fractalkine or neurotactin or abcd#3 or abcd-3 or c3xkine or cxc3 or cxc3c or ntn or 
ntt)  
S66 
(cluster of differentiation 191 or cd191 or ckr-1 or ckr#1 or cmkbr1 or hm145 or 
mip1ar or scyar1)  
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S67 
(ccr2# or cd192 or cluster of differentiation 192 or cc#ckr#2 or cc#ckr-2 or cc-ckr#2 or 
cc-ckr-2 or ccr#2 or ccr-2 or ckr-2# or ckr#2# or cmkbr2 or mcp#1#r or mcp-1#r or 
mcp#1-r or mcp-1-r)  
S68 
(cd193 or cluster of differentiation 193 or cc#ckr#3 or cc-ckr#3 or cc#ckr-3 or cc-ckr-3 
or ckr-3 or ckr#3 or cmkbr3)  
S69 
(cd194 or cluster of differentiation 194 or cc#ckr#4 or cc#ckr-4 or cc-ckr#4 or cc-ckr-4 
or ckr-4 or ckr#4 or cmkbr4 or chemr13 or hgcn:14099 or k5-5)  
S70 
(cd195 or cluster of differentiation 195 or cc#ckr#5 or cc#ckr-5 or cc-ckr#5 or cc-ckr-5 
or ccr#5 or ccr-5 or ckr-5 or ckr#5 or cmkbr5 or iddm22)  
S71 
(cd196 or cluster of differentiation 196 or bn#1 or bn-1 or cc#ckr#6 or cc#ckr-6 or cc-
ckr#6 or cc-ckr-6 or ccr#6 or ccr-6 or ckr-l3 or ckr#l3 or cmkbr6 or dcr2 or dry6 or g 
protein-coupled receptor 29 or g protein-coupled receptor cy4 or gpr29 or gprcy4 or 
strl22)  
S72 (cd197 or cluster of differentiation 197 or blr2 or cdw197 or cmkbr7 or ebi1)  
S73 
(cdw198 or cluster of differentiation w198 or cc#ckr#8 or cc#ckr-8 or cc-ckr#8 or cc-
ckr-8 or ccr#8 or ccr-8 or ckrl1 or cmkbr8 or cmkbrl2 or cy6 or g protein-coupled 
receptor cy6 or gprcy6 or ter1)  
S74 
(cdw199 or cluster of differentiation w199 or cc#ckr#9 or cc#ckr-9 or cc-ckr#9 or cc-
ckr-9 or g protein-coupled receptor 9-6 or gpr#9-6 or gpr-9-6 or g protein-coupled 
receptor 28 or gpr28)  
S75 (gpr2 or g protein-coupled receptor 2 or g protein coupled receptor 2)  
S76 
(interleukin 8 receptor or il-8ra or cd181 or cluster of differentiation 181 or cc#ckr#1 
or cc#ckr-1 or cc-ckr#1 or cc-ckr-1 or cd128 or cdw128a or ckr#1 or ckr-1 or cmkar1 or 
il8r1 or il8ra or il8rba)  
S77 
(il8rb or cluster of differentiation 182 or cd182 or cdw128b or cmkar2 or il#8r2 or il-
8r2 or il#8ra or il-8ra or il#8rb or il-8rb)  
S78 
(g protein-coupled receptor 9 or cd183 or cluster of differentiation 182 or cxcr3#a or 
cxcr3-a or cxcr3#b or cxcr3-b or cd182 or cd183 or ckr#l2 or ckr-l2 or cmkar3 or gpr9 
or ip10#r or ip10-r or mig-r or mig#r)  
S79 
(fusin or cd184 or cluster of differentiation 184 or d2s201e or fb22 or hm89 or hsy3rr 
or lap-3 or lap#3 or lcr#1 or lcr-1 or lestr or npy3r or npyr# or npyy3r or whim)  
S80 
(cd185 or cluster of differentiation 185 or burkitt lymphoma receptor 1 or blr#1 or 
blr-1 or mdr#15 or mdr-15)  
S81 (cd186 or cluster of differentiation 186 or bonzo or strl33 or tymstr)  
S82 
(ackr#3 or ackr-3 or cmkor#1 or cmkor-1 or cxc-r7 or cxcr-7 or cxcr#7 or g protein-
coupled receptor 159 or g protein coupled receptor 159 or gpr159 or rdc-1 or rdc#1)  
S83 
(g protein-coupled receptor 5 or g protein coupled receptor 5 or gpr5 or cc#xcr#1 or 
cc-xcr#1 or cc#xcr-1 or cc-xcr-1)  
S84 
(fractalkine receptor or g protein-coupled receptor 13 or g protein coupled receptor 
13 or gpr13 or ccrl1 or cmkbrl1 or cmkdr1 or g protein-coupled receptor v28 or g 
protein coupled receptor v28 or gprv28 or v28)  
S85 
S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 
OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 
OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 
OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 
OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 
OR S58 OR S59 OR S60 OR S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67 OR S68 
OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78 OR S79 
OR S80 OR S81 OR S82 OR S83 OR S84  
S86 
DE "Major Depression" OR DE "Anaclitic Depression" OR DE "Dysthymic Disorder" OR 
DE "Endogenous Depression" OR DE "Postpartum Depression" OR DE "Reactive 
Depression" OR DE "Recurrent Depression" OR DE "Treatment Resistant Depression"  
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S87 depress*  
S88 (beck depression or bdi or bdi#1a or bdi-1a or bdi#ii or bdi-ii)  
S89 (burns depression or bdc)  
S90 (center for epidemiologic studies depression or ces-d or ces#d)  
S91 (cornell scale for depression in dementia or csdd)  
S92 (edinburgh post#natal depression or edinburgh post-natal depression or epds)  
S93 (geriatric depression or gds)  
S94 
(hamilton rating scale for depression or hamilton depression rating scale or hrsd or 
hdrs or ham-d or ham#d)  
S95 (hospital anxiety and depression scale)  
S96 (inventory of depressive symptomatology or ids)  
S97 (inventory to diagnose depression or idd)  
S98 (kutcher adolescent depression or kads)  
S99 (major depress* or mdd or mdi)  
S100 
(montgomery-asberg depression rating scale or montgomery asberg depression 
rating scale or madrs)  
S101 (patient health questionnaire-9 or phq-9 or patient health questionnaire#9 or phq#9)  
S102 (quick inventory of depressive symptomatology or qids)  
S103 
(raskin depression rating scale or three-area severity of depression scale or three area 
severity of depression scale or rdrs)  
S104 
(rads-2 or reynolds adolescent depression scale or rads#2 or rads or rcds-2 or rcds or 
rcds#2 or reynolds child depression scale)  
S105 (wechsler depression rating scale or wdrs)  
S106 (zung self-rating depression scale or zung self rating depression scale or sds or zsrds)  
S107 
S86 OR S87 OR S88 OR S89 OR S90 OR S91 OR S92 OR S93 OR S94 OR S95 OR S96 OR 
S97 OR S98 OR S99 OR S100 OR S101 OR S102 OR S103 OR S104 OR S105 OR S106  
S108 S85 AND S107  
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Appendix 3:Custom data extraction template used for assessment of studies 
in meta-analysis 
Systematic Review Data Collection Tool 
Adapted from handbook.cochrane.org 
*Required 
Our Review Questions 
1 - Is depression as a state (presence of depressive symptoms) associated with 
altered levels of specific chemokines? 
2a - Is there a subtype of people with depressive symptoms which are associated 
with altered levels of specific chemokines vs a subtype who are not? (e.g. based 
on severity, based on the symptoms being part of a primary depressive illness or 
in the context of another syndrome/ disease) 
2b - Is depression as a trait associated with altered levels of specific 
chemokines? 
 
Review Author Notes 
Any comments, notes, questions or reminders for this study not covered below? 
E.g. 
conclusions drawn to not tie up with results etc. 
 
Source 
Study ID * 
A unique ID code given to an included or excluded study by the review author 
(e.g. first author's name and year of publication from the main report of the 
study). Although a study may have multiple reports or references, it should have 
one single Study ID to help review authors keep track of all the different sources 
of information for a study. 
 
Report ID * 
A unique ID code given to a publication or other report of a study by the review 
author (e.g. first author's name and year of publication). If a study has more 
than one report (e.g. multiple publications or additional unpublished data) a 
separate Report ID can be allocated to each to help review authors keep track of 
the source of extracted data. 
 
Review Author ID * 
 SL 
 LN 
 
Citation & contact details* 
 
Eligibility 
Confirm Eligibility * 
 Eligible 
 Not Eligible 
 Unsure 
Reason for exclusion 
(if not eligible) 
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Methods 
Study Design 
(Presumably all observational) 
 Case-Control Study 
 Cohort Study 
 Randomised Controlled Trial 
 Controlled Clinical Trail (no randomisation) 
 Cross-Sectional Study 
 Other: 
 
Total Study Duration 
in days to allow comparison 
 
Bias 
See: 
handbook.cochrane.org/chapter_8/table_8_5_a_the_cochrane_collaborations_to
ol_for_assessing.htm 
N.B. Some of these biases may not be applicable for many studies because our 
intervention is the presence or absence of depression which is not really 
allocated and can't be blinded to the participants. It can be to the investigators 
etc. 
 
Random Sequence Generation 
Describe the method used to generate the allocation sequence in sufficient 
detail to allow an assessment of whether it should produce comparable groups. 
 
Is there evidence selection bias (biased allocation to interventions) due to 
inadequate generation of a randomised sequence? * 
 Yes 
 No 
 Other: 
 
Allocation Concealment 
Describe the method used to conceal the allocation sequence in sufficient detail 
to determine whether intervention allocations could have been foreseen in 
advance of, or during, enrolment. 
Is there evidence of selection bias (biased allocation to interventions) due to 
inadequate concealment of allocations prior to assignment? * 
 Yes 
 No 
 Other: 
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Blinding of Participants 
Describe all measures used, if any, to blind study participants and personnel 
from knowledge of which intervention a participant received. Provide any 
information relating to whether the intended blinding was effective. 
Assessments should be made for each main outcome (or class of outcomes). 
 
Is there evidence of performance bias due to knowledge of the allocated 
interventions by participants and personnel during the study? * 
 Yes 
 No 
 Other: 
 
 
Blinding of Outcome Assessment 
Describe all measures used, if any, to blind outcome assessors from knowledge 
of which intervention a participant received. Provide any information relating to 
whether the intended blinding was effective. Assessments should be made for 
each main outcome (or class of outcomes). 
 
Is there evidence of detection bias due to knowledge of the allocated 
interventions by outcome assessors? * 
 Yes 
 No 
 Other: 
 
Completeness of Outcome Data 
Describe the completeness of outcome data for each main outcome, including 
attrition and exclusions from the analysis. State whether attrition and exclusions 
were reported, the numbers in each intervention group (compared with total 
randomized participants), reasons for attrition/exclusions where reported, and 
any reinclusions in analyses performed by the review authors. Assessments 
should be made for each main outcome (or class of outcomes). 
Is there evidence of attrition bias due to amount, nature or handling of 
incomplete outcome data? * 
 Yes 
 No 
 Other: 
 
Outcome Reporting 
State how the possibility of selective outcome reporting was examined by the 
review authors, and what was found. 
 
Is there evidence of reporting bias due to selective outcome reporting? * 
 Yes 
 No 
 Other: 
 
Is there evidence of bias due to problems not covered above? * 
 Yes 
 No 
 Other: 
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Other Sources of Bias 
 
Participants 
Where applicable indicate if information is for the whole study or for each 
intervention group separately 
Total Number 
 
Power Calculation Used? 
 No 
 Yes & Reached 
 Yes But Not Reached 
 Other: 
 
Setting of Study 
 Psychiatric Inpatient 
 Psychiatric Outpatient 
 Medical Inpatient 
 Medical Outpatient 
 Primary Care 
 Other: 
 
Setting of Study Included in Analysis as Confounder? 
 Yes 
 No 
 Other: 
 
Diagnostic Criteria Used 
DSM, ICD, other - indicate code (e.g. ICD10 F32.2 Severe depressive episode 
without 
psychotic symptoms); Scale - indicate cut off used 
 
Diagnostic Criteria Used Included in Analysis as Confounder? 
 Yes 
 No 
 Other: 
 
Age 
e.g. as means or medians, with SDs or ranges 
 
Age Included in Analysis as Confounder? 
 Yes 
 No 
 Other: 
 
Sex 
e.g. as percentages or counts 
 
Sex Included in Analysis as Confounder? 
 Yes 
 No 
 Other: 
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Country 
Indicate which one(s) and if important cultural characteristics that could affect 
delivery of an intervention and its outcomes? 
 
Country Included in Analysis as Confounder? 
 Yes 
 No 
 Other: 
 
Comorbidity 
 What information is provided? 
 Physical Illness (especially inflammatory) 
 Psychiatric Illness (including addictions) 
 Concomitant Medications 
 BMI / Other Measure of Adiposity 
 Smoking 
 Measures of Autonomic Function (e.g. HR, BP, etc) 
 Physical Activity 
 Genetic / Epigenetic factors 
 Other: 
 
Additional Info on Comorbidities? 
 
All Recorded Comorbidities Included in Analysis as Confounders? 
If only certain ones indicate which in answer 
 Yes 
 No 
 Other: 
Sociodemographics 
Qualitative or quantitative measures? 
 
Sociodemographics 
Included in Analysis as Confounder? 
 Yes 
 No 
 Other: 
 
Ethnicity 
 
Ethnicity Included in Analysis as Confounder? 
 Yes 
 No 
 Other: 
 
Start Date of Study 
dd/mm/yyyy 
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Intervention / Exposure 
Total Number of Intervention/ Exposure Groups? * 
(e.g. in our case would normally be 2 - depressed versus not depressed, where 
the 
intervention is the presence of depression) 
 
What is the Intervention / Exposure? * 
Provide details (enough for replication if possible). Comment on integrity of 
intervention - see 
http://handbook.cochrane.org/chapter_7/7_3_4_interventions.htm. In our case 
the intervention would normally be presence or absence of depression. However, 
could be a single group of depressed individuals where the intervention is a 
drug. If so, we may need to do some data conversion to answer our primary 
question. It may be helpful to indicate here if this is likely to be possible - e.g. if 
can differentiate by depression score of those treated and compare this with 
levels of chemokines. 
 
Outcomes 
Number of Outcomes & Time Points Collected? * 
e.g. 4 outcomes at 2 time point 
 
Number of Outcomes & Time Points Reported? * 
e.g. 2 outcomes at 1 time point 
 
For Each Outcome... * 
Give definition (e.g. serum chemokine level); unit of measurement; if scale - 
upper & lower limits; whether high or low is good 
 
How Was Outcome Measured? 
Time of day, season, fasting etc 
 
What Chemokines Are Included In This Study? 
Use international naming convention 
 
Results 
Number of Participants Allocated to Each Intervention Group * 
In our case the intervention would normally be the presence or absence of 
depression. 
 
Each Outcome of Interest * 
In our case continuous data so detail the sample size, the mean and the standard 
deviation for the outcome for each intervention group. These are often not 
available directly, especially the standard deviation, and alternative statistics 
enable calculation or estimation of the missing standard deviation (such as a 
standard error, a confidence interval, a test statistic (e.g. from a t-test or F-
test) or a P value). Finally, for each outcome detail any subgroup analysis and if 
this was pre-specified in the study methods or post-hoc. 
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Miscellaneous 
Ethical Approval Obtained? 
 Yes 
 No 
 Other: 
 
Any Potential Conflicts of Interest? 
For study authors. 
 
Key Conclusions From Study * 
 
Miscellaneous Comments from the Study Authors 
 
References to Other Relevant Studies 
Be aware of the possibility of citation bias 
 
Correspondence Required? * 
E.g. if we need more information or there is missing data. 
 Yes 
 No 
 Other: 
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Appendix 4: RIN Values determined by agilent bioanalyzer at Glasgow 
Polyomics 
Tissue Group Time-point RIN 
Brain Control 4h 7.8 
Brain Control 4h 8.2 
Brain Control 4h 8.2 
Brain Control 4h 8.2 
Brain Treated 4h 8.1 
Brain Treated 4h 8.2 
Brain Treated 4h 8.2 
Brain Treated 4h 8.2 
Brain Control 12h 8.3 
Brain Control 12h 8.2 
Brain Control 12h 8.1 
Brain Control 12h 8.4 
Brain Treated 12h 8.3 
Brain Treated 12h 8.2 
Brain Treated 12h 7.9 
Brain Treated 12h 7.9 
Brain Control 24h 8.1 
Brain Control 24h 8.1 
Brain Control 24h 8.1 
Brain Control 24h 8.3 
Brain Treated 24h 8.5 
Brain Treated 24h 8.3 
Brain Treated 24h 8.4 
Brain Treated 24h 8.3 
Brain Control 3d 8 
Brain Control 3d 8.1 
Brain Control 3d 8.1 
Brain Control 3d 8.2 
Brain Treated 3d 8.2 
Brain Treated 3d 8.1 
Brain Treated 3d 8.2 
Brain Treated 3d 8.2 
Brain Control 5d 8.1 
Brain Control 5d 7.8 
Brain Control 5d 8 
Brain Control 5d 8.3 
Brain Treated 5d 8.3 
Brain Treated 5d 8 
Brain Treated 5d 7.9 
Brain Treated 5d 8.3 
Brain time-course RIN Values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 4.6, Figure 4.7, Figure 4.8 
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Tissue Group Time-point RIN 
Skin Control 4h EXCLUDED 
Skin Control 4h 6.7 
Skin Control 4h 6.7 
Skin Control 4h 7.1 
Skin Treated 4h EXCLUDED 
Skin Treated 4h 7.2 
Skin Treated 4h 6.6 
Skin Treated 4h 6.9 
Skin Control 12h 4.9 
Skin Control 12h 4.7 
Skin Control 12h 7.3 
Skin Control 12h 6.7 
Skin Treated 12h 5 
Skin Treated 12h 6.3 
Skin Treated 12h 7.1 
Skin Treated 12h 7.3 
Skin Control 24h 7.6 
Skin Control 24h EXCLUDED 
Skin Control 24h 6 
Skin Control 24h 6.9 
Skin Treated 24h 6.5 
Skin Treated 24h 6.2 
Skin Treated 24h 6 
Skin Treated 24h 6 
Skin Control 3d 5.5 
Skin Control 3d 6.7 
Skin Control 3d 8.7 
Skin Control 3d 8.2 
Skin Treated 3d 6.6 
Skin Treated 3d 6.7 
Skin Treated 3d 7.2 
Skin Treated 3d 6 
Skin Control 5d 7.3 
Skin Control 5d 6.9 
Skin Control 5d 6.6 
Skin Control 5d 6.7 
Skin Treated 5d 7.3 
Skin Treated 5d 7.6 
Skin Treated 5d 7.3 
Skin Treated 5d 7.6 
Skin time-course RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 4.9, Figure 4.10, Figure 4.11  
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Tissue Group Time-point RIN 
PBL Control 4h 8.9 
PBL Control 4h 9.4 
PBL Control 4h 9 
PBL Control 4h 8.9 
PBL Treated 4h 9.2 
PBL Treated 4h 8.6 
PBL Treated 4h 8 
PBL Treated 4h 8.3 
PBL Control 12h 8.6 
PBL Control 12h 8.6 
PBL Control 12h 8 
PBL Control 12h 8.8 
PBL Treated 12h 9 
PBL Treated 12h 8.8 
PBL Treated 12h 8.7 
PBL Treated 12h 9.2 
PBL Control 24h 7.7 
PBL Control 24h 8.5 
PBL Control 24h 8.6 
PBL Control 24h 7.8 
PBL Treated 24h 7.9 
PBL Treated 24h 8.1 
PBL Treated 24h 7.9 
PBL Treated 24h 8.3 
PBL Control 3d 6.6 
PBL Control 3d 8.5 
PBL Control 3d EXCLUDED 
PBL Control 3d 7.8 
PBL Treated 3d 8.5 
PBL Treated 3d 7.6 
PBL Treated 3d 8.3 
PBL Treated 3d EXCLUDED 
PBL Control 5d 8.7 
PBL Control 5d 8.3 
PBL Control 5d 8.5 
PBL Control 5d 8.2 
PBL Treated 5d 9.1 
PBL Treated 5d 9.2 
PBL Treated 5d 9.2 
PBL Treated 5d 9.2 
PBL time-course RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 4.12, Figure 4.13, Figure 4.14   
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Tissue Group Time-point RIN 
Liver Control 4h 7.4 
Liver Control 4h 7.5 
Liver Control 4h 7.1 
Liver Control 4h 6.5 
Liver Treated 4h 7.1 
Liver Treated 4h 7.9 
Liver Treated 4h 7.6 
Liver Treated 4h 7.9 
Liver Control 12h 7.8 
Liver Control 12h 7.6 
Liver Control 12h 6.3 
Liver Control 12h 7.2 
Liver Treated 12h 7 
Liver Treated 12h 7.3 
Liver Treated 12h 7.5 
Liver Treated 12h 7.3 
Liver Control 24h 8.2 
Liver Control 24h 8.2 
Liver Control 24h 7.9 
Liver Control 24h 8.1 
Liver Treated 24h 8.1 
Liver Treated 24h 8.3 
Liver Treated 24h 8.5 
Liver Treated 24h 8.4 
Liver Control 3d 8.2 
Liver Control 3d 7.8 
Liver Control 3d 7.8 
Liver Control 3d 8.1 
Liver Treated 3d 8.1 
Liver Treated 3d 8.2 
Liver Treated 3d 8.3 
Liver Treated 3d 8.2 
Liver Control 5d 8.1 
Liver Control 5d 8.2 
Liver Control 5d 7.8 
Liver Control 5d 8.2 
Liver Treated 5d 8.8 
Liver Treated 5d 8.2 
Liver Treated 5d 8.5 
Liver Treated 5d 8.4 
Liver time-course RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 4.15, Figure 4.16, Figure 4.17  
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Tissue Group Time-point RIN 
Lung Control 4h 7.4 
Lung Control 4h 6 
Lung Control 4h 6.7 
Lung Control 4h 6.8 
Lung Treated 4h 7.7 
Lung Treated 4h 7.6 
Lung Treated 4h 8.2 
Lung Treated 4h 7.9 
Lung Control 12h 6.5 
Lung Control 12h 7.2 
Lung Control 12h 8 
Lung Control 12h 7.2 
Lung Treated 12h 6.8 
Lung Treated 12h 8.1 
Lung Treated 12h 8 
Lung Treated 12h 8.3 
Lung Control 24h 7.6 
Lung Control 24h 7.9 
Lung Control 24h 7.2 
Lung Control 24h 7.8 
Lung Treated 24h 8.5 
Lung Treated 24h 8 
Lung Treated 24h 8.6 
Lung Treated 24h 8.4 
Lung Control 3d 7.2 
Lung Control 3d 8 
Lung Control 3d 7.9 
Lung Control 3d 7.5 
Lung Treated 3d 8 
Lung Treated 3d 8.2 
Lung Treated 3d 8.1 
Lung Treated 3d 8.3 
Lung Control 5d 7.1 
Lung Control 5d 6.9 
Lung Control 5d 7 
Lung Control 5d 6.7 
Lung Treated 5d 8.1 
Lung Treated 5d 8 
Lung Treated 5d 8.2 
Lung Treated 5d 8.3 
Lung time-course RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 4.18, Figure 4.19, Figure 4.20  
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Tissue Group Genotype RIN 
Brain Treated WT 8 
Brain Treated WT 8.2 
Brain Treated WT 8 
Brain Treated WT 8 
Brain Treated HET 8.8 
Brain Treated HET 8 
Brain Treated HET 7.9 
Brain Treated HET 8 
Brain Treated HET 7.7 
Brain Treated HET 7.9 
Brain Treated KO 7.8 
Brain Treated KO 7.9 
Brain Treated KO 8.2 
Brain Treated KO 8.5 
Brain Treated KO 8.2 
Brain Treated KO 8.1 
Brain iCCRKO experiment 1 RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 5.2, Figure 5.3  
Tissue Group Genotype RIN 
Brain Control WT 5 
Brain Control WT 7.4 
Brain Control WT 7.8 
Brain Control WT 7.8 
Brain Control WT 7.7 
Brain Treated WT 8 
Brain Treated WT 8 
Brain Treated WT 8 
Brain Treated WT 8 
Brain Treated WT 8 
Brain Control KO 7.8 
Brain Control KO 7.7 
Brain Control KO 7.1 
Brain Control KO 7.4 
Brain Control KO 7.8 
Brain Control KO 7.5 
Brain Treated KO 7.8 
Brain Treated KO 7.9 
Brain Treated KO 7.3 
Brain Treated KO 7.6 
Brain Treated KO 7.9 
Brain iCCRKO eperiment 2 RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 5.4, Figure 5.5  
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Tissue Group Genotype RIN 
Brain Treated WT 8.4 
Brain Treated WT 8.4 
Brain Treated WT 8.2 
Brain Treated WT 8.3 
Brain Treated KO 7.9 
Brain Treated KO 8.2 
Brain Treated KO 8.3 
Brain Treated KO 8 
Brain IFNARKO1 RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 5.9  
Tissue Group Genotype RIN 
Skin Treated WT 7.4 
Skin Treated WT 5.9 
Skin Treated WT 7.4 
Skin Treated WT 7.6 
Skin Treated KO 7.7 
Skin Treated KO 8 
Skin Treated KO 8.2 
Skin Treated KO 7.5 
Skin IFNARKO1 RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 5.12  
Tissue Group Genotype RIN 
PBL Treated WT 6.9 
PBL Treated WT 8.3 
PBL Treated WT 8.7 
PBL Treated WT 8.5 
PBL Treated KO 8 
PBL Treated KO 8.7 
PBL Treated KO 7.6 
PBL Treated KO 8.9 
PBL IFNARKO1 RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 5.13  
  
265 
 
Tissue Group Genotype RIN 
Brain Control WT 8.0 
Brain Control WT 8.0 
Brain Control WT 8.0 
Brain Control WT 7.8 
Brain Treated WT 8.0 
Brain Treated WT 7.9 
Brain Treated WT 8.0 
Brain Treated WT 7.6 
Brain Control KO 7.3 
Brain Control KO 7.9 
Brain Control KO 7.8 
Brain Control KO 7.8 
Brain Treated KO 8.2 
Brain Treated KO 7.8 
Brain Treated KO 8.0 
Brain Treated KO 7.9 
Brain IFNARKO2 RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 5.10, Figure 5.11  
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Tissue Group Time-point RIN 
Brain Control 1d 7.4 
Brain Control 1d 7.7 
Brain Control 1d 7.3 
Brain Control 1d 7.5 
Brain Treated 1d 7.5 
Brain Treated 1d 7.5 
Brain Treated 1d 7.6 
Brain Treated 1d 7.5 
Brain Control 3d 7.6 
Brain Control 3d 7.5 
Brain Control 3d 7.5 
Brain Control 3d 7.6 
Brain Treated 3d 7.5 
Brain Treated 3d 7.7 
Brain Treated 3d 7.6 
Brain Treated 3d 7.4 
Brain Control 5d 7.7 
Brain Control 5d 7.7 
Brain Control 5d 7.7 
Brain Control 5d 7.8 
Brain Treated 5d 7.6 
Brain Treated 5d 7.6 
Brain Treated 5d 7.9 
Brain Treated 5d 7.8 
Brain single treatment RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 6.3, Figure 6.4  
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Tissue Group Time-point RIN 
Skin Control 1d 7.7 
Skin Control 1d 7.6 
Skin Control 1d 7.7 
Skin Control 1d 7.7 
Skin Treated 1d 7.6 
Skin Treated 1d 8.1 
Skin Treated 1d 8.3 
Skin Treated 1d 7.5 
Skin Control 3d 8.1 
Skin Control 3d 7.5 
Skin Control 3d 7.8 
Skin Control 3d 7.6 
Skin Treated 3d 7.9 
Skin Treated 3d 9 
Skin Treated 3d 8 
Skin Treated 3d 8 
Skin Control 5d 7.3 
Skin Control 5d 7.1 
Skin Control 5d 7.7 
Skin Control 5d 7.9 
Skin Treated 5d 7.7 
Skin Treated 5d 7.9 
Skin Treated 5d 8.2 
Skin Treated 5d 7.6 
Skin single treatment RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 6.5, Figure 6.6  
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Tissue Group Time-point RIN 
PBL Control 1d 8.7 
PBL Control 1d 8.9 
PBL Control 1d 8.1 
PBL Control 1d 9.1 
PBL Treated 1d 7.3 
PBL Treated 1d 8.5 
PBL Treated 1d 7.3 
PBL Treated 1d 8 
PBL Control 3d 8.6 
PBL Control 3d 8.9 
PBL Control 3d 8.4 
PBL Control 3d 9.1 
PBL Treated 3d 7.9 
PBL Treated 3d 8.6 
PBL Treated 3d 6.5 
PBL Treated 3d No reading 
PBL Control 5d 8.4 
PBL Control 5d 8.5 
PBL Control 5d 8.5 
PBL Control 5d 8.4 
PBL Treated 5d 7.6 
PBL Treated 5d 9 
PBL Treated 5d 8.7 
PBL Treated 5d 9.2 
PBL single treatment RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 6.7, Figure 6.8  
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Tissue Group Time-point RIN 
Liver Control 1d 7.9 
Liver Control 1d 7.9 
Liver Control 1d 7.4 
Liver Control 1d 7.6 
Liver Treated 1d 7.3 
Liver Treated 1d 7.7 
Liver Treated 1d 8 
Liver Treated 1d 7.3 
Liver Control 3d 8 
Liver Control 3d 7.6 
Liver Control 3d 8.1 
Liver Control 3d 7.6 
Liver Treated 3d 7.7 
Liver Treated 3d 7.9 
Liver Treated 3d 8 
Liver Treated 3d 7.5 
Liver Control 5d 8.1 
Liver Control 5d 7.6 
Liver Control 5d 7.8 
Liver Control 5d 8 
Liver Treated 5d 7.9 
Liver Treated 5d 8 
Liver Treated 5d 8.1 
Liver Treated 5d 7.9 
Liver single treatment RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 6.9, Figure 6.10  
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Tissue Group Time-point RIN 
Lung Control 1d 7 
Lung Control 1d 7 
Lung Control 1d 6.7 
Lung Control 1d 7.8 
Lung Treated 1d 7.4 
Lung Treated 1d 8 
Lung Treated 1d 7.2 
Lung Treated 1d 7.2 
Lung Control 3d 6.6 
Lung Control 3d 7.4 
Lung Control 3d 7.5 
Lung Control 3d 7.8 
Lung Treated 3d 7.8 
Lung Treated 3d 7.6 
Lung Treated 3d 8 
Lung Treated 3d 7.8 
Lung Control 5d 7.2 
Lung Control 5d 7.5 
Lung Control 5d 7.3 
Lung Control 5d 7.6 
Lung Treated 5d 7.8 
Lung Treated 5d 7.9 
Lung Treated 5d 8.1 
Lung Treated 5d 7.8 
Lung single treatment RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 6.11, Figure 6.12  
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Tissue Group Timepoint RIN 
Spleen Control 1d 7.6 
Spleen Control 1d 7.7 
Spleen Control 1d 8.1 
Spleen Control 1d 7.8 
Spleen Treated 1d 8.4 
Spleen Treated 1d 7.8 
Spleen Treated 1d 8.4 
Spleen Treated 1d 9.1 
Spleen Control 3d 8.3 
Spleen Control 3d 7.6 
Spleen Control 3d 8.1 
Spleen Control 3d 8 
Spleen Treated 3d 8.1 
Spleen Treated 3d 8.4 
Spleen Treated 3d 8 
Spleen Treated 3d 8.1 
Spleen Control 5d 7.9 
Spleen Control 5d 7.8 
Spleen Control 5d 7.8 
Spleen Control 5d 8 
Spleen Treated 5d 8.2 
Spleen Treated 5d 8.1 
Spleen Treated 5d 7.5 
Spleen Treated 5d 8.4 
Spleen single treatment RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 6.13, Figure 6.14  
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Tissue Group Timepoint RIN 
Gut Control 1d 7.5 
Gut Control 1d 8.5 
Gut Control 1d 6.1 
Gut Control 1d 8 
Gut Treated 1d 8.6 
Gut Treated 1d 8.8 
Gut Treated 1d 7.1 
Gut Treated 1d 5.2 
Gut Control 3d 7.7 
Gut Control 3d 8 
Gut Control 3d 7.2 
Gut Control 3d 7.4 
Gut Treated 3d 6.5 
Gut Treated 3d 7.2 
Gut Treated 3d 6.5 
Gut Treated 3d 8.6 
Gut Control 5d 6.9 
Gut Control 5d 7.4 
Gut Control 5d 5.6 
Gut Control 5d 7.4 
Gut Treated 5d 6.6 
Gut Treated 5d 8 
Gut Treated 5d 8.2 
Gut Treated 5d 8.3 
Gut single treatment RIN values 
Samples were analysed by Glasgow Polyomics at the University of Glasgow using Agilent 
Bioanalyzer to generate RIN values. Refers to Figure 6.15, Figure 6.16 
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